Epithelial cell adaptation to supernumerary centrosomes by Rhys, Alexander Daniel
PhD Thesis
Thesis Submitted in Partial Fulfillment of the
Requirements for the Degree of Doctor of Philosophy






I, Alexander D. Rhys, confirm that the research included within this thesis is my
own work or that where it has been carried out in collaboration with, or supported
by others, that this is duly acknowledged below and my contribution indicated.
I attest that I have exercised reasonable care to ensure that the work is original, and
does not to the best of my knowledge break any UK law, infringe any third party’s
copyright or other Intellectual Property Right, or contain any confidential material.
I accept that the College has the right to use plagiarism detection software to check
the electronic version of the thesis. I confirm that this thesis has not been previously
submitted for the award of a degree by this or any other university.
The copyright of this thesis rests with the author and no quotation from it or
information derived from it may be published without the prior written consent of
the author.
Signature:
Date: October 15, 2017
i
Acknowledgements
Firstly, I’d like to thank my supervisor Susana for giving me the opportunity to
become the first member of her lab, and the chance to work on such a fascinating
PhD project. Thank you too for the constant guidance and support, encouraging
me to ever become a better scientist.
I owe my thanks to the members of the Godinho lab for their assistance, support
and laughter which has never made the lab a dull place to be. To Teresa, Pedro and
Sophie thank you for everything you have done to help me along this path. To Aman,
Mohamed and Khash, the masters and undergraduate students I have supervised,
thank you for putting your trust in me, and for your assistance on the project. To
the extended KiSS Group, your wisdom and guidance has always been useful, and I
will always have fond memories of our retreats.
My thanks go to our collaborators - in particular to Malti Vaghela and Guillaume
Charras for their assistance with the atomic force microscopy experiments. Thank
you to Erik Sahai, Peter Schmid, John Marshall, Priscilla Soulie and David Pellman
for the donation of cell lines, and Birgit Leitinger for her DDR1 antibodies. I am
also grateful to Cancer Research UK for their funding and support.
To the “Kindergarten”, sharing an office with you all was fantastic fun. Who knew
that 10 of us under such close quarters would all get along as well as we did. I’m
glad to have made such special friends to have shared the joys of finally succeeding in
CRISPR, and the downs when a western blot antibody still won’t work. My special
thanks go to Katy and Cathy, to the two best friends that I could ask for, thank
you for always being there when a smile is needed, when I needed advice on how to
reassess an experiment and all-round support.
To my family, for your patience and support I am always grateful. Thank you all for
teaching me that I can do anything if I put my mind to it, and always being there
for the ups and downs.
However, my biggest thanks must be paid to my husband Hefin. We embarked
on our PhD journeys together, and not a day goes by where I am not thankful to
have you by my side. Not only do I owe you my thanks for your constant love and
support, but scientifically for your statistical assistance and generating my rosette
plots. Diolch, a dw i’n caru ti.
ii
Abstract
The centrosome is the main microtubule-organising centre in animal cells; important
to assemble a bipolar mitotic spindle ensuring proper chromosome segregation and
genomic stability. Whereas correct centrosome number (1-2) is tightly maintained
in normal cells, cancer cells usually have an increased number of centrosomes (>2),
termed centrosome amplification. Centrosome amplification has been correlated with
aneuploidy, increased tumour grade, chemoresistance and overall poor prognosis.
Cancer cells primarily adapt to supernumerary centrosomes by clustering them into
two poles resulting in a ‘normal’ pseudo-bipolar mitosis. Undermining centrosome
clustering is a potential target for cancer-specific treatment. Indeed, depleting the
kinesin HSET has already been shown to specifically kill cancer cells by impairing
the centrosome clustering mechanism. However, it is unclear whether this process
requires adaptation or it is inherent to all cell types.
Using a panel of non-transformed cell lines, we observed that cells expressing E-
cadherin have inefficient clustering mechanisms compared to cell lines without
E-cadherin. Loss of E-cadherin (siRNA/CRISPR) promotes centrosome clustering
and survival of epithelial cells with multiple centrosomes. In addition, loss of DDR1,
involved in regulating cortical contractility downstream of E-cadherin, increases
centrosome clustering in epithelial cells. Using Atomic Force Microscopy we confirmed
that indeed loss of E-cadherin leads to increased cortical contractility in mitotic
cells. Inhibition of actomyosin contractility prevents efficient clustering in cells
that do not express E-cadherin, further suggesting that it is important for this
process. Loss of E-cadherin and DDR1 is strongly correlated with high levels of
centrosome amplification in breast cancer cell lines suggesting that these changes
are an important adaptation mechanism to centrosome amplification.
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ECL enhanced chemiluminescence reagent
ECM extracellular matrix
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor




GFP green fluorescent protein
gRNA guide RNA






HURP hepatoma upregulated protein
IDC invasive ductal carcinoma
ILK integrin-linked kinase
InDels small nucleotide insertions or deletions
KLD Kinase/Ligase/Dpn1
LATS2 large tumour suppressor kinase 2
LB Luria broth
LIMK Lim kinase
MAPs microtubule associated proteins
MDC1 mediator of DNA damage checkpoint protein 1





NHEJ non-homologous end joining
Nlp Ninein-like protein
OD optical density
PAM protospacer adjacent motif





PCR polymerase chain reaction
pRB retinoblastoma protein
PVDF polyvinylidene fluoride




rpm revolutions per minute
RPMI Roswell Park Memorial Institute medium
SAC spindle assembly checkpoint
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
shRNA short hairpin RNA
siRNA small interfering RNA
SOC super optimal broth with catabolite repression
SPB spindle pole body
StDev standard deviation
TBS tris buffered saline







The centrosome is the main microtubule (MT) organising centre in animal cells,
consisting of two orthogonally positioned barrel-shaped centrioles, embedded in a
proteinaceous matrix called the pericentriolar material (PCM). The pair of centrioles,
which are made up of a nine-fold symmetry of microtubules, are structurally different
at their distal ends, with the older mother centriole containing distal and subdistal
appendages which are required for microtubule anchorage and ciliogenesis (Reviewed
in: Bettencourt-Dias and Glover, 2007). The PCM contains hundreds of proteins,
including cell cycle regulators and signalling molecules, and importantly proteins
including the γ-tubulin ring complexes (γ-TuRCs) that can organise and nucleate
microtubules (Andersen, Wilkinson, and Mayor, 2003; Arquint, Gabryjonczyk, and
Nigg, 2014)(Figure 1.1). Until relatively recently it was thought, based on electron
microscopy that the PCM was amorphous, until super-resolution microscopy has
shown that the PCM is organised in concentric layers around the centriole (Fu
and Glover, 2012; Lawo et al., 2012; Mennella et al., 2012; Sonnen, Schermelleh,
et al., 2012). Within proliferating cells the centrosome and its role in microtubule
nucleation is important for cell shape, motility and the formation of the bipolar
spindle (Reviewed in: Bettencourt-Dias and Glover, 2007). Additionally, within
many differentiated cell types, the mother centriole acts as the basal body which is
required for cilia formation (Reviewed in: Kim and Dynlacht, 2013).
Centrioles are present in all eukaryotic species that form cilia and flagella, but are
not found in species that do not have cilia, such as higher plants and higher fungi.
Interestingly, centrioles are found in the basal plant and fungal groups, suggesting
that centrioles are one of the earliest features within the earlier eukaryotic ancestors
(Carvalho-Santos et al., 2011; Fırat-karalar and Stearns, 2014). Whilst the centrioles
themselves are conserved across different species with their cylindrical structure
formed of the nine-fold triplet symmetry (Figure 1.1), the microtubule arrays can
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Figure 1.1: Centrosome structure.
The centrosome is composed of a pair of centrioles, each with a ninefold symmetry
of triplet microtubules. The centrosome is surrounded by the pericentriolar material,
the site of microtubule nucleation. The mother centriole contains distal and sub-distal
appendages. The centriole linker/tether connects the two centrioles together.
vary from singlet, doublet or triplet microtubules, and centriole length ranges from
100-400nm and diameter from 100-250nm in different species (Carvalho-Santos et al.,
2011). A large number of centriolar proteins have been identified by both proteomic
and genomic approaches (Andersen, Wilkinson, and Mayor, 2003; Dammermann
et al., 2004; Delattre et al., 2004; Keller et al., 2005; Leidel et al., 2005; Fritz-Laylin
et al., 2010; Jakobsen et al., 2011; Azimzadeh et al., 2012; Hoh et al., 2012). Some
of these proteins are conserved among the diverse eukaryotes with centrioles, further
supporting the presence of centrioles within an early eukaryotic ancestor (Hodges
et al., 2010; Carvalho-Santos et al., 2011; Fırat-karalar and Stearns, 2014), whereas
some of the proteins are specific to certain subsets of organisms, this is due to
variations in centriole assembly and function (Fırat-karalar and Stearns, 2014).
Centrosomes were first described by Theodor Boveri in the 1880s as “the organ for
cell division”, being seen as a vital organelle required for cells to divide (Bignold,
Coghlan, and Jersmann, 2006; Boveri, 2008). However, later studies started to
contest this, when seed plant cells were shown to not contain centrosomes (Pickett-
Heaps, 1971). Furthermore, experiments using flattened primary spermatocytes
from crane flies, which lack a centrosome at one or both poles, showed that these
cells could still effectively divide their chromosomes (Dietz, 1966). It is has now
been established that acentrosomal cells are still capable of forming bipolar spindles
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by nucleating microtubules from mitotic chromatin (Cavazza and Vernos, 2015).
This mechanism, initially observed in Xenopus egg extracts, has been shown to be
especially important for the formation of bipolar spindles in female oocytes, which
lack centrosomes prior to fertilisation (Karsenti, Newport, and Kirschner, 1984;
Heald et al., 1996; Manandhar, Schatten, and Sutovsky, 2005).
Although centrosomes may be dispensable for cell division to occur, their loss does
not come without a cost. Acentrosomal Drosophila mutants, lacking DSas-4, an
important protein required for centriole duplication, are able to produce flies (Basto,
Lau, et al., 2006). Whilst these flies are able to go through development without any
evident morphological abnormalities, they lack cilia and flagella, and die prematurely
(Basto, Lau, et al., 2006). Further examination showed defects in spindle positioning
and asymmetric cell division in the neuroblasts of these flies (Basto, Lau, et al., 2006).
Previous work done in haploid cells which were derived from unfertilised Drosophila
cells and therefore lack centrosomes, are inherently aneuploid, further supporting
that centrosomes may play an important role in preserving genetic stability (Debec,
1978). This hypothesis was more recently explored in DT40B chicken cells, where
it was shown that centrosome loss resulted in slower mitoses with higher rates of
chromosomal instability – this therefore suggested that centrosomes are important for
both rapid segregation of genetic material whilst also maintaining genetic integrity
(Sir et al., 2013).
1.1.1 Duplication cycle
In dividing cells, centrosome duplication occurs once per cell cycle, this regulation
ensures that on entering mitosis cells have two centrosomes that facilitate the
formation of a bipolar mitotic spindle. Defects in the regulation of centrosome
duplication have been linked to a number of human diseases, including cancer and
microcephaly. The morphological events that make up the centriole duplication
cycle have been well characterised through the use of electron microscopy (Robbins,
Jentzsch, and Micali, 1968; Allen, 1969; Cavalier-Smith, 1974; Vorobjev and Chentsov
Yu., 1982). Upon exiting mitosis, the daughter centriole disengages from the older
mother centriole, allowing the initiation of centrosome duplication. At the G1-S
phase transition a new centriole starts to form perpendicular to each of the original
centrioles, these then elongate through S and G2. In late G2 the centrosomes then
recruit additional PCM proteins, and separate ready for mitosis and the formation
of the spindle, where each daughter cell receives one centrosome (Figure 1.2).
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Figure 1.2: Centrosome duplication is tightly regulated in relation to the
cell cycle
In dividing cells, centrosome duplication is limited to once per cell cycle. Upon
exiting mitosis, the daughter centriole disengages from the older mother centriole,
allowing the initiation of centrosome duplication. In S phase a new centriole forms
perpendicular to each of the original centrioles. In late G2 the centrosomes then
recruit additional PCM proteins, and separate ready for mitosis, enabling the
formation of a bipolar spindle.
1.1.1.1 Centriole disengagement
Centriole disengagement occurs at the end of mitosis, and involves the daughter
centriole separating away from the mother centriole. This process is an important
regulator of the centrosome duplication cycle as it licenses the duplication to only
once within the coming cell cycle (Tsou and Stearns, 2006). It is thought that the
physical localisation of engaged centrioles prevents premature centriole duplication;
this is supported by work done by Loncarek et al. which showed that if a daughter
centriole is removed by laser ablation, reduplication can occur (Loncarek et al., 2008).
In vertebrates disengagement is controlled by the mitotic kinase PLK1 and the
protease separase, which is also required for the separation of sister chromatids at
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the metaphase-to-anaphase transition (Tsou, Wang, et al., 2009). This link between
chromatid separation and disengagement serves to link the timing of the two events
together, this ensures that centriole disengagement does not occur prematurely prior
to chromosome segregation in mitosis, which could otherwise result in multipolar
spindles and erroneous chromosome segregation. The mechanism for the role of
PLK1 and separase is not yet fully elucidated. It is suggested that there is a physical
link between the mother and daughter centriole, which can be cleaved through a
PLK1 driven separase mechanism (Fu, Hagan, and Glover, 2015), similar to the
PLK1 separase-dependent cleaveage of chromatid linker cohesin in sister chromatid
separation (Sumara et al., 2002). Whilst the model that chromatid separation and
centrosome disengagement having shared mechanisms may appear simple, the role
of cohesin as a substrate for separase in disengagement is not clear. Work done in
HeLa cells expressing a non-degradable form of the cohesin subunit SSC1 showed
that sister chromatid separation was prevented, but centriole disengagement could
occur, suggesting that cohesin is not the linker between the two centrioles (Tsou
and Stearns, 2006). However, two years later a similar experiment was performed
with the opposite results, re-implicating cohesin (Schockel et al., 2011). To examine
this further Schockël et al. engineered the SSC1 to contain cleavage sites for the
human rhinovirus (HRV) protease, resulting in centriole disengagement (Schockel
et al., 2011). These results were compelling that cohesin plays a role in linking
mother and daughter centrioles together. However, more recent work in Drosophila
embryos using a similar model showed that cohesin cleavage was not sufficient for
disengagement to occur (Oliveira and Nasmyth, 2013). Work has been done to try
and identify alternative substrates for separase, including identifying pericentrin, a
key component of the PCM as potentially being an important substrate for separase
in centriole disengagement (Lee and Rhee, 2012; Matsuo et al., 2012). Therefore
whilst a physical link between the centrioles is accepted, further work needs to be
done to understand the disengagement process. After disengagement a proteinaceous
tether, called the centrosome cohesion (Graser, Stierhof, and Nigg, 2007) or G1-G2
tether (Reviewed in: Nigg and Stearns, 2011) forms between the two centrosomes,
composed of C-Nap1/Cep250 and rootletin which keeps them within a localised
proximity to each other until centrosome separation (Reviewed in: Mardin and
Schiebel, 2012).
1.1.1.2 Centriole duplication
The physical duplication of centrioles begins at the G1/S transition with the formation
of a procentriole perpendicular to the base of the existing centriole. This process is
5
Chapter 1. Introduction
coupled to the cell cycle by requiring the activity of CDK2 complexed with cyclins
A or E (Hinchcliffe et al., 1999; Lacey, Jackson, and Stearns, 1999; Matsumoto,
Hayashi, and Nishida, 1999; Meraldi et al., 1999). Two possible pathways linking
CDK2 to procentriole formation have been proposed (Gönczy, 2015). The first is
that CDK2 may phosphorylate substrates which then trigger procentriole formation,
such as CP110, MPS1/TTK, and nucleophosmin, however it is not yet established if
these three proteins are fundamentally required for the formation of procentrioles
(Okuda et al., 2000; Fisk and Winey, 2001; Chen, Indjeian, et al., 2002; Gönczy,
2015). Another proposed model is that CDK2 inactivates the E3 ubiquitin ligase
anaphase promoting complex/cyclosome (APC/C) which is complexed with CDH1.
APC/CCDH1 ubiquitylates target proteins during G1, targeting them to the 26S
proteasome for degradation. By inactivating APC/CCDH1, CDK2 leads to the
accumulation of proteins required for S-phase entry (Peters, 2002; Peters, 2006). As
well as degrading proteins required for S-phase entry, APC/CCDH1 also degrades
proteins required for centriole duplication including SAS-6, STIL and CPAP, therefore
CDK2 activity can couple G1/S phase transition with the increase in proteins for
centriole duplication (Strnad et al., 2007; Tang, Fu, et al., 2009; Arquint, Sonnen,
et al., 2012).
It is well established that PLK4, SAS-6 and STIL, three centriolar proteins are
key in initiating the centriole duplication process. It was initially thought that
SAS-6 localised first for procentriole formation (Strnad et al., 2007). However,
more recent work has shown that PLK4 localises to a dot-like structure at this
site of procentriole formation first, and recruits SAS-6 (Sonnen, Schermelleh, et al.,
2012; Kim, Park, et al., 2013). Similar work in Caenorhabditis elegans, has shown
that ZYG-1, the orthologue of PLK4 recruits SAS-6, suggesting this process is
evolutionarily conserved (Kitagawa, Busso, et al., 2009; Lettman et al., 2013). This
localisation of PLK4 is regulated by two scaffolds CEP152 and CEP192. PLK4 is
recruited along with CEP152 to the centrioles through interaction with CEP192
(Kim, Park, et al., 2013; Sonnen, Gabryjonczyk, et al., 2013). CEP192 localises to
the inner ring of the centriole barrel, whereas CEP152 localises to the outer ring
(Lüders, 2012), where PLK4 is repositioned by competitively binding to the CEP152
from the CEP192 (Park, Park, et al., 2014). PLK4 then moves from surrounding the
centrioles to the sites of procentriole formation (Kim, Park, et al., 2013). However,
both CEP192 and CEP152 are symmetrically distributed around the centrioles
(Lawo et al., 2012; Sonnen, Schermelleh, et al., 2012), so whilst the mechanism of
recruitment of PLK4 to the centrioles is determined, how PLK4 then localises to a
single point for procentriole initiation is yet to be understood. It has been suggested
that STIL may play a role in this localisation and activation of PLK4.
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After PLK4 localisation, the next stage in the procentriole formation is the formation
of the cartwheel (Gönczy, 2012). Structural biology studies using X-ray crystallogra-
phy played an important role in showing that the cartwheel is formed of a central hub
surrounded by a ninefold symmetry of “spokes” made up of SAS-6 oligomers. Further
work using purified SAS-6 in vitro showed that the SAS-6 oligomers could assemble
into the ninefold cartwheel like structure. (Kitagawa, Vakonakis, et al., 2011; Breugel
et al., 2011; Brito, Gouveia, and Bettencourt-Dias, 2012). This cartwheel provides
the required ninefold symmetry of the centriole and initiates the formation of the
assembly of the triplet microtubules. The positioning of the cartwheel to the luminal
wall of the mother centriole is dependent on PLK4 and STIL (Fong et al., 2014). In
mature centrioles this cartwheel is then lost, suggesting that the cartwheel is required
for centriole generation but not maintenance, although the loss of the cartwheel
occurs in only some species (Tsou et al., 2009; Guichard et al., 2010; Gönczy, 2012).
From this cartwheel the ninefold symmetry of triplet microtubules can form (in
some species it is formed of singlet or doublet microtubules). The microtubules are
designated either A-, B- or C-tubules (Figure 1.1). The A-tubules are nucleated
by a conical structure similar to the γ-TuRC, and are proximal to the interior of
the centriole wall, whereas the B- and C-tubules each share a wall with the A- and
B-tubules, respectively (Erickson, 2000; Keating and Borisy, 2000). The B- and C-
tubules do not have the conical structure at their end, suggesting they are generated
by a different mechanism. The A-tubule of one triplet is connected to the C-tubule
of the adjoining triplet via a linker (Fujita, Yoshino and Chiba, 2016). This process
requires the highly conserved centrosomal protein CEP135. The SAS-6 proteins, once
formed into the cartwheel structure, are too short to bind the A-tubules, therefore
CEP135 is needed to bridge this gap by binding to SAS-6 at its C-terminal region,
and the tubules at its N-terminal (Lin et al. 2013). Depletion of CEP135 has been
shown to result in abnormal centrosome structure (Lin et al. 2013).
1.1.1.3 Centriole elongation
After the formation of procentrioles, these start to elongate during S phase, with
their distal regions elongating during G2 to a determined length, which is variable
between different species (0.2–0.5µm long) (Carvalho-Santos et al., 2011). The
centriolar protein CPAP (centrosomal P4.1-associated protein) is fundamental for
centrosome elongation, and its overexpression has been shown to generate centrioles
that are longer than normal (Schmidt et al., 2009; Tang et al., 2009). CPAP is
recruited to the cartwheel where it binds to CEP135, and stabilises the cartwheel
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structure (Lin et al. 2013). A number of proteins have been identified which play a
role co-operatively with CPAP for this elongation process including CEP120, PLK2,
Spice1 and centrobin (Chang et al., 2010; Gudi et al., 2011, 2014, 2015; Comartin et
al., 2013; Y. N. Lin et al., 2013). Notably centrobin is recruited to the centrosome,
and upon interaction with CPAP enables the elongation of the centrioles by binding
α- and β-tubulin dimers (Gudi et al., 2011, 2014). After elongation, CP110 and its
interacting proteins is then required to cap the distant ends of the centrioles once
they reach the correct length, and prevent further elongation (Kohlmaier et al., 2009;
Schmidt et al., 2009).
1.1.1.4 Centrosome maturation
Once centriole length has been achieved, centrosome maturation occurs towards the
end of G2, which is characterised by the recruitment of PCM proteins, including
γ-TuRC, which is required for MT nucleation. CPAP is further required for this
process, independently of its role in centriole elongation. CPAP forms a scaffolding
complex by binding to the proximal end of the centrosome, and to the PCM, tethering
the two together (Gopalakrishnan et al., 2011; Zheng et al., 2014). Alongside this, the
kinases PLK1 and Aurora A are required for centrosome maturation, and enabling
the process for centrosomes to nucleate and anchor MTs. PLK1 phosphorylates
a number of different PCM proteins including pericentrin, CEP215, CEP192 and
NEDD1 (Santamaria et al., 2011). This phosphorylation of pericentrin then enables
the recruitment of a number of other key PCM components: γ-tubulin, Aurora
A, CEP192, NEDD1 and PLK1 itself (Lee and Rhee, 2011). Both pericentrin and
CEP192 are required for the recruitment of NEDD1 and γ-tubulin (Zhu et al., 2008).
CEP215 stimulates MT nucleation through interacting with γ-TuRC (Chen et al.,
2008). PLK1 and Aurora A work together, with PLK1 recruiting Aurora A to the
centrosome, and Aurora A in initially activating PLK1 (Lens, Voest and Medema,
2010). Once PLK1 is activated, its continuous activity is then required for the
retention of PCM structure, going through into mitosis (Mahen et al., 2011).
1.1.1.5 Centrosome separation
At the end of G2, the centrosomes separate, this enables the formation of a bipolar
spindle in mitosis, with a centrosome at each pole. This process occurs via two
stages, the first is the disruption of the proteinaceous linker that connects the two
mother centrioles, then the force-dependent separation of the two centrosomes by
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Eg5, allowing the formation of the two separate spindle poles (Mardin and Schiebel,
2012; Fujita, Yoshino and Chiba, 2016).
The centriolar protein CEP250 localises to the tethering site at the proximal end
of mother centriole, where it binds to rootletin, and LRRC45 on the proteinaceous
tether (Fry et al., 1998; Bahe et al., 2005; He et al., 2013). The NIMA-related
kinase Nek2 is required for the phosphorylation-dependent dissolution of the tether
by phosphorylating CEP250, rootletin and LRRC45 at the G2/M transition, as well
as centlein which is also a tether protein (Fry et al., 1998; Bahe et al., 2005; He
et al., 2013). This process is temporally controlled by Aurora A. Aurora A actives
PLK1, which in turn binds and phosphorylates Mst2, a Hippo pathway effector
kinase (Mardin et al., 2011). Mst2 directly binds to Nek2 and controls its subsequent
localisation, and phosphorylation of CEP250 and rootletin (Mardin et al., 2010).
After the tether is dissolved, the centrosomes are then required to move to opposite
ends of the cell to form the bipolar spindle in mitosis, enabling the efficient segregation
of chromosomes into the two daughter cells. This is a force-driven process, the forces
are generated by the kinesin Eg5 (Mardin and Schiebel, 2012). Nek6, another NIMA-
related kinase protein is required to phosphorylate Eg5, enabling Eg5 to be targeted
to the centrosome by PLK1 and MTs (Bertran et al., 2011; Mardin et al., 2011;
Smith et al., 2011). Eg5 through its kinesin activity along with dynein then allows
for the separation of the two centrosomes to opposite ends of the cell, cortical dynein
is then important for the orientation of the subsequent mitotic spindle (Raaijmakers
et al., 2012; Raaijmakers and Medema, 2014; Tame et al., 2014). Interestingly, Eg5
is able to separate centrosomes, by force even if the tether remains (Mardin et al.,
2010). The centrosome duplication cycle then occurs again in the new daughter cells.
1.2 Centrosome amplification and cancer
The first proposal that supernumerary centrosomes could be linked to tumourigenesis
was made over a century ago by the German embryologist Theodor Boveri. Boveri
carried out experiments using dispermic fertilised sea urchin eggs, which therefore
contained extra centrosomes as the sperm provides the functioning centrosome
during embryogenesis. He observed that these cells formed multipolar spindles
leading to asymmetric distribution of the genetic material resulting in three or more
aneuploid daughter cells. The progeny from these divisions all displayed different
developmental phenotypes, and it was from this that the conclusion that chromosomes
were important for cellular traits was derived (Boveri, 1887, 1888). These conclusions
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were further supported by the observations of two of Boveri’s contempories: Gino
Galeotti and David von Hansemann, who first investigated genetic instability in
cancer by examining tumour histology. They reported that abnormal mitoses,
including multipolar spindles, are common features within tumours (Hansemann,
1890; Galeotti, 1893). Their observations also reinforced Boveri’s suggestion that
the multipolar spindles he observed resulted in unequal distribution of chromosomes,
which Galeotti termed as “asymmetric karyokinesis” (Hansemann, 1890; Galeotti,
1893). Based on these observations Boveri then put forward the proposal that as
extra centrosomes result in multipolar divisions, leading to genetic instability this in
turn could result in tumourigenesis (Boveri, 1902, 2008) (Figure 1.3).
However, Boveri’s hypothesis that extra centrosomes can lead to tumour formation
contrasted with that made by Hansemann. Hansemann stated that whilst multipolar
cell divisions are observed within tumours, a diagnosis of cancer should not be made
based solely on these abnormal mitotic divisions, as they are also observed within
benign lesions (Hansemann, 1890; Reviewed in: Bignold, Coghlan and Jersmann,
2006). As the cancer field progressed and focused mostly on genetics and the role
of oncogenes and tumour suppressors in tumourigenesis the role of centrosomes
was widely ignored until the late 1990s when it was observed that centrosome
amplification was associated with loss of p53 that the field started to re-emerge
(Fukasawa et al., 1996).
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Figure 1.3: Hypothesis that supernumerary centrosomes and multipolar
cell divisions may lead to tumours
Theodor Boveri stained dispermic sea urchin eggs and then made drawings based on
microscopic observation. He identified the abnormal presence of multiple centrosomes
(a-d) in a fertilised egg, leadings to the unequal distribution of chromosomes (I-IV)
in the resultant daughter cells. Based on these observations he hypothesised that
supernumerary centrosomes could lead to tumour formation (Boveri, 1888).
1.2.1 Prevalence of centrosome amplification in cancer
Since the association between centrosome amplification and loss of p53, an extensive
number of studies has established that the majority of solid as well as haematological
malignancies display centrosome abnormalities and, in particular, supernumerary
centrosomes, see Table 1.1 (Lingle et al., 1998; Pihan et al., 1998; Sato et al., 1999;
Nigg, 2002; Giehl et al., 2005; Krämer, Neben and Ho, 2005; Chan, 2011). In the
majority of cases, centrosome amplification has been shown to correlate with high-
grade tumours and poor prognosis. However, instances of centrosome amplification
have also observed in some early low-grade malignancies, supporting the initial
suggestion of Boveri that centrosome amplification could promote tumourigenesis
(Lingle et al., 1998; D’Assoro et al., 2002; Pihan et al., 2003; Yamamoto et al.,
2004; Giehl et al., 2005; Segat et al., 2010). Centrosome amplification has also
been associated with tumour recurrence and increased metastasis in some cancers,
therefore potentially making centrosome amplification as a biomarker for advanced










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.2.1.1 Centrosome aberrations in breast cancer
Whilst the majority of solid tumours and haematological malignancies have been
shown to contain supernumerary centrosomes, breast cancer has been the most
systematically studied in regards to centrosome aberrations (Chan, 2011). The first
study looking at centrosome amplification in primary human cancers was done in high
grade metastatic breast adenocarcinomas (Lingle et al., 1998). Lingle et al. identified
a number of centrosomal aberrations within the samples they analysed including
centrosome amplification, enlarged centrosomal and PCM volume, and increased
microtubule nucleation resulting from the supernumerary centrosomes (Lingle et al.,
1998). The same group, following this up with electron microscopy observed that
within the breast tumours as well as supernumerary centrosomes, there were often
irregularities in their structure – either missing triplet microtubules or variation in
centriole length, and further confirming an increase in PCM (Lingle and Salisbury,
1999). They also observed that these cells with supernumerary centrosomes had
higher levels of abnormal mitoses, supporting the first observations made by Boveri
(Lingle and Salisbury, 1999).
Shortly after these initial studies, further work was done reporting centrosome
amplification in other breast cancers including ductal carcinoma in-situ (DCIS)
(Lingle et al., 2002; Pihan et al., 2003; Kronenwett et al., 2005). These studies in early
stage breast cancers supported Boveri’s hypothesis that centrosome amplification may
play a causal role in tumourigenesis, particularly as chromosomal instability correlated
with centrosome amplification in the samples analysed (D’Assoro et al., 2002).
Furthermore, it was shown that the lesions with centrosomal aberrations resulted in
more advanced histological grade, supporting a role of centrosome amplification in
increased tumourigenesis (Pihan et al., 2003).
Subsequent studies by Kronenwett et al. have continued to build on this link between
centrosomal abnormalities and increased aggressiveness of tumours. They showed
that centrosome amplification, and the resultant mitotic spindle defects correlated
with higher levels of genome instability and aneuploidy, as well as increased tumour
grade, compared to those with normal centrosome number which had lower levels of
aneuploidy and were less invasive (Kronenwett et al., 2004, 2005). This work, along
with similar studies by other groups suggests that centrosome amplification could be
used as a potential biomarker for aggressive disease and poor prognosis within the
clinic (D’Assoro et al., 2002; Schneeweiss et al., 2003; Guo et al., 2007; Chan, 2011;
Denu et al., 2016).
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Interestingly, centrosome amplification has also been correlated with hormone re-
ceptor status of breast cancers by some studies, in particular with overexpression of
HER2/neu, as well as negative estrogen receptor (ER), and negative progesterone
receptor (PR) (Montagna et al., 2002; Schneeweiss et al., 2003; Guo et al., 2007).
Although, a contrasting study found no correlation between centrosome amplification
and hormone receptor status, nor with chromosomal instability, tumour size or grade
(Shimomura et al., 2009).
1.2.2 Structural abnormalities of centrosomes
Centrosomal defects can be broken down into two main categories – structural
and numerical abnormalities. Whilst numerical aberrations are the most widely
characterised, structural abnormalities have also been observed, usually reported
as alterations in centrosome size and length (Godinho and Pellman, 2014). The
origin of structural centrosomal abnormalities are not yet well understood, however
it has been hypothesised that they could result from genetic changes in regards
to the components that control centrosome structure. One such example is CPAP
which when overexpressed results in increased centriole length (Kirkham et al., 2003;
Kohlmaier et al., 2009; Schmidt et al., 2009; Tang et al., 2009).
Structural abnormalities are not well characterised, primarily as they are not easy to
identify. Centrioles are 0.2-0.5µM in length, which is close to the optical resolution
of light microscopy, therefore for more accurate analysis specialised fluorescence
microscopy must be used, or ideally electron microscopy, which is then hard to
apply to a systematic study of structural aberrations. Pericentriolar markers are
often used when assessing centrosomal abnormalities, however there are difficulties
in interpreting changes in PCM volume/diameter as either numerical of structural
centrosomal defects (D’Assoro et al., 2002; Guo et al., 2007). For example, if the
volume of PCM is increased, this may be considered to be a structural alteration,
however, this could also result from an increase in centrosome number, whereby the
supernumerary centrosomes are tightly packed together, this should therefore have
been classified as a numerical aberration rather than a structural one (D’Assoro et
al., 2002; Lingle et al., 2002; Godinho et al., 2014). Conversely, increased centriolar
length can lead to centriole fragmentation, which may then appear as a numerical
defect rather than a structural one (Kohlmaier et al., 2009). A large number of studies
investigating centrosomal defects within primary tumours rely on PCM staining,
which then makes it systematically harder to understand the role of numerical and
structural aberrations within cancer (Godinho and Pellman, 2014). This problem can
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be partly overcome by the use of centriole specific markers such as centrin, whereby
the number of centrioles can actually be assessed, although electron microscopy
would be required to determine if centriole fragmentation had occurred.
1.2.3 Causes of centrosome amplification
The most widely studied centrosomal abnormality within cancer is centrosome
amplification, however it is still not fully understood how cancer acquires these
supernumerary centrosomes. There are a number of different methods which can
lead to supernumerary centrosomes: centriole over duplication, mitotic slippage,
cytokinesis failure, cell-cell fusion, and de novo centriole assembly (Godinho, Kwon
and Pellman, 2009).
Centrosome over duplication can result from the deregulation of the centrosome
duplication cycle described above, which is normally tightly controlled by cell cycle
components. Whilst this cycle is normally robust in ensuring that centriole dupli-
cation only occurs once per cell cycle, it is only controlled by a small number of
positive and negative regulatory proteins which are widely conserved between species
(Reviewed in: Nigg and Stearns, 2011). As previously described, the master regulator
of centrosome duplication is PLK4 (Holland, Lan and Cleveland, 2010). Overexpres-
sion of PLK4 has been shown to lead to supernumerary centrosomes due to centriole
over duplication (Habedanck et al., 2005; Kleylein-Sohn et al., 2007). Conversely
loss of PLK4 results in a reduction in centriole number (O’Connell et al., 2001;
Bettencourt-Dias et al., 2005; Habedanck et al., 2005). PLK4 levels are therefore
regulated during the centriole duplication cycle, mostly through autophosphorylation
leading to SCFβTrCP/ubiquitin-dependent proteolysis (Cunha-Ferreira et al., 2009;
Rogers et al., 2009; Guderian et al., 2010; Holland et al., 2010; Sillibourne et al., 2010;
Brownlee et al., 2011). It is possible that the supernumerary centrosomes observed
in some tumours may arise from the deregulation of the ubiquitin regulators involved
in targeting PLK4 for proteolysis. For example the downregulation of βTrCP has
been shown to result in the stabilisation of PLK4, and subsequently centrosome
amplification was observed (Wojcik, Glover and Hays, 2000; Guardavaccaro et al.,
2003; Cunha-Ferreira et al., 2009; Rogers et al., 2009). CP110, a centrosomal protein
involved in controlling centriole length is also regulated by ubiquitin-dependent
proteolysis by SCFcyclinF, which is itself counteracted by USP33 a deubiquitinating
enzyme (Li et al., 2013). Overexpression of USP33 increases CP110, also resulting
in centrosome amplification (Li et al., 2013).
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HPV (High-risk human papillomavirus) associated tumours have also been reported
to be associated with centriole over duplication. The HPV-16 E7 oncoprotein has
been shown to increase PLK4 mRNA levels, resulting in centrosome amplification
(Korzeniewski, Treat and Duensing, 2011). Furthermore both the E6 and E7 onco-
proteins play a role in disrupting the cell cycle checkpoints, which helps facilitate the
viral replication. This disruption can then result in oncogenic transformation, and
may lead to centriole over duplication (Duensing et al., 2009; Korzeniewski, Treat
and Duensing, 2011).
As described previously, PLK4 levels are tightly regulated to ensure centriole du-
plication occurs once per cell cycle. p53 is able to regulate PLK4 mRNA levels by
recruiting HDAC (histone deacetylases) repressors to the PLK4 promoter region
(Li et al., 2005). This is interesting within a cancer setting, as loss of p53 could
then lead to increased levels of PLK4, in turn causing centriole over duplication.
This hypothesis is supported by observations in murine fibroblasts, that centrosome
amplification has been associated with loss of p53 (Fukasawa et al., 1996). However,
in p53-/- mice, when their brains were analysed, no evidence of centrosome amplifica-
tion was observed (Marthiens et al., 2013). Therefore it is still unclear as to whether
loss of p53 may directly, or even indirectly lead to the generation of supernumerary
centrosomes.
Alternatively, centrosome over duplication can occur via overexpression of some of the
PCM components, such as pericentrin and γ-tubulin (Starita et al., 2004; Loncarek
et al., 2008). For example increased γ-tubulin has been shown to result from the
loss of the tumour suppressor BRCA1 (Starita et al., 2004). Prolonged G2 arrest
can lead to centriole over duplication, where the centrosomes mature and disengage
prior to mitosis, and reduplicate due to PLK1 expression (Lončarek, Hergert and
Khodjakov, 2010). Therefore it is possible that conditions such as persistent DNA
damage, which result in elongated periods within G2 could result in centrosome
amplification (Godinho and Pellman, 2014).
Centrosome amplification can also occur due to cytokinesis failure, cell-cell fusion
or mitotic fusion, which then results in tetraploid cells containing supernumerary
centrosomes that have been shown to be tumourigenic (Fujiwara et al., 2005; Duelli
et al., 2007; Ganem, Storchova and Pellman, 2007; Davoli and de Lange, 2012).
Interestingly p53-/- tetraploid tumour cells have been shown to contain high levels
of supernumerary centrosomes, suggesting tetraploidy may be a route for tumours
generating supernumerary centrosomes (Fujiwara et al., 2005). Conversely, work done
in vitro where transient cytokinesis failure was induced did not result in the long-
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term maintenance of supernumerary centrosomes in culture, suggesting that these
supernumerary centrosomes are then lost (Krzywicka-Racka and Sluder, 2011). These
observations were supported by previous work showing that tetraploid cells lose their
supernumerary centrosomes over time (Ganem, Godinho and Pellman, 2009). These
observations would suggest that supernumerary centrosomes are deleterious, and are
therefore lost by cells overtime. Therefore, whilst there are different mechanisms that
may lead to the generation of supernumerary centrosomes, they do not inherently
lead to the permanent maintenance of extra centrosomes over continued growth.
Other conditions such as cell type or genetics must therefore play a role in the
maintenance of centrosome amplification, as well as their generation (Godinho and
Pellman, 2014).
Further confirming the deleterious effects of supernumerary centrosomes, centrosome
amplification has been shown to result in the stabilisation of p53 and p21, leading to
cell cycle arrest, which can be overcome if p53 is inhibited (Holland et al., 2012).
Centrosome amplification can lead to aneuploidy, which may have accounted for
the p53-dependent arrest observed, however the activation of p53 upon centrosome
amplification appears to be a distinct process independent of aneuploidy (Ganem,
Godinho and Pellman, 2009; Thompson and Compton, 2010; Holland et al., 2012).
Tetraploid cells containing supernumerary centrosomes have been shown to stabilise
p53 by activation of the Hippo tumour suppressor pathway (Ganem et al., 2014).
Therefore, cells can activate p53 and subsequently undergo cell cycle arrest by both
centrosome amplification and aneuploidy. Interestingly, recent work has shown that
the presence of supernumerary centrosomes can trigger activation of the PIDDosome
multiprotein complex, which leads to Caspase-2 mediated MDM2 cleavage and
therefore stabilisation of p53 resulting in cell cycle arrest (Fava et al., 2017). As
cancers have regularly been identified to contain supernumerary centrosomes there
must be mechanisms that take place that allow cells to actively maintain their
supernumerary centrosome population, overcoming the p53-dependent arrest observed
as well as the initial process of generating them.
1.2.3.1 Causes of centrosome amplification in breast cancer
Looking particularly at breast cancer, a number of independent studies have been
carried out, trying to understand the underlying mechanisms that lead to centrosome
amplification. Overall the combined evidence suggests that there are different, and




In the MCF7 cell line which has centrosome amplification, albeit at low levels of
~10% of cells containing supernumerary centrosomes, their extra centrosomes have
been shown to arise due to cytokinesis failure due to the expression of a small
isoform of cyclin E. The centrosome amplification was observed to increase upon
the loss of p53 (Bagheri-Yarmand, Biernacka, et al., 2010; Bagheri-Yarmand, Nanos-
Webb, et al., 2010). BRCA1 acts as a tumour suppressor within the breast and
ovaries, which when associated with BARD1 (BRCA1-associated RING Domain
1), acts as an E3 ubiquitin ligase (Starita et al., 2004). The BRCA1-BARD1
complex is able to help facilitate centrosome number by controlling reduplication
through the ubiquitination of γ-tubulin (Starita et al., 2004). Therefore, inhibition
of BRCA1, which is often observed within breast tumours can result in centrosome
overduplication, and negative BRCA1 expression has been correlated with centrosome
amplification (Schlegel, Starita and Parvin, 2003; Starita et al., 2004; Sankaran et
al., 2005; Ko et al., 2006; Shimomura et al., 2009). This phenotype is also observed
within mice, where the disruption of BRCA1 has been observed to result in both
centrosome amplification and subsequently aneuploidy (Xu et al., 1999; Deng, 2001).
Overexpression of another BRCA1 associated protein Nlp (Ninein-like protein) has
also been associated with centrosome amplification in rodent fibroblasts, and has been
shown to lead to spontaneous breast tumourigenesis in mice (Shao et al., 2010). Nlp
is a centrosomal protein, and has been shown to be overexpressed in human breast
cancers, which may then mimic BRCA1 loss, and cause centrosome amplification
within these tumours (Shao et al., 2010).
As described in Section 1.1.1, the kinase Aurora A is involved in the control of the
centriole duplication cycle, its overexpression has been shown lead to centrosome
amplification, aneuploidy and cell transformation (Zhou et al., 1998). Interestingly,
centrosome amplification has only been associated with Aurora A overexpression
in the non-invasive DCIS (ductal carcinoma in situ) suggesting that centrosome
amplification may play a role in initial tumour initiation (Hoque et al., 2003; Shi-
momura et al., 2009; Chan, 2011). In further support of this model of centrosome
amplification in breast cancer initiation, supernumerary centrosomes are often found
in early stages of breast cancer development within mouse models (Li et al., 2004).
Whilst Aurora A overexpression and centrosome amplification have been correlated,
the exact mechanism linking the two is not fully understood. It has been suggested
that the centrosome amplification observed may be due to cytokinesis failure, as
observed by the levels of aneuploidy upon Aurora A overexpression (Katayama et
al., 2004; Wang et al., 2006). In these cases, the AKT pathway was also activated,
allowing for the continued survival and proliferation of the tetraploid cells containing
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supernumerary centrosomes (Wang et al., 2006). Another possibility is that Aurora
A has been shown to be inhibited with the BRCA1 ubiquitin ligase by phosphory-
lation, so could promote centrosome phosphorylation through the impairment of
BRCA1-BARD1 as described above (Sankaran et al., 2007).
When examining proteins that are inversely correlated with centrosome amplification
in breast cancer, both MDC1 (Mediator of DNA damage checkpoint protein 1) and
BRIT1 (BRCT-repeat inhibitor of hTERT expression) were identified. Both of
these proteins negatively regulate Aurora A and PLK1 which are involved in the
centriole duplication pathway (Rai et al., 2008). Depletion of MDC1 was directly
observed to result in centrosome over-duplication, whereas BRIT1 depletion resulted
in cytokinesis failure resulting in centrosome accumulation (Rai et al., 2008).
Nek2, another centrosomal kinase has also been associated with cytokinesis failure in
breast epithelial cells, leading to the centrosome amplification. Nek2 overexpression
has been observed in both DCIS and IDC breast cancers, suggesting that Nek2 may
play a role in centrosome amplification in these tumours (Hayward et al., 2004).
Oncogenic K-Ras has been linked to centrosome amplification within precursor legions.
This can be impaired by abolishing expression of Nek2 and CDK4/cyclin D1, but not
by deleting cyclin E1 or B2 suggesting that K-Ras driven centrosome amplification
is an early oncogenic event, and supporting a role for K-Ras in tumour initiation
(Zeng et al., 2010). C-myc has been observed to induce centrosome amplification in
pre-formed tumours, suggesting a role for c-myc in tumour progression (Zeng et al.,
2010).
Overexpression of the prolyl isomerase Pin1, which activates a number of different
oncogenic pathways, has been shown to correlate with centrosome amplification in a
number of human breast cancer samples (Suizu et al., 2006; Chan, 2011). Pin1 has
been shown to localise to the centrosome during interphase, but not during mitosis,
and its overexpression results in centriole overduplication in cell lines which have
been arrested during S-phase (Suizu et al., 2006). Work done in mouse models has
shown that the centrosome amplification resulting from Pin1 overexpression can
lead to mammary hyperplasia and malignant tumour formation (Suizu et al., 2006).
Overexpression of YB-1, a Y-box binding protein has also been shown to lead to
centrosome amplification in breast cancer, this has been suggested to be through
cytokinesis failure through the mislocalistion of LIMK (Lim kinase) (Bergmann et
al., 2005; Davies et al., 2011). YB-1 is overexpressed in ~75% of human breast
carcinomas, and in mice its overexpression has been linked to the tumour initiation
of a variety of different histological types (Bergmann et al., 2005).
20
Chapter 1. Introduction
There are therefore a number of different mechanisms that have been associated with
the generation of supernumerary centrosomes within cancer, however the mechanism
in the majority of cancers has not yet fully been elucidated.
1.2.4 Effects of supernumerary centrosomes
Based on the detrimental effects arising from centrosome amplification, including cell
cycle arrest, as well as aneuploidy, it may be considered surprising that centrosome
amplification is so widely observed as a phenomenon within human tumours. It
is therefore expected that centrosome amplification must confer some advantage
to cancer cells that warrant tumours maintaining their population of cells with
supernumerary centrosomes, despite the potentially negative consequences. As
described previously, in vitro cell lines where supernumerary centrosomes have
been generated lose them over time, suggesting that mechanisms allowing for the
proliferation of cells with supernumerary centrosomes must be distinct from the
mechanisms which generate them in the first place (Ganem, Godinho and Pellman,
2009; Krzywicka-Racka and Sluder, 2011; Godinho et al., 2014). This effect may
be influenced by the role centrosome amplification plays in promoting aneuploidy
(Ganem, Godinho and Pellman, 2009; Silkworth et al., 2009), affecting asymmetric
cell division (Basto et al., 2008), altered cilia signalling (Mahjoub and Stearns, 2012),
or through developing invasive features, (Godinho et al., 2014) which are described
in more detail below (Figure 1.4). This may suggest that centrosome amplification
could arise in later stages of tumour development, after the cancer cells have adapted
to maintain their supernumerary centrosome population.
1.2.4.1 Centrosome amplification and tumourigenesis
Whilst observations within breast cancer have allowed the role of centrosome am-
plification in tumour initiation or development to be hypothesised, until recently
Boveri’s hypothesis that centrosome amplification can lead to tumourigenesis was
untested.
Transgenic mouse models were used to independently access the role of centrosome
amplification on tumourigenesis. Transient PLK4 overexpression, which has been
well characterised as leading to centrosome amplification by centriole overduplication


























































































































































































































































































































































Basto et al., 2008), was shown to accelerate tumour development in mice which
lacked p53 (Coelho et al., 2015; Serçin et al., 2015).
Serçin et al. showed that PLK4 overexpression in the absence of p53 leads to rapid
skin tumour formation (Serçin et al., 2015). They observed that the percentage of
cells containing supernumerary centrosomes decreased along with a reduction in
PLK4 mRNA levels after birth, and prior to the formation of tumours (Serçin et
al., 2015). Whilst centrosome amplification itself may have reduced, the aneuploidy
that had resulted from this transient amplification remained and skin tumours
were observed. Due to the loss of centrosome amplification over time, this further
supported that there must be an independent mechanism which allows cells to adapt
to maintain their supernumerary centrosome population. Conversely, another mouse
model of centrosome amplification showed that it does not cause tumour formation
in the brain, but instead results in microcephaly (Marthiens et al., 2013). This would
then suggest that centrosome amplification has different effects dependent on tissue
context.
Similar work done by Coelho et al. using inducible PLK4 overexpression showed that
centrosome amplification was able to advance lymphoma and sarcoma onset, as well
as hyperplasia of the skin and pancreas, again in the absence of p53 (Coelho et al.,
2015). Whilst p53-/- mice do succumb to early lymphomas, this work would suggest
an accelerated time course resulting from centrosome amplification (Coelho et al.,
2015). Taken together these studies would suggest that centrosome amplification
is not sufficient on its own to enable tumour development, but instead is able to
accelerate tumourigenesis upon p53 loss.
In contrast to these studies, use of a different mouse model to generate supernumerary
centrosomes, using ubiquitous PLK4 overexpression did not result in accelerated
tumourigenesis, even in the absence of p53 (Vitre et al., 2015). The reason for the
differences between the studies is not yet understood, however it is possible that
the difference between transient or ubiquitous PLK4 overexpression may account
for the variation. It is possible that ubiquitous PLK4 overexpression may impair
accelerated tumour formation, whereas transient PLK4 overexpression can increase
tumour progression (Coelho et al., 2015; Serçin et al., 2015; Vitre et al., 2015).
In support of this, more recent work by the same group that had showed no effect of
centrosome amplification on tumourigenesis, showed the reverse when supernumerary
centrosomes were generated by transient PLK4 overexpression (Levine et al., 2017).
They showed that inducing PLK4 overexpression resulted in centrosome amplifi-
cation as expected, although the higher PLK4 levels did not result in centrosome
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amplification in all tissues. Where centrosome amplification was observed they then
saw spontaneous tumour formation, these tumours did not expres p53 (Levine et al.,
2017). Whilst Boveri’s hypothesis that centrosome amplification remained largely
unanswered for 100 years, it is still yet to be fully understood if supernumerary
centrosomes are directly oncogenic, or are limited to accelerating tumourigenesis.
1.2.4.2 p53-mediated arrest
Centrosome amplification resulting from either cytokinesis failure (Andreassen et
al., 2001; Fujiwara et al., 2005), or from centriole over-duplication has been shown
to result in the stabilisation of p53, and consequently of p21, this leads to G1 cell
cycle arrest and therefore a reduction in cell proliferation (Holland et al., 2012). The
stabilisation of p53 was shown to be independent of the aneuploidy resulting from the
extra centrosomes (Holland et al., 2012). Loss of p53 was shown to rescue this cell
cycle affect, allowing for the continued proliferation of cells containing supernumerary
centrosomes (Holland et al., 2012). More recently, a screen was used to identify
the modulators involved in the p53 arrest in tetraploid cells (Ganem et al., 2014).
Ganem et al. identified LATS2 (large tumour suppressor kinase 2) as an important
factor for the maintenance of tetraploid cells, containing supernumerary centrosomes
during G1 (Ganem et al., 2014). They identified that cells containing supernumerary
centrosomes had increased levels of phosphorylated LATS2, which is involved in the
activation of the Hippo pathway which limits cell proliferation (Ganem et al., 2014).
Furthermore, decreased RhoA activity was also observed in cells with supernumerary
centrosomes, which can also lead to activation of the Hippo pathway (Ganem et al.,
2014; Godinho et al., 2014). The lower levels of RhoA in cells with supernumerary
centrosomes may arise from hyperactivation of Rac1 which has been to antagonise
RhoA (Sander et al., 1999), as a result of the increased microtubule nucleation arising
from the increase in centrosomes (Godinho et al., 2014). It is therefore possible that
loss or inhibition of the Hippo pathway may enable cells to adapt to maintain cell
proliferation in the presence of cells with supernumerary centrosomes, although this
hypothesis has not yet been tested in vivo.
More recent research has also shown that in cells where supernumerary centrosomes
are generated by either centrosome overduplication or cytokinesis failure can activate
the PIDDosome multiprotein complex, leading to Caspase-2 mediated cleavage of
MDM2, therefore resulting in p53 activation and p21-dependent cell cycle arrest (Fava
et al., 2017). This pathway has also been implicated in development, by controlling
the polyploidisation of hepatocytes by regulating p53 levels in liver organogenesis
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(Fava et al., 2017). This would suggest that the PIDDosome can help protect cells
against supernumerary centrosomes by activating p53 and cell cycle arrest.
1.2.4.3 Chromosomal instability
One of the most well established consequences of supernumerary centrosomes is
multipolar mitoses, which can then lead to poorly tolerated levels of aneuploidy (Kwon
et al., 2008; Ganem, Godinho and Pellman, 2009; Krzywicka-Racka and Sluder, 2011).
Whilst there is a correlation between centrosome amplification and chromosomal
instability (CIN), which is the persistent rate of chromosomal alterations, in tumours,
it is unlikely that this CIN arises from poorly tolerated multipolar divisions. Whilst
aneuploidy and CIN can help facilitate tumourigenesis, high levels can be detrimental
to tumour development (Weaver et al., 2007; Reviewed in: Holland and Cleveland,
2012). In support of this, multipolar divisions arising from centrosome amplification
in mouse neuronal cells lead to high levels of aneuploidy, and consequently undergo
apoptosis. This then results in brain developmental defects, with no observed tumour
formation (Marthiens et al., 2013).
Studies have shown that CIN can be driven by centrosome amplification, indepen-
dently of multipolar mitoses. Supernumerary centrosomes are able to form transient
multipolar spindles, prior to centrosome clustering, this can lead to the formation of
erroneous merotelic attachments (Figure 1.5) (Ganem, Godinho and Pellman, 2009;
Silkworth et al., 2009). Such erroneous attachments can comprise of microtubules
from both spindle poles attaching to a single kinetochore. These attachments can
then go unrepaired as the SAC (spindle assembly checkpoint) is satisfied when sister
kinetochores are under tension, and cannot distinguish if the attachments are correct
or not (Reviewed in: Wang et al., 2014). These merotelic attachments can then lead
to lagging chromosomes, and consequently aneuploid daughter cells (Cimini, 2008).
Therefore, centrosome amplification can lead to aneuploid cells without undergoing
multipolar divisions.
More recent work has implicated lagging chromosomes as having a broader role in
the generation of CIN observed in cancer. Lagging chromosomes can result in DNA
damage, where the chromosomes are caught at the cytokinetic furrow (Janssen et al.,
2011), or where they are segregated into micronuclei (Crasta et al., 2012; Hatch et
al., 2013). Micronuclei are formed where lagging acentric chromosomes or chromatid
fragments are incorporated into a smaller separate nucleus. Therefore aneuploidy,
CIN, DNA damage, and “chromothripsis” where a chromosome or chromosome
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arm is broken and reassembled randomly can occur as a result of supernumerary
centrosomes (Stephens et al., 2011; Crasta et al., 2012; Zhang et al., 2015). These
abnormalities can then drive genetic heterogeneity within tumours, which enable
tumours to evolve by gaining advantageous features (Thompson and Compton,
2011). Recent work in support of this model has shown that transient centrosome
amplification can lead to low levels of aneuploidy, which results in skin carcinomas
in p53 null mice (Serçin et al., 2015). Therefore whilst centrosome amplification can
play a role in tumourigenesis by CIN and aneuploidy, a balance has to be found
where these processes do not become detrimental to the tumour.
1.2.4.4 Asymmetric cell division
Work done in Drosophila where neuroblasts with supernumerary centrosomes were
transplanted into the abdomen of adult flies led to the formation of fast growing
tumours (Basto et al., 2008). What was particularly interesting was that these
tumours showed low levels of aneuploidy (Basto et al., 2008), and that aneuploidy
was not sufficient to drive tumour formation within this model system (Castellanos,
Dominguez and Gonzalez, 2008). It was observed that whilst these cells are able to
cluster their supernumerary centrosomes efficiently, and divide in a bipolar manner,
there were defects in asymmetric cell division (Basto et al., 2008; Castellanos,
Dominguez and Gonzalez, 2008). This is important in the cancer setting as defects
in asymmetric cell division can lead to expansion of the stem-cell compartment and
consequently promote tumour formation (Caussinus and Gonzalez, 2005).
One of the key characteristics of stem cells is their ability to “self-renew”, allowing
for the maintenance of the stem-cell compartment, whilst allowing for their daughter
Figure 1.5: Supernumerary centrosomes can give rise to merotelic attach-
ments and lagging chromosomes
Supernumerary centrosomes can promote merotelic attachments (when one kineto-
chore attaches to microtubules that emanate from opposite spindle poles) due to
altered spindle geometry. This merotely can then result in lagging chromosomes and
subsequently aneuploid daughter cells.
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cells to differentiate. Asymmetric cell division is an important mechanism to allow
stem cells to do this, with one daughter cell differentiating, whilst the other is
maintained as a stem-cell (Betschinger and Knoblich, 2004; Morrison and Kimble,
2006).
The mechanism linking supernumerary centrosomes to the observed defects in
asymmetric cell division are not fully understood, although different models have
been proposed (Godinho and Pellman, 2014). It is possible that the presence
of supernumerary centrosomes could disrupt the cues that are normally directed
by the mother and daughter centrosome during mitosis, as ordinarily the mother
and daughter centrosomes are differentiated into the daughter differentiating or
stem cell (Reina and Gonzalez, 2014). Alternatively, the astral microtubules which
link the centrosome to the cell cortex could become disorganised upon centrosome
amplification which may then result in defects in spindle orientation (Siller and Doe,
2009). Defects on spindle orientation were identified in murine epidermis cells with
supernumerary centrosomes which underwent asymmetric cell division; such defects
in spindle orientation were not observed in symmetric cell divisions (Kulukian et al.,
2015). However, such spindle mis-positioning was not observed in mouse neuronal
cells, suggesting that such defects may be cell type dependent (Kulukian et al., 2015).
Another suggestion is that supernumerary centrosomes may lead to a change in the
cellular localisation of polarity determinants (Caussinus and Gonzalez, 2005).
1.2.4.5 Cell polarity, invasion and microtubules
During interphase, the centrosomes play an important role in the organisation of
microtubules, which are important for cell shape, motility and polarity (Bettencourt-
Dias and Glover, 2007). It is therefore a possibility that independently of their role on
generating aneuploidy, supernumerary centrosomes may play a role in tumourigenesis
by impacting on the microtubule array, and thus altering the cellular organisation
and architecture. In support of this cells with supernumerary centrosomes and
consequently increased microtubule nucleation has been positively correlated, in-
dependently of aneuploidy with high histological grade breast cancers (Salisbury,
D’Assoro and Lingle, 2004).
During interphase, the supernumerary centrosomes are normally clustered together,
through a yet to be fully elucidated process. Just before mitosis these centrosomes
then separate allowing for the formation of the mitotic spindle. These clustered
supernumerary centrosomes are then able to recruit extra PCM, resulting in increased
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microtubule nucleation capacity (D’Assoro et al., 2002; Lingle et al., 2002).
Centrosomes play a fundamental role in directing cellular polarity, by directing the
organisation of microtubules which in turn control cell shape and motility (Tang and
Marshall, 2012). For instance, the centrosome localisation in neurons is important
for the site of axon growth (Tang and Marshall, 2012). Similarly, the position of the
centrosome has also been implicated in the formation of the immunological synapse
by controlling the proper secretion of lytic granules, and for positioning the Golgi at
the leading edge of cells undergoing directional migration (Tang and Marshall, 2012).
Whilst the impact of these clustered supernumerary centrosomes during interphase
on these processes has not been directly studied, it is possible that the increased
microtubule nucleation may lead to stronger cellular polarisation (Godinho and
Pellman, 2014).
There have been a number of different cellular processes that have been suggested
to be affected by the increase in microtubule nucleation arising from centrosome
amplification. Microtubules have been shown to regulate the disassembly of focal
adhesions, a process required for cell migration (Stehbens and Wittmann, 2012).
Microtubules have also been implicated in affecting Rho GTPases activity, which play
key roles in controlling cellular invasion (Reviewed in: Lozano, Betson and Braga,
2003). Indeed, depolymerisation of microtubules is thought to lead to the release of
GEF-H1 and p190RhoGEF, two guanine nucleotide exchange factors, resulting in
RhoA activation (Van Horck et al., 2001; Chang et al., 2007). Conversely microtubule
nucleation can lead to Rac1 activation, and consequently trigger Arp2/3-mediated
actin polymerisation which is required for the formation for lamellipodia and for
cellular migration (Waterman-Storer et al., 1999). Therefore, it was hypothesised
that supernumerary centrosomes and the resultant increase in microtubule nucleation
could affect cellular processes, including those involved in cellular migration, playing
a role in tumour formation independently of aneuploidy (Godinho and Pellman,
2014). More recent work has shown a direct link between centrosome amplification
and cellular invasion in three-dimensional culture models (Godinho et al., 2014).
Godinho et al. showed that supernumerary centrosomes, and the resultant increased
microtubule nucleation increased Rac1 activity which was then driving the invasive
phenotype observed (Godinho et al., 2014). This work further supports the link
between the positive correlation between centrosome amplification and more advanced
tumour grades, as well as the correlation with metastasis (Salisbury, D’Assoro and




Alongside a role in CIN and the changes affected by increased microtubule nucleation,
a role for supernumerary centrosomes in cellular signalling in tumour formation
has also been identified. Many signalling pathways make use of a scaffold to help
concentrate signalling molecules until the required threshold is reached to activate
downstream effectors, or to localise different signalling molecules into the same
localisation. The centrosome has been identified as such a signalling platform in
fission and budding yeasts (Reviewed in: Bardin and Amon, 2001; Jaspersen and
Winey, 2004).
In fission yeast, the centrosome (spindle pole body (SPB)) promotes the required
signalling which enabled entry into mitosis (Hagan and Grallert, 2013). Work by
Grallert et al. showed that the SPB is used as a platform, which through a positive
feedback loop involving Plo1, the PLK1 homologue, leads to increased cyclin B/Cdk1
activity resulting in mitotic entry (Grallert et al., 2013). Plo1 is recruited to the
SPB during late G2, by Fin1, which normally impairs Plo1 localisation to the SPB
(Grallert et al., 2013). This recruitment and activation of Plo1 is thought to enhance
Cdc25 and inhibit the Cdk1 inhibtor Wee1, resulting in the activation of cyclin
B/Cdk1 (Hagan, 2008). This control of mitotic entry by centrosomes is thought to
be widely conserved, being observed in C. elegans, Xenopus and also in humans
(Perez-Mongiovi et al., 2000; Jackman et al., 2003; Hachet, Canard and Gönczy,
2007; Portier et al., 2007).
Interestingly, use of proteomic analysis on purified centrosomes has identified a
number of different signalling molecules that associate with centrosomes, however,
some of these associations may only be transient (Andersen, Wilkinson and Mayor,
2003; Jakobsen et al., 2011). For example, the Wnt pathway, which has been shown
to contribute to tumour formation is inhibited by Diversin which has been shown
to localise to the centrosome (Kfoury et al., 2008; Itoh et al., 2009). Use of mutant
Diversin which was impaired from localising to centrosomes was no longer able to
impair Wnt signalling (Itoh et al., 2009).
The centrosome has also been observed to change size upon inhibition of the protea-
some, or increased levels of misfolded proteins (Wigley et al., 1999). It has therefore
been suggested that as well as acting as a signalling platform, the centrosome may
play a role in sequestering proteins from the cytoplasm, in situations such as pro-
teasome inhibition (Reviewed in: Godinho and Pellman, 2014). In support of this,
inhibition of the proteasome was shown to lead to increased phosphorylated Smad1,
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which localised to the centrosomes, this also resulted in the hypothesis that the
centrosome may play a role in proteasome-mediated degradation, although more
work needs to be done to elucidate this process (Fuentealba et al., 2007).
1.2.5 Coping with extra centrosomes
The ability for tumours to actively maintain their supernumerary centrosome popu-
lation suggests that there must be mechanisms for cells to adapt to the detrimental
effects that arise as a result. It was previously accepted, that the presence of supernu-
merary centrosomes would automatically result in multipolar cell divisions in mitosis.
However, work done in the early 1980s in the N1E-115 mouse neuroblastoma cell
line, where ~100% of cells contain supernumerary centrosomes, showed that there
is the capacity for centrosomes to remain within close proximity during mitosis, in
a process now referred to as “centrosome clustering” (Ring, Hubble and Kirschner,
1982). This centrosome clustering then enables the formation of a pseudo-bipolar
spindle, allowing for chromosome segregation into two daughter cells, with little to
no aneuploidy (Ring, Hubble and Kirschner, 1982; Brinkley, 2001; Basto et al., 2008;
Ganem, Godinho and Pellman, 2009).
Alternatively to centrosome clustering, other mechanisms have been identified which
enable cells to survive in the presence of supernumerary centrosomes including
centrosome loss, asymmetric segregation of supernumerary centrosomes during mitosis
and centrosome inactivation (Reviewed in: Godinho, Kwon and Pellman, 2009).
However, within the cancer setting, only centrosome clustering has been described
so far (Figure 1.6).
1.2.5.1 Centrosome inactivation
Whilst centrosome clustering is the most widely characterised and understood process
for cells to survive in the presence of supernumerary centrosomes, centrosome inacti-
vation has also been reported as a mechanism enabling cells to form bipolar spindles
and subsequently divide into two daughter cells. Work done in Drosophila neuroblasts,
where centrosome amplification was driven by SAK/PLK4 overexpression showed
that these cells were able to undergo bipolar cell divisions. Whilst centrosome cluster-
ing was observed in the majority of spindles, a number of un-clustered centrosomes
were identified, which showed reduced PCM levels, and a reduction in microtubule






































































































































































































































































































































































































































































































































un-clustered centrosomes are unable to nucleate microtubules and are therefore
“inactivated”, so that they do not contribute to the mitotic spindle. A similar process
had previously been described by Iwao et al. where they showed that a gradient of
γ-tubulin can result in centrosome inactivation in polyspermic newt eggs, to ensure
that only the centrosome that is associates with the principal sperm nucleus can
facilitate the formation of mitotic spindle (Iwao et al., 2002). More recent work has
started to elucidate the mechanisms involved in the inactivation of centrosomes. In
Drosophila where centrosome amplification was driven by SAK/PLK4 overexpression
it was observed that moesin, a member of the ezrin/radixin/moesin (ERM) protein
family was upregulated and localised to the centrosomes in the epithelial wing disks,
which inhibited centrosome inactivation leading to multipolar cell divisions. However,
in neuroblasts with supernumerary centrosomes, this upregulation and localisation
of moesin was not observed, and centrosome inactivation occurred (Sabino et al.,
2015). To further test the role of moesin on impairing centrosome inactivation, a
hypomorphic moesin mutant was used, resulting in a reduction in the centrosomin
recruitment, a PCM protein at the centrosome (Sabino et al., 2015). This evidence
therefore suggests that PCM regulation by moesin impairs centrosome inactivation.
Furthermore, this work suggests that different cell types can cope with centrosome
amplification differently, as observed by the differences between the epithelial wing
disks and the neuroblasts. Centrosome inactivation has not yet been reported within
human cells.
1.2.5.2 Centrosome loss
During oogenesis, centrosome removal is used to remove/destroy the maternal cen-
trosome, this ensures that after fertilisation there are not multiple centrosomes, with
only the spermatic centrosome remaining (Manandhar, Schatten and Sutovsky, 2005).
It is thought that a reduction in PCM, and the resultant decrease in microtubule
nucleation could lead to the disintegration of the maternal centrosome (Mikeladze-
Dvali et al., 2012). This is supported by recent work in Drosophila Melanogaster
which showed that down-regulation of PCM in the female germ line during oogenesis,
results in centriole loss (Pimenta-Marques et al., 2016). Whilst this exact process has
not been fully understood, it has been shown that in C. elegans, this process requires
Cki-2, a cyclin-dependent kinase inhibitor. In oocytes, depleted of Cki-2, it was
observed that the maternal centriole is not destroyed, leading to multipolar zygotic
cell divisions (Kim and Roy, 2006). More recent work by Mikeladze-Dvali et al. also
in C. elegans showed that depletion of the helicase CHG-1 resulted in a delay in the
loss of the maternal centrosome, potentially by impairing the degradation of specific
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mRNAs that are involved in the centrosome removal mechanism (Mikeladze-Dvali
et al., 2012). Work done in Dictyoistelium showed that some cells are also able to
directly extrude their centrosomes (Gräf et al., 2003). It has also been hypothesised
that cells may be able to utilise asymmetric cell division, to allow one daughter cell
to have one centrosome, enabling it to successfully proliferate during future divisions,
whilst the other daughter cell inherits the remaining supernumerary centrosomes
(Chiba et al., 2000). However, similarly to centrosome inactivation, centrosome loss
has not been observed within human cells, so is unlikely to be an important process
for enabling the survival of cancer cells with supernumerary centrosomes.
1.2.5.3 Centrosome clustering
Centrosome clustering is the most well-characterised mechanism of cells coping with
supernumerary centrosomes. Centrosome clustering is where a cell is able to bring the
supernumerary centrosomes together at each pole during mitosis, forming a pseudo-
bipolar spindle that leads to two daughter cells. This process was first identified
in the murine cell line N1E-115, where ~100% of cells contain extra centrosomes,
since then cells containing a high proportion of cells with centrosome amplification
(>30%) have been shown to be efficient at centrosome clustering (Ring, Hubble and
Kirschner, 1982; Brinkley, 2001; Quintyne et al., 2005; Kwon et al., 2008; Ganem,
Godinho and Pellman, 2009).
Two genome-wide screens were carried out, one in Drosophila S2 cells and the other
in the human oral squamous carcinoma cell line UPCI:SCC114, to identify key
proteins involved in the centrosome clustering process (Kwon et al., 2008; Leber et
al., 2010). The screens identified four independent mechanisms as being important
for centrosome clustering: the spindle assembly checkpoint (SAC) and chromosomal
passenger complex CPC, kinetochore-microtubule tension, the actin cytoskeleton,
and microtubule associated proteins (MAPs) (Kwon et al., 2008; Leber et al., 2010).
Spindle assembly checkpoint (SAC) and chromosomal passenger complex
(CPC)
The SAC is important in delaying anaphase onset until each duplicated chromosome
is properly attached to the mitotic spindle (Weaver and Cleveland, 2005; Nezi and
Musacchio, 2009; Maresca and Salmon, 2010).
In a normal mitotic cell, containing two centrosomes, when all of the kinetochore-
microtubule attachments are stabilised, this satisfies the SAC, allowing for the onset
of anaphase and progression through mitosis (Lara-Gonzalez, Westhorpe and Taylor,
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2012). However, in cells with supernumerary centrosomes, these attachments take
longer to form and stabilise due to multipolar intermediates, leading to a SAC-
dependent delay in mitosis, giving time for the centrosomes to cluster (Basto et
al., 2008; Kwon et al., 2008; Yang et al., 2008). Loss of Mad2, a component of the
SAC was observed to prevent efficient centrosome clustering (Basto et al., 2008;
Kwon et al., 2008; Yang et al., 2008), resulting in multipolar spindles and decreased
viability in Drosophila with supernumerary centrosomes (Basto et al., 2008). Work
done by Kwon et al. showed that the treatment of Mad2 depleted cells with the
proteasome inhibitor MG132, which causes a delay in anaphase onset, was able to
rescue the centrosome clustering phenotype (Kwon et al., 2008). This would suggest
that it is the delay in anaphase onset caused by the SAC, giving sufficient time for
centrosome clustering that is important in centrosome clustering, rather than the
SAC itself. This prolonged time in mitosis in cells with supernumerary centrosomes
due to the SAC could partially explain the increased mitotic index observed in
tumours (Lambert, 1913). In support of this hypothesis, it was observed that the
transformed human fibroblast cell line SV40 have higher levels of tetraploidy and
centrosome amplification, alongside an increased mitotic index, compared to their
non-transformed equivalents (Levine et al., 1991). However, this delay in mitosis in
cells with extra centrosomes does not occur in all cells. The binucleated rat kangaroo
kidney epithelial cell line Ptk2 which has centrosome amplification, divides without
mitotic delay. However, these cell lines are also unable to cluster their centrosomes
efficiently, undergoing multipolar cell divisions (Sluder et al., 1997). This further
supports that delaying SAC inactivation, and delaying anaphase onset might be an
important process to avoid multipolarity.
A role for the CPC has also been identified in facilitating centrosome clustering,
alongside the SAC (Leber et al., 2010). The CPC plays a role in identifying and
correcting erroneous chromosome-microtubule attachments that are not bi-orientated,
these include merotely and syntely, where a chromatid may be attached to both
spindle poles, or two sister chromatids attached to the same spindle pole (Nezi and
Musacchio, 2009). The knockdown of the CPC components in the USCI:SCC114
cancer cell line, including AuroraB, borealin, INCENP and survivin, resulted in
impaired centrosome clustering and multipolar cell divisions (Leber et al. 2010). It
is possible that CPC components facilitate clustering through the destabilisation of
syntelic and merotelic attachments that will elicit a SAC response resulting in an
anaphase delay that promotes centrosome clustering.
Kinetochore/Microtubule tension
Tension produced by the kinetochore-microtubule interface has been identified to
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play a role in maintaining centrosome clustering at the spindles poles. Knockdown
of components of the Ndc80 complex, including SPC24, SPC25 or HEC1 which
are involved in the stabilisation of kinetochore-microtubule attachments (Ciferri,
Musacchio and Petrovic, 2007), were observed to result in defects in centrosome
clustering (Leber et al., 2010). The same effect was observed upon the depletion of
proteins involved in generating kinetochore tension including SGOL1, CENPT and
sororin (Leber et al., 2010). Similarly, hepatoma up-regulated protein HURP was
identified as being involved in centrosome clustering (Breuer et al., 2010). HURP has
been shown to act during mitosis as a kinetochore-microtubule stabilising factor (Silljé
et al., 2006; Wong and Fang, 2006). Even in the absence of centrosome amplification,
forces acting on the spindle pole are required to prevent multipolarity by opposing the
traction forces produced during chromosome congression in prometaphase (Logarinho
et al. 2012). It is therefore possible that clustered supernumerary centrosomes could
impact the spindle forces at the spindle poles, therefore resulting in cells with
supernumerary centrosomes being more reliant on correct kinetochore-microtubule
tension to maintain intact spindle poles (Figure 1.6).
Actin Cytoskeleton
The actin cytoskeleton has been shown to be integral during mitosis in translating
cortical cues via the formation of retraction fibres (Mitchison 1992; Théry et al.
2005). Work using micro-contact printing by Théry et al. showed that in mitotic
cell rounding, the actin-rich retraction fibres, linked to the sites of substrate adhe-
sion, remain attached, working to translate the spatial imprint to the cell. Astral
microtubule interaction with the cortical cues directed by these retraction fibres was
observed to be involved in controlling spindle positioning (Théry et al., 2005). These
cues also dictate whether supernumerary centrosomes are able to cluster or not.
Interestingly, cells where a “bipolar” distribution of retraction fibres was maintained
upon cell rounding, were capable of clustering their supernumerary centrosomes
efficiently, compared to those that had a more distributed pattern (Kwon et al.,
2008). Astral microtubules were shown to be important in translating these cues to
allow centrosomes to cluster (Kwon et al., 2008).
More recent work has been done to try and understand the mechanisms by which
astral microtubules are able to respond to these cortical cues. Pools of subcortical
actin assemble near the retraction fibres, these were then shown to be important for
the pulling forces on the astral microtubules, enabling the position of the centrosomes
near the retraction fibres (Fink et al., 2011). Subsequently, Kwon et al. showed that
the unconventional myosin, Myo10, which binds to actin and to microtubules, is
essential for the localisation of centrosomes towards the actin pools and retraction
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fibres, this process is achieved through the regulation of the microtubule dynamics
and end-on cortical-microtubule interactions (Kwon et al. 2015). Previous work had
shown the depletion of Myo10, which was observed to prevent centrosome clustering
(Kwon et al., 2008) made cells unresponsive to the cell adhesion footprint (Kwon et
al., 2015).
It is still not fully understood how this cell adhesion can then direct the cortical
cues through mitosis. However, integrin-linked kinase ILK, which controls integrin-
mediated cell adhesion localises to centrosomes and to focal adhesions, and has
been to shown to have a role in centrosome clustering through ch-TOG and TACC3,
which are two proteins involved at the spindle poles in regulating the minus end of
microtubules (Fielding et al., 2008). It is therefore possible, that there is a role in the
control of centrosome clustering for cell adhesion proteins. However, further work is
required to understand the link between adhesion proteins, the actin cytoskeleton
and the cortical cues that control this process.
Work by Kwon et al. showed that the inhibition of cortical contractility prevents
efficient centrosome clustering, suggesting that the actin cytoskeleton may be able to
facilitate centrosome clustering through controlling cortical contractility (Kwon et
al., 2008). Both Myosin II and actin are important for the separation of centrosomes
during centrosome duplication, by providing the required cortical forces (Rosenblatt
et al., 2004). Centrosomal separation during mitosis is aided my astral microtubules
inhibiting cortical myosin II contractility, this results in asymmetrical cellular con-
tractility, driving the centrosomes to opposing sides of the cell (Rosenblatt et al.,
2004). However, whilst this process explains separation of mitotic cells with two
centrosomes to opposing poles, it is unclear how this would then affect cells with
multiple centrosomes.
Microtubule associated proteins
Cells with supernumerary centrosomes have been shown to depend on microtubule
motors and associated proteins, which are important in the organisation of the
mitotic spindle, in order to cluster their extra centrosomes (Godinho, Kwon and
Pellman, 2009; Krämer, Maier and Bartek, 2011; Reviewed in: Marthiens, Piel and
Basto, 2012). The first microtubule proteins suggested to be involved in centrosome
clustering were dynein, a minus-end direct motor, and NuMA, a mitotic apparatus
protein involved in the mitotic spindle (Quintyne et al. 2005). NuMA has been
shown in human cells to control the centrosomal localisation of dynein, which is
then important for efficient centrosome clustering. Work done in cancer cells with
supernumerary centrosomes, where the level of NuMA was increased resulted in the
36
Chapter 1. Introduction
dissociation of dynein from the spindle poles, this impaired centrosome clustering
leading to multipolar mitoses (Quintyne et al. 2005). Titration of NuMA levels
restored the localisation of dynein, rescuing the centrosome clustering (Quintyne
et al. 2005). These data suggest a combined role for both NuMA and dynein in
centrosome clustering.
The essential E3 ligase the anaphase-promoting complex/cyclosome (APC/C) is
involved in proteasome-mediated protein degradation which is required for the
regulation of mitotic progression (Pines 2011). When APC/C is bound to CDH1,
its co-activator, it regulates the metaphase to anaphase transition, and has also
been shown to facilitate centrosome clustering (Drosopoulos et al. 2014). Eg5, a
microtubule motor and a substrate of APC/C-CDH1 is stabilised after APC/C-
CDH1 inhibition, this results in imbalance of forces within the spindle, which impairs
efficient centrosome clustering (Drosopoulos et al., 2014).
Another minus-end directed motor HSET/KIFC1 (nonclaret disjunctional, Ncd, in
Drosophila), a member of the kinesin-14 protein family has also been shown to be
involved in centrosome clustering (Kwon et al. 2008). Depletion of HSET/KIFC1 by
siRNA in cells with supernumerary centrosomes resulted in an increase in multipolar
cell divisions, but not in cells with a normal complement of centrosomes, suggesting
that HSET/KIFC1 has a role specific to centrosome clustering (Kwon et al. 2008).
Similarly, in flies, the loss of Ncd decreases the survival of flies with supernumerary
centrosomes, but does not adversely affect wild type flies, further supporting a
specific role for HSET/KIFC1 in centrosome clustering (Endow & Komma 1998;
Basto et al. 2008). This specificity of HSET/KIFC1 makes it a promising drug target
to drive multipolarity and cell death in cancer cells with centrosome amplification.
1.2.6 Therapeutic advantage of centrosome amplification
Cells with supernumerary centrosomes have unique requirements in order to survive,
such as centrosome clustering. Impairment of centrosome clustering results in
multipolar mitoses, leading to high levels of aneuploidy and subsequently cell death,
or cell cycle arrest (Rebacz et al., 2007; Kwon et al., 2008; Ganem, Godinho
and Pellman, 2009; Karna et al., 2011). This therefore makes the impairment of
centrosome clustering an attractive therapeutic approach for treating cancer cells
with centrosome amplification.
A number of drugs have been suggested to impair centrosome clustering. Griseofulvin,
a nontoxic antifungal, as well as impairing mitosis has been observed to result in un-
37
Chapter 1. Introduction
clustered supernumerary centrosomes in a number of different human cancer cell lines,
killing tumour cells at concentrations which are non-toxic to normal cells (Rebacz
et al. 2007). Furthermore, in a range of 2’-subsituted derivatives of griseofulvin,
the compound which was the most efficient at impairing centrosome clustering also
had the highest potency, however further work is required to fully understand the
link between the un-clustered centrosomes and the observed cell death (Raab et al.,
2012).
Phenanthrene-derived poly-ADP-ribose polymerase (PARP) inhibitors have also
been identified as a set of compounds which have the potential as being used to
impair centrosome clustering (Castiel et al., 2011). The normal role of PARP-1 is to
identify DNA damage and initiate base-excision repair, as well as activating DNA
damage checkpoints or cell-death via apoptosis. However, a number of PARP related
proteins have also been identified as being important for centrosome clustering (Tong
et al., 2007; Kwon et al., 2008). Tumours with centrosome amplification which
were treated with PJ-34, a PARP-1 inhibitor showed increased multipolar spindles,
and subsequently mitotic catastrophe and cell death, supporting a role for PARP
inhibitors in impairing centrosome clustering (Castiel et al. 2013). Non-transformed
cells also treated with PJ-34 showed no defects in their spindle morphology, and cell
viability was maintained, supporting a supernumerary centrosome specific mechanism
for the cell death observed in the tumours (Pannu et al., 2014). Furthermore, a more
recent study has shown that PJ-34 can supress HSET/KIFC1 expression, this could
then explain the impairment of the centrosome clustering observed in the tumour
samples, as HSET/KIFC1 is required for centrosome clustering (Li et al., 2015).
The identification of key proteins in the centrosome clustering process such as
HSET/KIFC1, which do not appear to have essential functions in cells with normal
centrosome number, make them an attractive therapeutic target. For example,
recently developed HSET/KIFC1 inhibitors have been shown to lead to multipolar
mitoses due to the impairment of centrosome clustering in cells with extra centrosomes,
but no change on mitosis was observed in cells with normal centrosome number (Wu
et al., 2013). Similarly, CW069, an alternative allosteric HSET/KIFC1 inhibitor
has been shown to result in multipolar cell divisions in a panel of cell lines with
centrosome amplification, resulting in impaired viability. However, in the MCF-7 cell
line, which has low levels of centrosome amplification, whilst the spindle formation was
unimpaired as expected with CW069 treatment, there was still reported impairment
in cell growth, suggesting that this drug may have some toxicity independently of its
role in inhibiting centrosome clustering (Watts et al., 2013; Wu et al., 2013; Reviewed
in: Bhakta-Guha et al., 2015).
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Therefore, whilst targeting key components of the centrosome clustering mechanisms
is an attractive therapeutic strategy, more work needs to be done in developing more
specific inhibitors, which are then less toxic to normal cells. The effectiveness of
these drugs in impairing centrosome clustering and subsequently cell viability of cells
with supernumerary centrosomes in vivo is still unclear, and more work is needed to
properly assess the validity of this approach as a beneficial cancer treatment.
1.3 Cell-cell adhesion
Epithelial tissues play a role in separating different compartments in the body by
acting as selective barriers. This compartmentalisation is required to allow distinct
organs and tissues to perform their specific functions, whilst being able to receive
signals from the external environment. Epithelial cells adhere to one another to form
the epithelial barrier which is able to regulate the movement of different fluids, solutes
and molecules (Hartsock and Nelson, 2008; Van Itallie and Anderson, 2014). This
cell-cell adhesion is composed of tight junctions (TJs) and adherens junctions (AJs)
(Figure 1.7). Both types of junction are connected to the actomyosin cytoskeleton,
and are often impaired in cancer.
Figure 1.7: Epithelial cell-cell adhesion
Epithelial cells adhere to one another establishing an epithelial barrier through
tight junctions (involving claudins and occuldins), and through adherens junctions
(involving E-cadherin). The epithelial barrier allows for a regulated and selective




The organisation of cells into tissues is fundamental to the development of multicellu-
lar organisms. This organisation and maintenance of tissues is mediated by a number
of cell-membrane localised receptors and ligands localised within the extracellular
matrix. Cadherins are a large family of cell-membrane localised receptors, which
play a key role in the adhesion of cells within tissues in a Ca2+-dependent manner
(Gumbiner, 2005; Halbleib and Nelson, 2006; Lien, Klezovitch and Vasioukhin, 2006).
There are at least five major subfamilies of cadherins, the most prominent being the
classical cadherins consisting of epithelial (E-), neuronal (N-) and vascular endothelial
(VE-). All of the classical cadherins have a conserved cytoplasmic tail, which is
involved in binding to the actin cytoskeleton and to catenins (Biswas and Zaidel-Bar,
2017).
E-cadherin is a multi-domain glycosylated protein of 120kDa, containing an extra-
cellular domain including five cadherin repeats (ECs), a trans-membrane domain,
and a smaller intracellular domain (Pinho et al., 2011; Reviewed in: Brasch et al.,
2012). The ECs are each ~110 amino acids long and form an immunoglobulin-like
structure, this structure then changes conformation after Ca2+ binding between each
of the EC regions (Pokutta et al., 1994; Nagar et al., 1996; Pertz et al., 1999). The
transmembrane domain contains a leucine-zipper motif, which has been suggested to
be involved in the oligomerisation of E-cadherin, and may facilitate interaction with
other trans-membrane proteins (Bignold, Coghlan and Jersmann, 2006; Coon et al.,
2015; Biswas and Zaidel-Bar, 2017). The shorter and highly conserved intracellular
domain is ~150 amino acids in length, and is able to bind adaptor proteins including
β-catenin and p120, as well as binding to the actin cytoskeleton (McEwen, Escobar
and Gottardi, 2012; Zaidel-Bar, 2013; Guo et al., 2014). This ability to bind to a
number of different effectors allows E-cadherin to not only have a role in cellular
adhesion, but also to control a range of signalling pathways.
E-cadherin plays a fundamental role in adhering epithelial cells to each other. They
are normally concentrated at adherens junctions, which are specialised structures
allowing for cell-cell adhesion between adjoining cells with an intermembrane space
of ~15-30nm (Meng and Takeichi, 2009; Reviewed in: Brasch et al., 2012). At these
junctions, E-cadherin forms bonds between the ectodomains of opposing E-cadherin
units from the two adjoining cells, within the intermembrane space, meanwhile the
cytoplasmic domain can bind to β-catenin, linking E-cadherin to the cytoskeleton, as
well as to p120 which controls the cadherin turnover and facilitates actin assembly
(Reynolds and Carnahan, 2004; Shapiro and Weis, 2009; Yonemura, 2011) (Figure
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Figure 1.8: E-cadherin at the adherens junctions
E-cadherin proteins from two adjoining cells may form Ca2+-dependent bonds within
their extracellular domains, linking the two cells together. The intracellular domain
of E-cadherin can interact with the actin cytoskeleton through β- and α-catenins,
E-cadherin can also form bonds with p190. These cadherin-catenin complexes then
form the adherens junctions.
1.8).
1.3.1.1 E-cadherin and centrosome positioning
Alongside a role in cell adhesion, E-cadherin has been implicated in controlling
centrosome and nucleus position, as well as cellular polarisation through the regulation
of cellular interactions and control of the cytoskeleton (Dupin, Camand and Etienne-
Manneville, 2009; Inaba et al., 2010). Work done by Dupin et al. in rat astrocytes
plated on micropatterns showed that individual cells, or cells surrounded in a
monolayer, showed a randomly localised nucleus and centrosomes (Dupin, Camand
and Etienne-Manneville, 2009). In contrast to this, cells with neighbouring cells on
a few sides showed polarised localisation of their nuclei and centrosomes towards the
cell contacts. This then suggested a role for cell-cell adhesions in controlling nuclei
and centrosome positioning. To further test this they depleted calcium, therefore
impairing cadherin-dependent adhesion for 3 hours, and showed that this polarisation
of nuclei position and of the centrosomes was also impaired. This data therefore
suggested that cadherins, including E-cadherin are then important for controlling
the cellular polarity of the nucleus and centrosomes (Dupin, Camand and Etienne-
Manneville, 2009). This was supported by work done in Drosophila by Inaba et al.
which showed that E-cadherin is important for mediating the maintenance of the
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germline stem cell (GSC) population by controlling asymmetric cell division (Inaba
et al., 2010). They showed that within GSCs the centrosomes and spindle orientate
to the adherens junctions, they hypothesised that these adherens junctions can then
provide the required polarity cues to enable the required asymmetric cell division,
maintaining the stem cell population (Inaba et al., 2010).
More recent work has been undertaken to try and elucidate the role of E-cadherin on
this cellular polarisation and the orientation of cellular division. Work by Gloerich et
al. showed that the control of spindle orientation by E-cadherin is mediated by the
evolutionarily conserved LGN/NuMA complex, which is involved in the regulation
of cortical attachments of astral microtubules (Gloerich et al., 2017). They showed
that LGN can directly bind to the cytosolic tail of E-cadherin. Upon mitotic entry,
NuMA is released from the nucleus and displaces LGN from E-cadherin forming
the LGN/NuMA complex. This complex can then facilitate the stabilisation of
astral microtubules associations at the cell cortex, which in turn orientates the
mitotic spindle. Therefore E-cadherin is important in mediating the localisation of
the LGN/NuMA complex at the cell-cell contacts which in turn dictates spindle
orientation (Gloerich et al., 2017).
1.3.1.2 E-cadherin in cancer
It has been well established that epithelial tumours lose E-cadherin either partially
or completely as they become more malignant (Strumane, Berx and Van Roy, 2004;
Van Roy and Berx, 2008). There is also evidence that E-cadherin plays a role in
being anti-invasive and anti-metastatic (Frixen et al., 1991; Vleminckx et al., 1991;
Perl et al., 1998). A number of different mechanisms have been identified for the loss
of E-cadherin in tumours including mutations, epigenetic silencing, and cadherin
switching (Van Roy and Berx, 2008).
The first evidence that loss of E-cadherin may play a role in tumour development
came from studies that showed regular loss of heterozygosity of chromosome 16q21-22
in a number of different cancer types (Reviewed in: Strumane, Berx and Van Roy,
2004). The 16q22.1 region was identified as being the site of the CDH1 gene, which
encodes for E-cadherin (Berx et al., 1995). Further work identified that this loss
of heterozygosity of 16q is frequently observed in breast cancer, occurring in ~50%
of ductal carcinomas (Cleton-Jansen et al., 2001) and more so in lobular breast
carcinomas (Berx et al., 1996).
The first described E-cadherin inactivating mutations were observed in diffuse gastric
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cancer, where somatic mutations were regularly observed to result in a skipping of
exons 7 and 9, resulting in in-frame deletions (Becker et al., 1993). Comparatively,
such observations have not been seen in lobular breast carcinomas where inactivating
mutations are found more broadly across the gene rather than at a particular
localisation (Machado et al., 2001). These mutations then result in out-of-frame
mutations which are suggested to lead to truncated E-cadherin fragments, or no
expression of the protein at all (Machado et al., 2001). It was also reported that
alongside these mutations promoter methylation of the CDH1 gene was also increased,
further resulting in loss of E-cadherin (Berx et al., 1996, 1998). In some cases of
lobular breast carcinomas, germline mutations have been observed across the CDH1
gene (Caldas et al., 1999; Pharoah, Guilford and Caldas, 2001; Brooks-Wilson et al.,
2004; Suriano et al., 2005; Hansford et al., 2015). In such cases the lifetime risk of
those with such mutations of getting breast cancer is 39% (Carneiro et al., 2008).
Hypermethylation of the CDH1 promoter has also been implicated in the loss of
E-cadherin expression during tumour progression. Within the 5’ proximal promoter
region of CDH1 a large CpG island has been identified as being regularly hyperme-
thylated in a number of different cancers, leading to a loss of E-cadherin protein
expression (Berx et al., 1995; Graff et al., 1995; Yoshiura et al., 1995; Chang et
al., 2002; Kanazawa et al., 2002). Similarly, CDH1 CpG island methylation is ob-
served to increase during tumour progression within both breast and hepatocellular
carcinomas (Kanai et al., 2000; Nass et al., 2000). Other repressors of E-cadherin
transcription have also been associated with tumour progression. Increased Snail
expression is strongly associated with loss of E-cadherin in ductal breast carcinomas,
high-grade breast carcinomas and lymph node tumours (Cheng et al., 2001; Blanco
et al., 2002). A number of transcription factors have also been identified such as
Twist, and deltaEF1/ZEB1 as resulting in loss of E-cadherin (Guaita et al., 2002;
Yang et al., 2004; Eger et al., 2005; Martin et al., 2005; Spaderna et al., 2008; Yu et
al., 2010).
Whilst genetic mutations, and epigenetic silencing are the most well established
mechanisms for E-cadherin silencing in tumour development, other mechanisms have
been identified which may play a role in impairing the normal function of E-cadherin
(Reviewed in: Van Roy and Berx, 2008). During the normal life-cycle of E-cadherin
it is recycled to new sites of cell-cell adhesion by endocytosis, it has been hypothe-
sised that impairment of this process could then lead to its premature degradation
(Reviewed in: Van Roy and Berx, 2008). Activation of oncogenes including c-Met,
Src and EGFR have been shown to result in the increased phosphorylation of the
tyrosine residues in the cytoplasmic tail of E-cadherin, this results in the recruitment
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of Hakai, an E3-ubiquitin ligase, leading to ubiquitin-dependent degradation of E-
cadherin (Fujita et al., 2002; Shen et al., 2008). A similar role in inducing E-cadherin
degradation has also been implicated for MDM2, another E3-ubiquitin ligase (Yang
et al., 2006). Upregulation of enzymes which can directly cleave E-cadherin have also
been suggested to potentially play a role in E-cadherin silencing in cancer progression
such as some of the matrix metalloproteases as well as calpain (Steinhusen et al.,
2001; Rios-Doria et al., 2003; De Wever et al., 2007; Reviewed in: Van Roy and Berx,
2008).
Loss of E-cadherin expression can also be induced by expression of mesenchymal
cadherins, such as N-cadherin during processes such as epithelial to mesenchymal
transition (EMT). This process of change of cadherin expression is termed “cadherin
switching” (Hazan et al., 2004; Wheelock et al., 2008). Overexpression of N-cadherin
can also result in increased invasion and metastatic potential of cells when injected
into nude mice, even in the presence of E-cadherin (Hazan et al., 2004; Wheelock et
al., 2008).
1.4 Discoidin Domain Receptor 1
One of the proteins that E-cadherin can signal downstream through is DDR1 (Dis-
coidin Domain Receptor 1). There are two discoidin domain receptor DDR proteins,
DDR1 and DDR2 which are part of a larger family of tyrosine kinase receptors.
DDR1 was first described in Dictyostelium discoideum and was shown to mediate cell
aggregation (Breuer and Siu, 1981; Springer, Cooper and Barondes, 1984). DDR2
was then identified by homology cloning based on their catalytic kinase domains
(Shrivastava et al., 1997). Both DDR1 and DDR2 were then classified as orphan
receptors, until further work then identified that they were actually activated by
collagen (Shrivastava et al., 1997; Vogel et al., 1997). DDR1 is activated by collagen
types I, IV, V, VI and VII, whereas DDR2 is only activated by fibrillary collagens
such as collagen types I, III and X (Shrivastava et al., 1997; Vogel et al., 1997;
Leitinger and Kwan, 2006).
Structurally, both receptors are comprised of four different regions. An extracellular
region containing both a discoidin domain, and a discoidin-like domain which are then
able to bind to collagen (Rammal et al., 2016). The juxta-membrane region in DDR1
has an extracellular region of ~50 amino acids, followed by a larger cytosolic juxta-
membrane region of ~170 amino acids (Leitinger, 2011; Carafoli and Hohenester,
2013). The cytosolic region is then much larger of ~300 amino acids and is the site
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of the catalytic tyrosine kinase domain which after phosphorylation then activates
downstream signalling (Leitinger, 2011; Carafoli and Hohenester, 2013).
There are five different isoforms of DDR1 in humans – DDR1a, b, c, d and e, which
have been described based on differences in their phosphorylation, glycosylation,
function, expression patterns and their protein interactions (Vogel, 1999; Carafoli
and Hohenester, 2013). DDR1a, b and c are all kinase active, whereas DDR1d and e
due to frame shift truncations are kinase deficient (Alves et al., 2001). DDR1a and
b are the most abundant isoforms, however it can be hard to distinguish isoforms by
normal protein analysis as they are all of a similar size, with the exception of DDR1d
which is much smaller (DDR1a – 97kDa, b – 101kDa, c – 102kDa, d – 56kDa, and e
– 86 kDa) (Alves et al., 1995, 2001; Rammal et al., 2016).
The DDR dimerization, phosphorylation and activation upon binding to collagen
are then important in several different cellular processes, including proliferation,
migration and adhesion (Rammal et al., 2016). The phosphorylation of the tyrosine
residues upon collagen activation has been shown to recruit different Src homology
2 (SH2) and phosphotyrosine binding domain containing proteins, and is thought
to autophosphorylate other tyrosines in the juxta-membrane region allowing for
downstream signalling (Ikeda et al., 2002; Carafoli and Hohenester, 2013). Whilst
work has been done to try and understand the role of the different DDRs and
isoforms, due to the range of expression, and the activation by different collagen
types more work is needed to fully understand these processes and the role of DDRs
in cellular behaviour.
1.4.1 DDR1 and E-cadherin
Alongside DDR1’s role upon activation by collagen, it has also been implicated in
regulating cortical contractility at adherens junctions, in a mechanism independent
of collagen activation, and of its tyrosine kinase activity (Hidalgo-Carcedo et al.,
2011).
Work by Hidalgo-Carcedo et al. showed that E-cadherin is able to recruit DDR1 to
the cell membrane, where through a signalling cascade DDR1 leads to an impairment
of the phosphorylation of myosin light chain (p-MLC), resulting in a reduction in
cortical contractility at the adherens junctions. This work was done in interphase
cells, in a model for collective cell migration. They hypothesised that this reduction
in cortical contractility at the adherens junctions was required for the maintenance
of adherens junctions, enabling cells to remain together during migration rather
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Figure 1.9: DDR1 structure
Schematic diagram of the DDR1 protein including the extracellular discoiding domain,
transmembrane domain, and intracellular juxtamembrane and catalytic domains.
than moving off as individual cells. They suggested a mechanism where E-cadherin
recruits DDR1 to the membrane at the adherens junctions, then subsequently DDR1,
through an unknown mechanism recruits Par3 and Par6. This recruitment of the Par
proteins then controls the localisation of RhoE/p190RhoGAP which subsequently
antagonises RhoA/ROCK-1. RhoA/ROCK-1 normally lead to the phosphorylation
of MLC, therefore by activating RhoE/p190RhoGAP this phosphorylation process
is inhibited (Figure 1.10) (Hidalgo-Carcedo et al., 2011). The full mechanism of
this control was not fully elucidated, and the mechanism that leads DDR1 to be
recruited to the membrane by E-cadherin is unclear.
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Figure 1.10: Regulation of cortical contractility at adherens junctions
E-cadherin has been shown to localise DDR1 to the cell membrane, where through
Par3 and Par6 it can then activate, through a yet to be elucidated mechanism, RhoE
and p190RhoGap. RhoE/p190RhoGAP antagonise RhoA-GTP/ROCK, resulting
in a loss of p-MLC and therefore reduction in cortical contractility at the adherens
junctions.
1.4.2 DDR1 in cancer
Both of the DDRs have been linked to tumour progression in a number of human can-
cers, and studies have shown that their activation and expression can be dysregulated
within tumours, including the identification of somatic mutations in various cancers
(Ford et al., 2007; Valiathan et al., 2012). Dependent on the type of cancer the
expression of DDR1 has been reported as both pro- and anti-tumourigenic (Tables
1.2 and 1.3).
The silencing of DDR1 by siRNA in both pancreatic adenocarcinoma and glioma
cell lines inhibited cell proliferation and impaired tumour growth in xenograft mice
models (Yamanaka et al., 2006; Rudra-Ganguly et al., 2014). Similarly, the inhibition
of DDR1 in breast cancer, colon, and Hodgkin lymphoma cell lines after DNA damage
resulted in increased cell death, suggesting that DDR1 may confer a chemotherapeutic
resistance effect to cancer cell lines, potentially through NfκB or notch signalling
(Cao and Prescott, 2002; Ongusaha et al., 2003; Das et al., 2006; Cader et al., 2013).
Conversely, in luminal breast cancer cells, DDR1 has been reported to induce the
pro-apoptotic Bcl-2 interacting killer protein (BIK) which can trigger apoptosis, and




During the process of EMT, where cells become more invasive and motile, and can
promote tumour progression (Thiery et al., 2009), there is a reported switch from
DDR1 (epithelial) to DDR2 (mesenchymal) (Maeyama et al., 2008; Toy et al., 2015).
Therefore, suggesting that in some cancers DDR1 may need to be silenced to allow for
EMT to occur and DDR2 expression, which can then drive further pro-tumourigenic
factors (Rammal et al., 2016).
Whilst DDR1 has been shown to be beneficial for the regulation of cell migration in
breast, colorectal, pancreatic, lung, glioma and hepatocarcinomas (Ram et al., 2006;
Park et al., 2007; Huang et al., 2009; Castro-Sanchez et al., 2010; Yang et al., 2010;
Neuhaus et al., 2011; Hu et al., 2014; Rudra-Ganguly et al., 2014), other reports
have also suggested an inhibitory effect on cell migration (Hansen et al., 2006; Koh
et al., 2015).
As well as a potential role in the regulation of cell migration, DDR1 has also been
implicated in cell invasion (Valiathan et al., 2012). DDR1 has been observed to be
highly expressed in invasive tumours. Evidence that collagen type I can act as a
barrier within the ECM, suggests a role for DDR1 in inducing the metalloproteases,
MMP-2 and MMP-9, that can then assist in degrading the ECM in a variety of
different cancers (Ram et al., 2006; Park et al., 2007; Yoshida and Teramoto, 2007;
Shimada et al., 2008; Castro-Sanchez et al., 2010; Yang et al., 2010; Hidalgo-Carcedo
et al., 2011; Miao et al., 2013; Hu et al., 2014; Juin et al., 2014).
Therefore, whilst there is accumulating evidence that DDR1 activity can be pro-
tumourigenic, there is also evidence that in certain tumour types DDR1 can also be
inhibitory towards tumour progression. Further work needs to be done to more fully











































































































































































































































































































































































































































































































































































































































































































Table 1.3: Putatative roles of DDR1 in blocking tumour progression.
Function Cancer Type References
Proliferation/survival Breast cancer (Maquoi et al., 2012; Assent et al., 2015)
EMT Breast cancer (Koh et al., 2015)
Migration Breast cancer (Hansen et al., 2006; Koh et al., 2015)
1.5 Project aims
Whilst centrosome clustering has been characterised as a mechanism for cell survival
in the presence of supernumerary centrosomes, it is not currently known whether all
cell types are inherently able to cluster, or if this is limited to certain cell types.
Work is currently being undertaken to identify drugs which can impair centrosome
clustering. However, current technology to identify patients with tumours with
centrosome amplification requires the use of fluorescent microscopy techniques by
a trained microscopist, making this too expensive and difficult to regularly use as
a diagnostic tool. Furthermore, more research is needed to better understand why
some tumours support centrosome amplification at high levels, and other tumours
do not. This can then potentially be used to help identify patients who would then
benefit from this anti-centrosome clustering treatment. The aims of the project were
to:
• Determine the mechanisms of adaptation to extra centrosomes, in particular
those that promote centrosome clustering.
– Investigate centrosome clustering in a panel of cell lines, using multiple
mechanisms of generating supernumerary centrosomes to identify if all cell
lines are inherently able to cluster supernumerary centrosomes efficently.
• Identify key molecules that affect centrosome clustering.
– Use siRNA, shRNA and CRISPR-Cas9 to knockdown/knockout genes of
interest to identify if the proteins affect efficient centrosome clustering.
• Determine if adaptation to centrosome amplification is required for cell survival.
– Use colony formation assays, and cell growth assays to assess if increased




• Characterise if the mechanisms of adaptation to centrosome amplification
correlate within human tumours.
– Use a panel of cancer cell lines to identify if the mechanisms of adaptation







Dulbecco’s modified Eagle’s medium (DMEM): 4.5g/L glucose, 2mM L-
glutamine and 100mg/L sodium pyruvate (D6429, Sigma-Aldrich, MO, USA). Media
was stored at 4oC.
Roswell Park Memorial Institute medium (RPMI): 2.0g/L glucose, 2.1mM
L-glutamine and 2g/L sodium bicarbonate (R8758, Sigma-Aldrich, MO, USA). Media
was stored at 4oC.
Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 Ham
(DMEM:F12): 3.15g/L glucose, with 2.5mM L-glutamine, 15mM HEPES, and
14.2mM sodium bicarbonate (D847, Sigma-Aldrich, MO, USA). Media was stored at
4oC.
McCoy’s 5A (modified), GlutaMAX®: 3.0g/L glucose, 1.5mM L-Alanyl-L-
Glutamine (36600, Thermo Scientific, MA, USA). Media was stored at 4oC.
Opti-MEM® reduced serum medium: L-glutamine, no Phenol Red, was used
for nucleic acid transfection. (31985062, Gibco, NY, USA). Media was stored at 4oC.
Serum: 50ml aliquots were stored at -20oC. Prior to use aliquots were thawed in a
37oC water bath. Aliquots were added to the appropriate media and concentration
(see Table 2.1) (Foetal Bovine Serum: 10500064, Gibco, NY, USA. Horse Serum:
H1138, Sigma-Aldrich, MO, USA. HyClone Fetal Bovine Serum (U.S.), Tetracycline
Screened: SH30070.03T, GE Healthcare, OH, USA. Donor Calf Serum: Donor Calf
Serum Heat Inactivated, PAA Laboratories Ltd, UK).
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Cholera toxin: Stock solution of 1mg/ml cholera toxin was prepared in autoclaved
distilled water was stored at 4oC. Final concentration used was 100ng/ml (C8052-
2MG, Sigma-Aldrich, MO, USA).
Epidermal growth factor (EGF): Stock solution of 25µg/ml of EGF was prepared
in 1% v/v Horse Serum in DMEM:F12 and stored at -20°C. Final concentration used
was 20ng/ml (E4127, Sigma-Aldrich, MO, USA).
Hydrocortisone: Stock solution of 1mg/ml of hydrocortisone was prepared in
absolute ethanol, and stored at -20oC. Final concentration used was 0.5µg/ml
(H0881, Sigma-Aldrich, MO, USA).
Insulin: Stock solution of 4mg/ml of human recombinant insulin was stored at
-20oC. Final concentration used was 10µg/ml (12585014, Invitrogen, ON, Canada).
2.1.2 Antibiotics
Penicillin/Streptomycin: 100U/ml penicillin and streptomycin, was used in
growth media. Storage was at -20oC for long term and 4oC whilst in use (P4333,
Sigma-Aldrich, MO, USA).
Puromycin: Stock solution of 10mg/ml was stored at -20oC. Final concentration
used was 1 – 5µg/ml (ant-pr, Invivogen, CA, USA).
Blasticidin hydrochloride: A sterile-filtered aqueous solution of 10mg/ml blasti-
cidin hydrochloride in 20mM HEPES was stored at -20oC. Final concentration used
was 2.5 – 20µg/ml. (EZSolution® 2805, Biovision, USA).
Geneticin® (G418) Sulphate: Stock solution of 50mg/ml was stored at -20oC.
The final concentration used was 0.5 – 1mg/ml (108321-42-2, Santa Cruz, CA, USA).
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2.1.3 Maintenance of a monolayer culture
Adherent cell lines were maintained at 37oC with 5% CO2 atmosphere, primarily in
25cm2 flasks in a monolayer culture. Cells were cultured in their respective media as
per Table 2.1.
Cells were examined using an inverted light microscope at 400X magnification, and
were passaged when they reached 80% confluency. To passage cells, medium was
aspirated from cells, cells were then washed in 5 ml of autoclaved phosphate-buffered
saline (PBS) and incubated with 1 ml 0.05% v/v Trypsin-ethylenediaminetetraacetic
acid (EDTA) with phenol red (25300-054, Thermo Scientific, MA, USA) or for
MCF10A with 0.25% v/v Trypsin-EDTA with phenol red (25300-056, Thermo
Scientific, MA, USA) for approximately 5 minutes at 37oC. Flasks were then tapped
to remove any remaining cells adhering to the surface. 5ml of growth medium was
then added to neutralise the enzymatic activity of the Trypsin-EDTA. For MCF10A
cells, resuspension medium was used consisting of DMEM:F12 with 10% v/v horse
serum and 100 U/ml Penicillin/Streptomycin, as the normal growth medium had
a lower volume of serum (5% v/v) which would not inactivate the Trypsin-EDTA
as effectively. The cell suspension was then pipetted up and down to ensure that
any cell clumps were dissociated and that the Trypsin-EDTA was fully neutralised.
The cell suspension was then transferred to a 15ml centrifuge tube and cells were
pelleted by centrifugation at 1200rpm for 3 minutes. The supernatant was then
discarded, and the cell pellet was resuspended in 5ml of medium (MCF10A cells
were resuspended in Resuspension Medium). 0.5-1ml was then plated into a new
flask, according to cell line doubling time and experimental requirements. Growth
medium was added to the flask to make a total volume of 7ml, and the flask was
gently rocked to evenly distribute cells and placed in an incubator.
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Table 2.1: Cell lines
Cell line Cell type Growth medium Source
MCF10A Mammary epithelial
DMEM:F12 +






HaCaT Skin keratinocyte DMEM + 10% FBS John Marshall (BCI)
EpH4-J3B1A Mammary epithelial




RPE-1 Retinal epithelial DMEM:F12 + 10% FBS David Pellman (Harvard)
BJ Foreskin fibroblast DMEM + 10% FBS David Pellman (Harvard)
NIH-3T3 Murine embryonic
fibroblast
DMEM + 10% FBS David Pellman (Harvard)
HEK-293M Embryonic kidney cells DMEM + 10% FBS David Pellman (Harvard)
A431 Epidermoid carcinoma DMEM + 10% FBS Erik Sahai (Francis Crick)
MCF-7 Breast cancer, luminal RPMI + 10% FBS Peter Schmid (BCI)
BT-474 Breast cancer, luminal DMEM + 10% FBS Peter Schmid (BCI)
SKBR-3 Breast cancer, luminal McCoy’s 5A + 10% FBS Peter Schmid (BCI)
JIMT-1 Breast cancer, luminal DMEM + 10% FBS Peter Schmid (BCI)
MDA-453 Breast cancer, luminal DMEM + 10% FBS Peter Schmid (BCI)
HCC1954 Breast cancer, basal RPMI + 10% FBS Peter Schmid (BCI)
BT20 Breast cancer, basal DMEM + 10% FBS Peter Schmid (BCI)
MDA-468 Breast cancer, basal DMEM + 10% FBS Peter Schmid (BCI)
HCC-38 Breast cancer, basal RPMI + 10% FBS Peter Schmid (BCI)
HCC-1143 Breast cancer, basal RPMI + 10% FBS Peter Schmid (BCI)
BT-549 Breast cancer, basal RPMI + 10% FBS Peter Schmid (BCI)
CAL-120 Breast cancer, basal DMEM + 10% FBS Peter Schmid (BCI)
HCC1937 Breast cancer, basal RPMI + 10% FBS Peter Schmid (BCI)
HS578T Breast cancer, basal DMEM + 10% FBS Peter Schmid (BCI)
MDA-231 Breast cancer, basal DMEM + 10% FBS Peter Schmid (BCI)
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2.1.4 Freezing
The same process of passaging cells was applied as in Section 2.1.3, although cells
were typically grown in 175cm2 flasks to allow enough cells to freeze down. After
centrifugation of the cell suspension (see Section 2.1.3), the supernatant was removed
and the cell pellet was resuspended in 5ml of 10% v/v dimethyl sulfoxide (DMSO)
in Growth Medium (MCF10A cells were resuspended in 5ml of 10% v/v DMSO in
Resuspension Medium). The cell suspension was then aliquoted at 1ml per cryovial
and frozen at -80oC in a Nalgene® Mr. Frosty freezing container, allowing for an
optimal cooling rate of -1oC/minute. For long term storage, the cryovials were
transferred to liquid nitrogen stores and kept at -196oC.
2.1.5 Thawing
Cells removed from liquid nitrogen were transported on dry ice at -78.5oC to prevent
premature defrosting of the cell suspensions. The cryovials were then placed in a
37oC water bath until defrosted. The cell suspension was then added to 5ml of
growth medium in a 15ml centrifuge tube and centrifuged at 1200rpm for 3 minutes.
The supernatant was then removed and the cell pellet was resuspended in 5ml of
growth medium and placed into a 25cm2 flask. Six hours later the medium was
changed to remove any dead cells that did not survive the DMSO and freeze-thaw
process.
2.1.6 Cell counting
When a specific number of cells were required for experimentation, such as measuring
cell viability, cells in suspension were counted using a TC20® Automated Cell
Counter (Bio-Rad Laboratories, CA, USA). The suspension was evenly mixed by
pipetting up and down with a p1000 pipette, and 10µl of suspension was added to
the chamber in a counting slide (1450011, Bio-Rad Laboratories, CA, USA), which
was inserted into the instrument, and the cell number quantified. Readings were
done in triplicate per slide and an average taken.
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2.1.7 Drug treatments
Dihydrocytochalasin B (DCB)
DCB is an actin-depolymerising agent, resulting in cytokinesis failure and tetraploid
cells. To generate tetraploid cells, therefore containing supernumerary centrosomes,
cells were treated with 4µM DCB for 20 hours. Cell medium was then removed and
replaced with Growth Medium containing 10µM of p38 inhibitor (SB203580, New
England Biolabs, MA, USA) to ensure cells re-entered the cell cycle, for 24 hours.
Stock solution of 10mM DCB was prepared in DMSO and stored at -20oC (D1641,
Sigma-Aldrich, MO, USA).
Blebbistatin
Blebbistatin is an inhibitor of non-muscle Myosin II, resulting in cytokinesis failure.
To generate tetraploid cells, cells were treated with 50µM blebbistatin for 20 hours.
Cell medium was then removed and replaced with Growth Medium containing 10µM
of the p38 inhibitor SB203580 (New England Biolabs, MA, USA) for 24 hours.
To analyse the effects of cortical contractility on centrosome clustering, cells were
treated with 50µM blebbistatin for 4 hours prior to fixation. Stock solution of 50mM
blebbistatin was prepared in DMSO and stored at -20oC (B0560, Sigma-Aldrich,
MO, USA).
RO-3306 (CDK1 inhibitor)
RO-3306 is a selective ATP-competitive inhibitor of CDK1, causing cell cycle arrest
at G2. Prolonged arrest at this stage causes centrosome overduplication. Cells were
treated with 5µM RO-3306 for 40 hours. Cell medium was then removed and washed
twice with 37oC Growth Medium to ensure full washout of the drug, and replaced
with Growth Medium containing 10µM of the p38 inhibitor SB203580 (New England
Biolabs, MA, USA) for 24 hours. Stock solution of 10mM RO-3306 was prepared in
DMSO and stored at -20oC (SML0569, Sigma-Aldrich, MO, USA).
Doxycycline hyclate (Dox)
Dox was used to induce PLK4 overexpression in the TetR PLK4 and pInducer PLK4
cell lines, 2µg/ml Dox was added for 48 hours. Stock solution of 2mg/ml Dox was
prepared in autoclaved, deionised water and stored at -20oC (D9891, Sigma-Aldrich,
MO, USA).
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MG132
MG132 is a proteasome inhibitor which can be used to arrest cells during metaphase
in mitosis. Cells were treated with 10µM MG132 for 4 hours. Cell medium was
then removed and cells were washed twice with 37oC Growth Medium to ensure full
washout of the inhibitor. Cells were then incubated for an hour to allow release from
metaphase. Stock solution of 10mM MG132 was prepared in DMSO and stored at
-20oC (1748, Tocris Bioscience, UK).
Nocodazole
Nocodazole is a microtubule-depolymerising drug. In order to deplete cells of astral
microtubules during mitosis, 5nM nocodazole was added for 3 hours. Stock solution of
10mM Nocodazole (methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate)
was prepared in DMSO and stored at -20oC (M1404, Sigma-Aldrich, MO, USA).
Working stocks were then prepared when required of 10µM in DMSO and stored at
-20oC for up 4 weeks.
Calyculin-A
Calyculin-A is a protein phosphatase inhibitor. In order to increase the levels of
phosphorylated myosin II, 1µM Calyculin-A was added to cells for 2 hours. Stock
solution of 1mM Calyculin-A was prepared in DMSO and stored at -20oC (CAY19246,
Cambridge Bioscience, UK).
Y-27632 dihydrochloride (ROCK1 inhibitor)
Y-27632 dihydrochloride is a ROCK1 inhibitor. Cells were treated with 10µM for
4 hours to perturb ROCK1 driven contractility. Stock solution of 10mM Y-27632
dihydrochloride was prepared in autoclaved, deionised water and stored at -20oC
(1254, Tocris Bioscience, UK).
DDR1-IN-1 (DDR1 kinase inhibitor)
DDR1-IN-1 is a selective DDR1 kinase inhibitor. For quantification of DDR1
activation in the presence of collagen - cells were plated in 6cm diameter tissue
culture dishes, and were pre-treated with 0 – 15mM DDR1-IN-1 for 1 hour. The
medium was then removed and replaced with medium containing 10µg/ml of collagen
(Collagen I, Rat tail, 354236, Corning, NY, USA) and DDR1-IN-1 for 2 hours. Stock
solution of 10mM DDR1-IN-1 was prepared in autoclaved, deionised water in a 60oC
water bath for full solubility before storing at -20oC (5077, Tocris Bioscience, UK).
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2.1.8 SiRNA transfection
Cells were plated in a 6-well tissue culture plate in 2ml of Growth Medium per well
which did not contain Penicillin/Streptomycin. For the transfection, Lipofectamine®
RNAiMAX (Thermo Scientific, MA, USA) was used to form liposomes around the
siRNA which could then be internalised by the cells. If antibiotics were present in
the medium then they would be encapsulated by the liposome and kill the cells after
uptake. Cells were transfected at 50% confluency. 10µl lipofectamine® RNAiMAX
was diluted in 250µl Opti-MEM® per well in a microcentrifuge tube, whilst 5µl
of siRNA (Stocks were made at 20µM, diluted in RNase-free water and stored at
-20oC) was diluted in 250µl Opti-MEM® per well in a separate microcentrifuge tube.
Solutions were incubated at room temperature for 5 minutes to allow equilibration.
The siRNA solution was then added dropwise onto the Lipofectamine® RNAiMAX
solution and incubated at room temperature for 20 minutes, allowing the formation
of liposomes. The solution was then added onto the cells. The medium was replaced
6 hours later with normal Growth Medium. Cells were analysed 72 hours post
transfection. siNegative (1027310, Qiagen, MD, USA) was used as a control. Details
of specific siRNAs used can be found in Table 2.2.
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2.2 Bacterial Culture Methods
2.2.1 Media and Antibiotics
Luria broth (LB): 2% w/v LB (L3022, Sigma-Aldrich, MO, USA) was dissolved
in deionised water and autoclaved for 20 minutes at 125oC. Once cooled, antibiotics
were added (see below) and LB was stored at 4oC.
LB-Agar: 3.5% w/v LB-agar (L2897, Sigma-Aldrich, MO, USA) was dissolved in
deionised water and autoclaved for 20 minutes at 125oC. Once cooled enough to
hold, antibiotics were added and the solution was mixed by swirling. The LB-agar
was poured into sterile 10cm diameter circular plates and were left to set at room
temperature. LB-agar plates were stored at 4oC.
Kanamycin: 50mg/ml Kanamycin solution was stored at 4oC (K0254, Sigma-
Aldrich, MO, USA). Kanamycin was diluted in the LB and LB-Agar to a working
concentration of 50µg/ml.
Ampicillin: 100mg/ml Ampicillin solution was stored at 4oC (A5354, Sigma-Aldrich,
MO, USA). Ampicillin was diluted in the LB and LB-Agar to a working concentration
of 100µg/ml.
2.2.2 Transformation of chemically competent cells
One Shot® Stbl3™ Chemically Competent E. coli were stored at -80oC (C737303,
Thermo Scientific, MA, USA). Prior to transformation, one vial of Stbl3™ cells was
allowed to thaw on ice. Once thawed, 1µl of plasmid was added to the bacterial cells
and mixed by pipetting. The mixture was then incubated for 30 minutes on ice to
allow the plasmid to fuse to the bacterial cell membrane. The cells were then heat
shocked at 42oC in a water bath for 45 seconds. The heat shock causes the bacterial
cells to release lipids, forming pores in the cell wall, which allow the plasmid DNA
to enter. Cells were then placed back on ice for 2 minutes, causing the pores to close,
and the DNA to be contained within the bacterial cells. 500µl of super optimal broth
with catabolite repression (SOC) medium was then added, and the mixture was
incubated at 37oC whilst shaking at 200rpm for 1 hour. 100µl of cell suspension was
then plated onto an LB-agar plate with plasmid-selective antibiotic and incubated
overnight at 37oC. Colonies were then selected using a pipette tip and inoculated
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into 5ml of LB containing antibiotic which was then placed at 37oC at 200rpm for 8
hours. To make bacterial stocks, a 1:1 dilution was made of bacterial suspension
and 30% v/v glycerol in water, 1ml was placed into a cryovial and stored at -80oC.
2.2.3 Propagation of chemically competent cells
A 5ml starter culture of LB with the appropriate antibiotic was inoculated by scraping
a pipette tip against the frozen transformed bacterial cells and placing it into the
broth. The starter culture was then placed at 37oC whilst shaking at 200rpm for 8
hours. The starter culture was then added to 50ml of LB with appropriate antibiotic
in a conical flask and placed at 37oC whilst shaking at 200rpm overnight.
2.2.4 Plasmid DNA extraction from bacteria
To extract plasmid DNA from bacterial cultures, a Genopure Plasmid Midi Kit
(Roche, Germany) was used. Bacterial cells were pelleted by centrifugation at
3000g at 4oC for 10 minutes. The supernatant was removed and the cell pellet
was resuspended in 4ml Suspension Buffer with added RNase. 4ml of Lysis Buffer
was added, and the mix was inverted 7 times to ensure it was evenly mixed before
incubating at room temperature for 3 minutes. 4ml of chilled Neutralisation Buffer
was added to counteract the Lysis Buffer, forming a cloudy suspension of cell debris,
and inverted until a homogenous mixture had formed. The suspension was then
incubated on ice for 5 minutes. Whilst the mixture was incubating, a glass funnel
was placed into a 50ml centrifuge tube, and filter paper was placed into the funnel,
which was moistened with a few drops of Equilibration Buffer. The mixture was
then poured into the funnel and the flow through, containing the plasmid DNA was
collected. A Midi Prep column was then placed into a 50ml centrifuge tube and
2.5ml of Equilibration Buffer was added to the column and allowed to pass through
by gravity flow. The collected lysate from the bacterial culture was then added to the
column, and passed through by gravity flow, allowing the DNA to bind to the anion
exchange resin under low salt and pH conditions. The column was then washed twice
with 5ml of Wash Buffer to remove any remaining contaminants. The column was
then placed into a collection tube capable of undergoing high speed centrifugation
and the DNA was eluted using the prewarmed 50oC high salt concentration Elution
Buffer. The DNA was precipitated by the addition of 3.6ml of isopropanol. The
suspension was then centrifuged immediately at 15,000g at 4oC for 30 minutes to
pellet the DNA. The supernatant was carefully discarded so as to not dislodge the
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pellet. 3ml of 4oC 70% v/v ethanol in distilled water was then carefully added to
remove precipitated salt, and to displace the isopropanol, making the DNA more
soluble. The tube was then centrifuged at 15,000g at 4oC for 10 minutes before
removing the ethanol. The pellet was then allowed to air dry at room temperature
before dissolving the pellet in 50µl of sterile DNase free water.
2.2.5 Determination of DNA concentration
DNA concentration was determined using a Nanodrop-1000 spectrophotometer
(Thermo-Scientific, MA, USA). Prior to quantification, a blank measurement was
taken using 1µl of sterile DNase free water. Quantification of DNA concentration
was then taken by adding 1µl of the DNA solution. The Nanodrop-1000 measured
absorbance at 260nm, the wavelength at which nucleic acids absorb light. The
absorbance was then converted into a concentration in ng/µl using a derivative of the
Beer-Lambert equation. The Nanodrop-1000 also measured absorbance at 280nm,
the wavelength where proteins absorb light. The purity of the DNA could then
be determined by dividing the OD260 (Optical Density) by the OD280 value. An
OD260/OD280 of less than 1.8 indicated that there was protein contamination within
the sample and could not be used for future applications.
2.3 Lentivirus and Generation of Cells
As a sub-class of retroviruses, lentiviruses were used to create genetically modified
cell lines by making use of their ability to integrate into the genome in both dividing
and non-dividing cells.
2.3.1 Lentivirus preparation
HEK 293M cells were used for lentiviral production due to their transfectability. HEK
293M were plated in 6-well plates in Growth Medium without Penicillin/Streptomycin.
Cells were transfected 24 hours post seeding, when plates were 50% confluent.
The transfection reagent used was Lipofectamine® 2000 (Thermo Scientific, MA,
USA). 10µl Lipofectamine® 2000 was added to 250µl Opti-MEM® per well in a
microcentrifuge tube, whilst 2µg of plasmid DNA, 1µg Gag-Pol DNA and 0.5µg
VSV-G DNA were added to 250µl Opti-MEM® in a separate microcentrifuge tube
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(Gag-Pol: psPAX2 plasmid, 12260, Addgene, MA, USA; VSV-G: pMD2.G plasmid,
12259, Addgene, MA, USA). Gag is a structural precursor protein, Pol is a polymerase,
and VSV-G is an envelope gene required for the formation of the lentivirus, which
then encapsulates the plasmid of interest. The mixtures were incubated at room
temperature for 5 minutes before pipetting the plasmid mixture dropwise onto the
Lipofectamine® 2000 mixture to allow the formation of liposomes, and incubated
at room temperature for 20 minutes. The mixture was then added to the HEK
293M. 6 hours later the medium was replaced with 1.5ml Growth Medium. Twenty-
four hours later, virus was harvested by removing the medium with a pipette and
passing it through a 10ml syringe attached to a 0.45µM Millex-HP Syringe Filter
Unit (SLHP033RS, Merck Millipore, Germany), into a 15ml centrifuge tube. By
filtering the medium, any dislodged or dead cells in the medium were removed,
whilst the virus was small enough to pass through. The virus collected was then
aliquoted into cryovials at 1.5ml and stored at -80oC. 1.5ml pre-warmed 37oC Growth
Medium was then carefully added to the transfected HEK 293M so as to not dislodge
them. A second viral collection was then taken 48 hours post initial transfection.
All pipette tips, syringes and plates that were used for lentiviral preparation were
decontaminated in 1% w/v Virkon S, a virucidal disinfectant for 15 hours.
2.3.2 Lentivirus infection
Cells were plated in 6cm diameter cell culture plates in 3ml of Growth Medium.
Twenty-four hours post seeding, the first collection from the lentiviral harvest was
thawed at 37oC in a water bath. The Growth Medium was removed from the cells
and replaced with 1ml of Growth Medium without Penicillin/Streptomycin. The
lentivirus was added on top of the cells with 8µg/ml polybrene (Hexadimethrine
bromide: H9268, Sigma-Aldrich, MO, USA). Polybrene is a cationic polymer which
increases the transduction efficiency by neutralising the charge between sialic acid
on the cell surface and the lentiviral virions. A stock solution of polybrene was
prepared at 8mg/ml in autoclaved deionised water and stored at -20oC. Six hours
later, the medium was removed and replaced with 3ml of Growth Medium. Forty-
eight hours post seeding, the infection was repeated using the second lentiviral
collection. Twenty-four hours post final infection, antibiotic selection was started, or
cells were amplified for cell sorting. To sort cells based on fluorescence, cells were
passaged as previously described from a 175cm2 flask. Cells were resuspended in
1ml of serum-free medium to prevent aggregation of cells. Cells were then passed
through a cell strainer cap (352235, BD Bioscience, CA, USA) and collected. The
cell suspension was sorted on a BD FACSAria II (BD Bioscience, CA, USA). For a
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full list of cell lines generated by lentiviral infection, refer to Table 2.3.
Table 2.3: Generated cell lines from lentiviral infection and their selection
Cell line Generated by Selection Antibiotic
concentration
MCF10A.H2B-GFP Susana Godinho Cell sorting for GFP -
HaCaT.H2B-GFP Alexander Rhys Cell sorting for GFP -
RPE-1.H2B-GFP Alexander Rhys Cell sorting for GFP -
BJ.H2B-GFP Susana Godinho Cell sorting for GFP -
MCF10A.TetR Susana Godinho Blasticidin 5µg/ml
HaCaT.TetR Alexander Rhys Blasticidin 10µg/ml
RPE-1.TetR Alexander Rhys Blasticidin 10µg/ml
NIH-3T3.TetR Alexander Rhys Blasticidin 5µg/ml
BJ.TetR Alexander Rhys Blasticidin 5µg/ml
MCF10A.TetR.PLK4 Susana Godinho Geneticin 1mg/ml
HaCaT.TetR.PLK4 Alexander Rhys Geneticin 0.5mg/ml
RPE-1.TetR.PLK4 Alexander Rhys Geneticin 0.5mg/ml
NIH-3T3.TetR.PLK4 Alexander Rhys Geneticin 0.5mg/ml
BJ.TetR.PLK4 Alexander Rhys Geneticin 0.5mg/ml
MCF10A.TetR.PLK4.shCDH1 #8 Alexander Rhys Puromycin 10µg/ml
MCF10A.TetR.PLK4.shCDH1 #9 Alexander Rhys Puromycin 10µg/ml
MCF10A.TetR.PLK4.shCDH1 #10 Alexander Rhys Puromycin 10µg/ml
MCF10A.TetR.PLK4.shCDH1 #11 Alexander Rhys Puromycin 10µg/ml
MCF10A.CDH1-/- Alexander Rhys Puromycin 10µg/ml
HaCaT.CDH1-/- Alexander Rhys Puromycin 10µg/ml
MCF10A.CDH1-/-.TetR Alexander Rhys Blasticidin 5µg/ml
HaCaT.CDH1-/-.TetR Alexander Rhys Blasticidin 10µg/ml
MCF10A.CDH1-/-.TetR.PLK4 Alexander Rhys Geneticin 1mg/ml
HaCaT.CDH1-/-.TetR.PLK4 Alexander Rhys Geneticin 0.5mg/ml
MCF10A.TetR.PLK4.H2B-GFP Alexander Rhys Cell sorting for GFP -
HaCaT.TetR.PLK4.H2B-GFP Alexander Rhys Cell sorting for GFP -
MCF10A.CDH1-/-.TetR.PLK4.H2B-GFP Alexander Rhys Cell sorting for GFP -
HaCaT.CDH1-/-.TetR.PLK4.H2B-GFP Alexander Rhys Cell sorting for GFP -
MCF10A.Centrin-GFP Alexander Rhys Cell sorting for GFP -
MCF10A.CDH1-/-.Centrin-GFP Alexander Rhys Cell sorting for GFP -
MCF10A.pInducer.PLK4 Alexander Rhys Cell sorting for GFP -
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2.3.3 Inducible PLK4 overexpression vectors
To generate cell lines transiently overexpressing PLK4, cell lines were initially infected
with lentivirus containing the tetracycline repressor (TetR), pLenti-CMV-TetR-Blast
(17492, Addgene, MA, USA) and selected using Blasticidin (2.5 - 20µg/ml), or
pInducer and selected via cell sorting for green fluorescent protein (GFP), pInducer21
ORF-EG (46948, Addgene, MA, USA)(Meerbrey et al. 2011). These enabled the
expression of PLK4 to be inducible. PLK4 cDNA was previously cloned using the
Gateway system into the pLenti-CMV/TO-Neo-Dest vector by Susana Godinho
(Godinho et al. 2014). After selection, cells were then secondarily infected with the
PLK4-containing lentivirus and selected with Geneticin (0.5 - 1mg/ml). Due to the
TetR and pInducer overexpression of PLK4 could not occur until the addition of
Dox.
2.3.4 shCDH1
To generate cell lines expressing shCDH1, MCF10A.TetR.PLK4 cell lines were
infected with lentivirus containing pLKO.1 lentiviral vectors expressing 4 different
CDH1 short hairpin RNA (shRNA; #8, #9, #10 and #11) which were obtained
from Dana-Farber Cancer Institute and Broad Institute, Boston, USA. Cell lines
were then selected using 10µg/mL puromycin.
2.3.5 CRISPR-Cas9 Gene Knockout
To generate cell lines with stable gene knockout, CRISPR-Cas9 lentiviral gene editing
was used (Cong et al. 2013).
2.3.5.1 Principle of CRISPR-Cas9 Gene Knockout
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and
CRISPR-associated (Cas) genes were first discovered in bacteria, and act as a
mechanism of defence against foreign DNA, either viral or plasmid (Mali et al. 2013;
Jinek et al. 2012; Hwang et al. 2013; Cong et al. 2013). Since 2013, this technology
has been used to perform gene editing. The CRISPR-Cas9 system is made up
of two components: the guide RNA and the Cas9 enzyme (CRISPR-associated
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protein-9 nuclease). The guide RNA (gRNA) consists of a 20-base pair length of
RNA which is designed to be complementary to the targeted region of DNA for
the gene of interest. The 20-base pair region of DNA is immediately followed by a
protospacer adjacent motif (PAM), which is an essential targeting component for
the CRISPR-Cas9 system. This gRNA is then located within a longer RNA scaffold.
The Cas9 enzyme can then localise to the targeted region and make a double strand
incision, which is then repaired using non-homologous end joining (NHEJ). NHEJ is
a rapid process of repairing double strand breaks, but often results in small nucleotide
insertions or deletions (InDels). These InDels can result in in-frame amino acid
deletions/insertions, or frameshift mutations, leading to premature stop codons in
the targeted gene. Therefore, the protein may be prematurely truncated if there is
a stop codon, or a loss of function if incorrect amino acids are now incorporated
due to frame shifts. The knock-out phenotype is then determined by residual gene
function (Figure 2.1).
2.3.5.2 Site-Directed Mutagenesis
The LentiCRISPRv2 plasmid was used, as it contains two expression cassettes,
hSpCas9, and one for the guide RNA which localises the nuclease to the exact
location on the DNA for the gene editing event to occur (52961, Addgene, MA,
USA)(Shalem et al. 2014). Using site directed mutagenesis, the LentiCRISPRv2
could be edited to substitute the 20 base pair target sequence for a different targeting
sequence. For primers and primer design see Page 69.
The Q5® Site-Directed Mutagenesis Kit (E0554S, New England Biolabs, MA, USA)
was prepared in a thin-walled PCR tube as per the dilutions in Table 2.4.
Table 2.4: Reagent dilutions for site-directed mutagenesis
Reagent Per 25µl reaction mix Final concentration
Q5 Hot Start High-Fidelity
2X Master Mix
12.5µl 1X
10µM Forward primer 1.25µl 0.5µM
10µM Reverse primer 1.25µl 0.5µM
Template DNA (10ng/µl) 1µl 10ng
Nuclease-free water 8.3µl -
DMSO 0.7µl 2.8% v/v
The addition of DMSO was to reduce secondary structures in the DNA which can then
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Figure 2.1: CRISPR-Cas9 gene editing
CRISPR-Cas9 gene editing. Schematic of CRISPR-Cas9 gene editing. gRNA with
the target sequence localises to the Cas9 enzyme forming a complex. The gRNA
then targets the complex to the correct location within the DNA, where the Cas9
enzyme forms a double strand break. This is repaired using non homologous end
joining (NHEJ). NHEJ is error prone so can result in either a repaired wild type gene,
or where gene editing has occurred insertion/deletion of base pairs or a mutation
resulting in frame shift.
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inhibit polymerase progress. The PCR tubes were then centrifuged on a benchtop
PCR centrifuge for 5 seconds to ensure the mixture was collected at the bottom of
the tube, and transferred to a C1000 Touch™ Thermal Cycler (Bio-Rad Laboratories,
CA, USA). The lid of the Thermal Cycler was set to 100oC to stop condensation
within the lid, which would reduce the concentration within the mixture. The PCR
was then run under the conditions in Table 2.5.
Table 2.5: PCR conditions for site-directed mutagenesis
Step Temp Time
Initial denaturation 98oC 30s
98oC 10s
50-72oC (primer specific) 30s25 cycles
72oC 30s
Final Extension 72oC 10min
Hold 4oC -
During the PCR process, the specifically-designed primers substituted the previous
target sequence, generating a new plasmid with the new target sequence incorporated.
At the completion of the PCR, a KLD enzyme reaction mix was prepared as per
Table 2.6.
Table 2.6: Conditions for KLD enzyme reaction
Reagent Volume Final Concentration
PCR product 1µl -
2X KLD reaction buffer 5µl 1X
10X KLD enzyme mix 1µl 1X
Nuclease-free water 3µl -
The kinase and ligase respectively allow for the phosphorylation and circularisation
of the plasmid whilst the Dpn1 removes any residual template DNA. The reaction
was incubated at room temperature for 5 minutes. One Shot® Stbl3™ Chemically
Competent E. coli were then transformed as per Section 2.2.2.
2.3.5.3 Sequence design
Guide RNAs were designed using the ATUM CRISPR gRNA design tool (ATUM, CA,
USA). They were designed for use with the wild-type Cas9, and within the first exon
of the gene. By targeting the first exon this minimises the risk of truncated protein
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expression, which may still be active, instead of full protein loss. The top guide
RNAs were selected based on their predicted likelihood of being specific to the target
gene, therefore reducing the risk of off-target effects. Primers were then designed
to enable the guide RNAs to be incorporated into the LentiCRISPRv2 plasmid
by site directed mutagenesis. Primers were designed using the NEBaseChanger®
(New England Biolabs, MA, USA). Primers were purchased from Sigma-Aldrich
(Sigma-Aldrich, MO, USA) and resuspended to a stock concentration of 100µM in
nuclease free water and stored at -20oC; working stocks were made at 10µM (R0582,
Invitrogen, ON, Canada). For details of primers please see Table 2.7 for E-cadherin
and Table 2.8 for DDR1.
Table 2.7: Mutagenesis primers for CDH1
Lowercase letters identify guide RNA to be inserted, uppercase identify alignment to the
plasmid



















Table 2.8: Mutagenesis primers for DDR1
Lowercase letters identify guide RNA to be inserted, uppercase identify alignment to the
plasmid
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2.3.5.4 Selection
Following lentiviral production and infection as described above, cells were treated
with puromycin at 1 – 5µg/ml to select for cells that had been infected with the
lentivirus. Cells were then seeded at 100 cells per 10cm diameter cell culture plates
and incubated for 7 days to allow colonies to form from single cells. Growth Medium
was changed every 2 days. Colonies to be selected were identified by using an
inverted light microscope using a 40X objective, and marked on the bottom of the
plate. Growth medium was removed and the cells were washed in autoclaved PBS.
Autoclaved 8mm glass cloning cylinders had one end dipped in autoclaved Vaseline,
this end was then placed onto the plate forming a well around the colony to be
selected, this was repeated for all the colonies (c1059, Sigma-Aldrich, MO, USA).
20µl of Trypsin-EDTA was then added to the cylinder and incubated for 10 minutes,
the Vaseline formed a hydrophobic seal with the plate keeping the Trypsin-EDTA
within the cylinder, coating the cells to be selected. 200ul of Growth Medium was
then added to the cylinder and pipetted up and down to ensure the cells were in
suspension. The cell suspension was then transferred to a well in a 96-well plate; this
was repeated for each clone. The clonal cylinders were washed in 1% w/v Virkon
followed by 70% v/v ethanol, before being autoclaved for future use. The cells were
grown until 80% confluency, where they were then amplified into a 24-well plate and
subsequently further amplified into 12-well, 6-well and 25cm2 plates until they could
be analysed by western blot for protein loss.
2.3.6 E-cadherin
To overexpress E-cadherin, pWZL-blast-DN-E-cadherin (18800, Addgene, MA, USA)
and pWZL-blast-E-cadherin (18804, Addgene, MA, USA) were used (Onder et al.
2008). Cells were selected with 2.5 – 20µg/ml blasticidin.
2.3.7 H2B GFP and H2B RFP
The LV-GFP plasmid (25999, Addgene, MA, USA) was used to express H2B-GFP,
and LV-RFP (26001, Addgene, MA, USA) for H2B RFP (Beronja et al. 2010).
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2.3.8 Centrin GFP
Lentilox Centrin1-eGFP construct was a gift from J. Loncarek (National Cancer
Institute, USA). Cells were sorted as per Section 2.3.2.
2.4 Protein analysis
2.4.1 Reagents
Radioimmunoprecipitation assay (RIPA) buffer: Pre-mixed 25mM Tris-HCl
pH 7.6, 150mM NaCl, 1% v/v NP-40, 1% w/v sodium deoxycholate, 0.1% v/v
sodium dodecyl sulphate (SDS) diluted in distilled water was stored at 4oC (89901,
Thermo Scientific, MA, USA).
Protease Inhibitor: 1 tablet of cOmplete™ Mini Protease Inhibitor Cocktail was
dissolved in 10ml RIPA buffer in a 15ml centrifuge tube using a vortex (11836153001,
Roche, Germany). 1ml aliquots were prepared in microcentrifuge tubes and stored
at -20oC. Aliquots were thawed on ice prior to use.
Phosphatase Inhibitor: For experiments looking at phosphorylated proteins,
a 1:100 dilution of Phosphatase Inhibitor Cocktail was made with RIPA buffer
containing protease inhibitor and used immediately (5870, New England Biolabs,
MA, USA). Phosphatase Inhibitor Cocktail was stored at 4oC.
Bovine serum albumin (BSA): A stock of 10mg/ml BSA in deionised water was
stored at -20oC (A2153, Sigma-Aldrich, MO, USA). Protein standards were made to
0 – 6mg/ml in microcentrifuge tubes and stored at 4oC.
Laemmli SDS sample buffer 4x: Premixed 250mM Tris-HCl pH 6.8, 8% v/v
SDS, 40% v/v glycerol, 8% v/v beta-mercaptoethanol, and 0.02% w/v bromophenol
blue was stored at room temperature (J60015, Alfa Aesar, UK).
N,N,N’,N’-Tetramethylethylenediamine (TEMED): TEMED was stored at
room temperature (T9281, Sigma-Aldrich, MO, USA).
Ammonium persulphate (APS): A solution of 10% w/v APS was made in
deionised water (A3678, Sigma-Aldrich, MO, USA). 1ml aliquots were made in
microcentrigufe tubes and stored at -20oC.
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ProtoFLOWGel: ProtoFLOWGel is a pre-mixed 30% w/v acrylamide/methylene
bisacrylamide solution in a 37.5:1 ratio in distilled water (H16996, Scientific Labora-
tory Supplies, UK).
Resolving gel buffer: 4X Resolving Buffer was diluted when required in deionised
water forming a solution of 0.375M Tris-HCl and 0.1% v/v SDS, pH 8.8 (EC-892,
Scientific Laboratory Supplies, UK).
Stacking gel buffer: 4X Stacking Buffer was diluted when required in deionised
water forming a solution of 0.125M Tris-HCl and 0.1% v/v SDS, pH 6.8. (EC-893,
Scientific Laboratory Supplies, UK).
Running buffer: 10X Tris Glycine SDS (250mM Tris, 2M Glycine and 1% w/v
SDS) was diluted to 1X when required in deionised water. (20640050, Severn Biotech,
UK). The buffer was used immediately.
Transfer Buffer: 10X Tris Glycine (250mM Tris and 2M Glycine) was diluted to
1X when required in deionised water (20630050, Severn Biotech, UK). A solution
of 20% v/v methanol was then made in the 1X Tris Glycine. The buffer was used
immediately.
TWEEN® 20: TWEEN® 20 was stored at room temperature (P9416, Sigma-
Aldrich, MO, USA).
Tris buffered saline (TBS)-T: TBS was diluted to 1X in deionised water as
required (20730110, Severn Biotech, UK). The 1X TBS solution consisted of 137mM
Sodium Chloride and 20mM Tris. 0.1% v/v Tween-20 was added to create TBS-T.
The buffer was used immediately.
Blocking solution: 5% w/v skimmed milk powder (70166, Sigma-Aldrich, MO,
USA) was dissolved in TBS-T. Blocking solution was stored at 4oC for a maximum
of 48 hours.
Phospho-blocking solution: 5% w/v BSA was dissolved in TBS-T. Phospho-
blocking solution was stored at 4oC for a maximum of 48 hours.
2.4.2 Protein harvesting
Cells to be processed for protein analysis were plated on 6-well plates or 6cm diameter
cell culture dishes. At 80% confluency, Growth Medium was removed and cells were
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washed in 5ml of autoclaved PBS. After PBS was removed, 150µl of RIPA buffer with
protease inhibitors was added. For analysis of phosphorylated proteins, phosphatase
inhibitors were also used. The plates were then stored at -80oC for 24 hours to prevent
protein degradation. Cells were thawed on ice and using a cell scraper the lysed cell
mix was pippeted into a microcentrifuge tube. The suspension was centrifuged at
10,000g for 15 minutes to pellet cell debris. The supernatant containing the protein
was then pipetted into a new microcentrifuge tube and the pellet discarded.
2.4.3 Bradford assay
A Bradford assay was used to determine the protein concentration of each sample.
In a 96-well plate, 1µl of BSA protein standards (1-6µg/ml) and protein sample was
loaded in triplicate. 200µl of Bradford Protein Assay Dye Reagent was added to
each well (5000006, Bio-Rad Laboratories, CA, USA). The dye contains Coomassie
brilliant blue G-250 dye which, on binding to protein, changes colour. The absorbance
of each well was quantified using a Victor3 Multilabel Counter plate reader (Perkin
Elmer, MA, USA) at an excitation of 595nm. Using the BSA standards, a standard
curve was generated using concentration plotted against absorbance in Microsoft
Excel. Microsoft Excel generated an equation for the standard curve using a linear
regression. The protein concentrations for the samples could then be calculated
by substituting the average absorbance from the triplicates into the equation. To
ensure equal protein loading between samples, the samples were diluted to a final
concentration of 1µg/µl in the RIPA buffer with protease inhibitor. Laemmli Buffer
was then added to a final concentration of 1X. To denature the proteins, the samples
were placed in a heat block at 98oC for 5 minutes. The samples were then placed
in a benchtop centrifuge for 5 seconds to collect any condensation that occurred.
Samples were stored at -80oC until required.
2.4.4 SDS-PAGE
Depending on the size of the protein of interest, protein samples were resolved on
10% or 12% acrylamide sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) using the Mini-PROTEAN® system (Bio-Rad Laboratories, CA, USA).
Glass plates were prepared for the gels, a glass front plate was placed over a 1mm
back plate and held within a green casting cassette. Resolving gels were prepared by
adding 5ml of the required percentage of ProtoFLOWGel to each cassette as per the
recipe in Table 2.9 (10ml was made for 2 gels).
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Table 2.9: Protocol for resolving gel preparation
Reagent Volume for 10% v/v gel Volume for 12% v/v gel
ProtoFLOWGel 3.3ml 4.0ml
4% ProtoGel Resolving Buffer 2.5ml 2.5ml
Deionised water 4.1ml 3.4ml
10% APS 100µl 100µl
TEMED 10µl 10µl
The mixture was immediately added between the glass plates, leaving space for the
stacking gel. 500µl isopropanol was pipetted onto the solution to ensure the gel
set evenly. The gel was left to solidify at room temperature for 10 minutes and
the isopropanol was removed with blotting paper. 5ml of stacking gel solution was
prepared as per the recipe in Table 2.10 for 2 gels.
Table 2.10: Protocol for resolving gel preparation
Reagent Volume
ProtoFLOWGel 650µl




The Stacking Gel solution was pipetted on top of the set resolving gel, and a 10-well
or 15-well comb inserted. The gel was incubated at room temperature for 20 minutes
to solidify. The gels were inserted into the clamped electrode apparatus and placed
within the electrophoresis tank. The tank was then filled with running buffer and the
combs carefully removed. The wells were loaded with 15µl (15µg) of protein sample,
leaving at least one well to be loaded with 5µl PageRuler™ Plus Prestained Protein
Ladder (26619, Thermo Scientific, MA, USA) as a marker for protein size. 80V was
applied to the gels for 15 minutes to allow the proteins to enter the resolving gel,
and 120V then applied for 1.5 hours, or until the proteins had resolved to a sufficient
degree based on the protein ladder.
2.4.5 Western blot transfer
Resolved proteins were then transferred onto polyvinylidene fluoride (PVDF) mem-
branes (03010040001, Roche, Germany) via the Mini Trans-Blot® wet transfer
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system (Bio-Rad Laboratories, CA, USA). PVDF membranes were equilibrated in
methanol for 5 minutes. Cassettes were prepared in a plastic tray filled with 1L
of Transfer Buffer. 3 pieces of chromatography paper were placed on the negative
side of the cassette (11567393, Fisher Scientific, UK). The gels were removed from
the electrophoresis tank, and carefully removed from the glass plates. The stacking
gel was removed from the gel, and the resolving gel placed onto the chromatogra-
phy paper. The PVDF membrane was then placed onto the gel, and 3 pieces of
chromatography paper placed on top, ensuring no air bubbles remained within the
stack. The cassette was then closed and placed within the transfer tank. An ice
block was placed with the tank, to prevent overheating during the transfer process.
The transfer buffer was then poured from the plastic tray into the tank. 100V was
then applied to the tank for 1.25 hours, enabling the negatively charged protein to
transfer onto the membrane.
2.4.6 Immunoblot detection
After transfer, membranes were removed from the cassettes and immediately placed
in 10ml of blocking solution (for phosphorylated proteins, phospho-blocking solution
was used) for 1 hour at room temperature with gentle rocking. Membranes were then
cut to size for the specific proteins of interest with a scalpel and ruler based on the
protein ladder, and placed in a 30ml universal container. Membranes were incubated
in 2ml of diluted primary antibody in the appropriate blocking buffer overnight at
4oC with gentle rolling (see Table 2.11 for antibody dilutions). Membranes were
washed 3 times for 5 minutes each at room temperature with gentle rolling in TBS-
T. Membranes were then incubated in 2ml of diluted secondary, species-specific,
horseradish peroxidase (HRP)-conjugated antibody in the appropriate blocking buffer
for 1 hour at room temperature with gentle rolling (see Table 2.11 for antibody
dilutions). Membranes were washed 3 times for 5 minutes each at room temperature
in TBS-T. Membranes were then placed protein side up on clear plastic film. A
1:1 mixture of Peroxide Solution and Luminol Enhancer in the Pierce™ enhanced
chemiluminescence reagent (ECL) Western Blotting Substrate (32106, Thermo
Scientific, MA, USA) was made in a centrifuge tube. 1ml of ECL was then added to
each membrane and incubated at room temperature for 5 minutes. Excess ECL was
then removed and the membranes were placed protein side up between clear plastic
sheets in an autoradiography cassette, which was taped down to prevent movement.
In a dark room, under red light, X-ray film (MOL7016, Scientific Laboratory Supplies,
UK) was placed onto the membrane and exposed for an appropriate time depending
on signal strength, between 5 second – 5 minutes. Films were developed using a
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SRX-101A table top film processor (Konica Minolta, NJ, USA). Developed films
were then scanned onto a computer and saved.
Table 2.11: Antibody list with dilutions




β-actin 13E5 4970 Cell Signalling Rabbit 1:5000
E-cadherin HECD1 ab1416 Abcam Mouse 1:200
DDR1 C-20 sc-532 Santa Cruz Rabbit 1:200
KIFC1/HSET 1-50 A300-951A-T Bethy Laboratories Rabbit 1:500
Mad2 100-150 A300-300A-T Bethy Laboratories Rabbit 1:500
Rnd3/RhoE 4 R6153 Sigma-Aldrich Mouse 1:100
P190 30 610149 BD Bioscience Mouse 1:250
STARD8/
DLC3
731-830 sc-166725 Santa Cruz Mouse 1:100
N-cadherin 32 610920 BD Bioscience Mouse 1:500
Vimentin RV202 550513 BD Pharmingen Mouse 1:500
ERM 567 3142 Cell Signalling Rabbit 1:500
p-MLC T18/S19 3674 Cell Signalling Rabbit 1:500
pDDR1 T513 TA311934 Origene Rabbit 1:100








Polyclonal NA931V GE Healthcare Sheep 1:5000
2.4.7 Antibody stripping and re-probing
When required, membranes were stripped of primary and secondary antibodies using
5ml of Restore™ Western Blot Stripping Buffer for 10 minutes at room temperature
with gentle rocking (21059, Thermo Scientific, MA, USA). Membranes were then
washed in TBS-T for 5 minutes at room temperature with gentle rocking. Membranes
were then re-blocked and probed as per Section 2.4.6.
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2.5 Microscopy
2.5.1 2D indirect immunofluorescence microscopy
2.5.1.1 Reagents
Formaldehyde: 16% v/v formaldehyde (28906, Thermo Scientific, MA, USA) was
stored at room temperature in the dark for up to 1 month. 4% v/v formaldehyde
was prepared in PBS when required and used immediately.
Methanol: ≥99.9% methanol was stored at -20oC (154903, Sigma-Aldrich, MO,
USA).
Acetone:Methanol: A 50:50 v/v solution of methanol and acetone was prepared
and stored at -20oC.
Permeabilisation buffer: A solution of 0.2% v/v Triton X-100 in PBS was pre-
pared and stored at room temperature.
Blocking solution: 5% w/v BSA and 0.1% v/v Triton X-100 were dissolved in PBS.
The solution was filtered through a 0.2µM 500ml Rapid Flow Filter Unit (156-4020,
Thermo Scientific, MA, USA). Blocking solution was stored at 4oC for up to two
months.
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2.5.1.2 Immunofluorescence Microscopy
Cells were split as per Section 2.1 and resuspended in serum-free medium. 100 - 200µl
of cell suspension (dependent on cell number) was carefully plated on 18mm uncoated
glass coverslips (CS-18R15, Warner Instruments, CT, USA) in 12-well dishes. Plates
were incubated for 1 hour. Serum-free medium was used to prevent cell aggregates
forming, allowing cells to adhere as a monolayer onto the coverslips. 1ml of growth
medium was then carefully pipetted into each well so as not to disturb cell adhesion.
Prior to fixation, Growth Medium was removed and cells were washed in autoclaved
PBS. Cells were then fixed dependent on the antibodies to be used, either in 4% v/v
formaldehyde at room temperature for 15 minutes, ice-cold methanol at -20oC or
ice-cold 1:1 methanol/acetone at -20oC for 10 minutes. For a list of antibodies and
fixation method see Table 2.12. Cells were washed twice in autoclaved PBS, before
being permeabilised at room temperature for 5 minutes in 1ml permeabilization
buffer. Cells were then blocked in 1ml blocking solution per well for 30 minutes. The
blocking solution was then removed and primary antibodies were diluted in 50µl
per coverslip in blocking solution. 25µl of diluted primary antibodies was added
onto each coverslip and incubated at room temperature for 30 minutes, onto which
another 25µl was added for a further 30 minutes. Cells were then washed twice for 5
minutes at room temperature in PBS. The remaining steps were done in the dark.
Secondary antibodies were diluted in 50µl per coverslip in blocking solution. 25µl of
diluted secondary antibodies was added onto each coverslip and incubated at room
temperature for 25 minutes, onto which 25µl was added for a further 25 minutes.
For details of secondary antibodies see Table 2.13. For F-actin staining, Phalloidin
conjugated with Alexa Fluor 568 (A12380, Life Technology) was used at 1:250
dilution and incubated for 1 hour at room temp in combination with the secondary
antibodies. Cells were then washed twice for 5 minutes at room temperature in PBS.
Hoechst 33342 was diluted at 1:5000 in PBS (H3570, Thermo Scientific, MA, USA).
1ml of diluted Hoechst 33342 was added per well and incubated at room temperature
for 5 minutes. Coverslips were then washed in PBS for 10 minutes. Coverslips were
inverted onto glass slides with a drop of ProLong® Gold Antifade Reagent (P36934,
Thermo Scientific, MA, USA). Excess mounting reagent was removed with tissue
paper. Slides were stored in slide boxes at -4oC. Cells were imaged on an Olympus
DeltaVision microscope (GE Healthcare, OH, USA) equipped with a coolsnap HQ
camera. Details of the DelataVision optical filters can be found in Table 2.14.
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Table 2.12: Primary antibodies for immunofluorescence and fixation
Antibody (clone) Species raised Product number Manufacturer Dilution Fixation
α-tubulin
(DM1α) Mouse T9026 Sigma Aldrich 1:1000 Methanol or
formaldehyde
Centrin-2
(N-17-R) Rabbit sc-27793-R Santa Cruz 1:100 Methanol
γ-tubulin
(GTU88) Mouse T5326 Sigma Aldrich 1:500 Formaldehyde
E-cadherin








(Imperial, UK) 1:500 Formaldehyde
Pericentrin Rabbit ab4448 Abcam 1:1500 Formaldehyde
EB1




(DM1α) Mouse F2168 Sigma Aldrich 1:500 Methanol or
Formaldehyde
Table 2.13: Secondary antibodies for immunofluorescence
Antibody Species raised Product number Manufacturer Dilution
Anti-Rabbit
Alexa Fluor 488
Goat A11008 Life Technologies 1:1000
Anti-Rabbit
Alexa Fluor 568
Goat A11011 Life Technologies 1:1000
Anti-Mouse
Alexa Fluor 488
Goat A11001 Life Technologies 1:1000
Anti-Mouse
Alexa Fluor 568
Goat A11004 Life Technologies 1:1000
Table 2.14: DeltaVision Microscope optical filters used
Channel Band (nm) Center Wavelength (nm) Bandwidth (nm)
DAPI 411–459 435 48
FITC/GFP 501—549 525 48
TRITC 574.5—619.5 597 45
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2.5.2 Live cell imaging
H2B-GFP expressing cells were seeded onto glass-bottom dishes with 2ml of Growth
Medium (P35G-0-10-C, MatTek, MA, USA). Cells were imaged on an Olympus
DeltaVision microscope (GE Healthcare, OH, USA) equipped with a coolsnap HQ
camera. The microscope was enclosed within temperature and CO2-controlled
environments that maintained an atmosphere at 37oC and 3-5% humidified CO2.
GFP and brightfield images were captured at multiple points for 16 hours at 40X
(1.3 NA) objective. Captured images from each experiment were analysed using the
softWoRx Explorer software (GE Healthcare, OH, USA)
2.6 Cell viability
2.6.1 Colony formation assay
Using serial dilution, 100 cells were plated on 6cm diameter cell culture dishes in
triplicate per each condition. Cells were incubated for 10 days, with Growth Medium
being replaced every 48 hours. Growth Medium was removed and cells were washed
in 5ml of PBS. Cells were fixed in v/v 1% glutaraldehyde in PBS for 15 minutes at
room temperature (G6257, Sigma-Aldrich, MO, USA). Cells were washed in PBS
before incubating in 3ml of 0.5% w/v Crystal Violet (C6158, Sigma-Aldrich, MO,
USA) and 20% v/v methanol in deionised water for 30 minutes at room temperature.
Cells were washed 3 times in PBS for 5 minutes each at room temperature with
gentle rocking before being air dried overnight. Images of the plates were taken
on an Amersham Imager 600 (GE Healthcare, OH, USA). Crystal violet was then
dissolved in 3ml of 0.05% Triton-X 100 in PBS overnight with gentle rocking. 200µl
of the dissolved crystal violet was pippeted into a 96-well plate in triplicate for each
plate. The absorbance of crystal violet was analysed at 560nm and 405nm on the
Victor3 Multilabel Counter plate reader (Perkin Elmer, MA, USA).
2.6.2 IncuCyte
H2B-GFP-expressing cells were passaged and counted as described in Section 2.1.
Using serial dilution, 3×103 cells were plated per well in a 12-well plate in triplicate
with 1ml of Growth Medium. Plates were incubated for 24 hours to allow cells to
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adhere, and were then placed into an IncuCyte Zoom (Essen Bioscience, MI, USA)
for 7 days within an incubator at 37oC and 5% CO2. Brightfield and GFP images
were acquired at 100X magnification every hour, at 4 locations per well. Images
were then quantified using a “top-hat” mask based upon GFP using the IncuCyte
Zoom software to identify the number of individual nuclei based on the H2B-GFP
and thus cell number.
2.7 qRT-PCR
RNA was prepared using the Qiagen RNAeasy kit (Qiagen, MD, USA). Cells grown
in 6cm diameter dishes were passaged as previously described and resuspended in
1ml of Growth Medium. The cell suspension was placed in a 1.5ml autoclaved
microcentrifuge tube and centrifuged at 300g for 5 minutes. The medium was
removed and the cell pellet resuspended in 350µl RLT buffer to lyse the cells, the
suspension was then passed through a sterile 20-gauge needle to aid lysis. 350µl of
70% v/v ethanol in autoclaved deionised water was added and mixed by pipetting
to precipitate the RNA. The sample was then transferred to a RNeasy spin column
placed in a 2ml collection tube. The column was then centrifuged for 15 seconds at
8000g and the flow through discarded, allowing the RNA to bind to the membrane
in the column. 700µl of RW1 Buffer was added to the column and centrifuged at
8000g for 15 seconds and the flow through discarded. The column was then further
washed twice with 500µl RPE Buffer and centrifuged at 8000g, the first time for
15 seconds, and the second time for 2 minutes. The column was then transferred
to a new microcentrifuge tube and centrifuged for 1 minute to ensure no residual
buffer remained. The column was placed into a sterile microcentrifuge tube and 50µl
RNase-free water was carefully pipetted directly onto the spin column membrane
and incubated for 1 minute at room temperature. The column was then centrifuged
at 8000g for 1 minute and the flow through was quantified using the Nanodrop-1000
for RNA concentration as described in Section 2.2.5. RNA was stored at -20oC.
RNA was diluted in RNase-free water to 200ng/µl. Using the High-Capacity RNA-
to-cDNA™ Kit (4387406, Thermo Scientific, MA, USA) RNA was reverse transcribed
into cDNA. Per reaction, 5µl of RNA was added to 10µl 2X Reaction Mix, 1µl
Enzyme Mix and 4µl RNase-free water in a PCR tube. The tubes were then placed
in a C1000 Touch™ Thermal Cycler (Bio-Rad Laboratories, CA, USA). The lid of
the Thermal Cycler was set to 100oC to stop condensation within the lid, which
would reduce the concentration within the mixture. The PCR was then run under
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the following conditions:
Reverse transcription 37oC 60 minutes
Reverse Transcription inactivation 95oC 5 minutes
Hold 4oC -
cDNA generated from the reverse transcription was then analysed by qRT-PCR
in triplicate using the Power SYBR® Green PCR Master Mix (4367659, Thermo
Scientific, MA, USA). A PCR cocktail was made for each gene being analysed made
up of 12.5µl 2X Power SYBR® Green PCR Master Mix, 3.75µl of both the gene
specific forward and reverse primers at 10µM, and 4µl nuclease free water per well.
24µl of PCR cocktail was added to each well of a 96-well PCR plate, with 1µl of
cDNA, for a final volume of 25µl. The 96-well plate was then sealed and centrifuged
in a plate centrifuge for 5 seconds to collect samples at the bottom of the wells. The
plate was then placed in a 7500 Real Time PCR machine (Thermo Scientific, MA,
USA) and the following programme was run:
Enzyme activation 95oC 10 minutes
PCR cycle 95oC 15 seconds
Primer annealing and amplification 6oC 1 minute
40 cycles
Dissociation curve Default settings
The Ct (Cycle threshold) values (the number of cycles required for the fluorescent
signal to cross the threshold) generated from qRT-PCR were analysed using the
comparative Ct method (2-ΔΔCt). GAPDH was used as a housekeeping gene for
normalisation. The primers used for qRT-PCR are shown in Table 2.15.
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2.8 Atomic force microscopy
Cells were plated onto glass bottom MatTek dishes. When cells reached 70%
confluency they were arrested at metaphase for 2 hours using 10µM MG132 in
Leibovitz L15 medium (11415064, Life Technologies, CA, USA) supplemented with
serum and cell specific additives. Leibovitz L15 medium is designed for cell growth in
environments without CO2 equilibration, allowing cells to survive within the Atomic
Force Microscope environment. Atomic Force Microscopy experiments were kindly
performed by Malti Vaghela in Dr. Guillaume Charras’s lab at UCL. Indentations
of cells by AFM were performed using a JPK NanoWizard-1 AFM (JPK, Berlin,
Germany) mounted on an inverted microscope (IX-81, Olympus, Berlin, Germany).
For measurements, soft cantilevers with V-shaped tips were used (BioLever (OBL-10),
Bruker; nominal spring constant of 0.006 N m-1). The actual spring constant of the
cantilever was calibrated using the thermal noise method implemented in the AFM
software (JPK SPM). Before each experiment, the sensitivity of the cantilever was
measured from the slope of force-distance curves that were acquired on glass. For
each measurement, the cantilever was first aligned above a metaphase cell using the
optical microscope. Then, force-distance curves were acquired over the centre of
the cell at the 4 vertices of a square with a 2µm side length. At each of these four
positions, up to 10 curves were acquired with an approach speed of 2.5 µm/s and
a target force of 2.5nN. Experimental force-distance curves were post-processed to
compute an apparent elastic modulus. The contact point between the cantilever tip
and the cell was determined using the method outlined by Crick and Yin implemented
in MATLAB (MathWorks, Natick,MA, USA)(Crick & Yin 2007). The indentation
depth was then calculated by subtracting the cantilever deflection d from the piezo
displacement beyond the contact point z (δ=z-d). The resultant force-indentation
curves were then averaged over each position and fitted with the Sneddon model in
order to calculate the apparent elasticity of each location probed in the cell (Sneddon
1965). Curve fitting was restricted to indentation depths shallower than 800nm to
maximise contributions of the cortex to restoring force and minimise contributions
from the cytoplasm.
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2.9 Statistics
Appropriate statistics were carried out using GraphPad Prism version 5.0 for Windows
(GraphPad Software, CA, USA). For each experiment see specific figure legends.
Rosette plots were created by Hefin Rhys (Queen Mary, University of London, UK)
in R 3.3.1 (R Development Core Team 2016) using packages ggplot2 2.1.0, and dplyr




Centrosome clustering efficiency varies in different
cell types
3.1 Models for generating supernumerary
centrosomes
To understand if cells have the same capacity to efficiently cluster supernumerary
centrosomes, centrosome amplification was induced in a panel of 6 non-cancer-derived
cell lines: MCF10A (human mammary epithelium), HaCaT (human keratinocyte),
J3B1A (murine mammary epithelium), RPE-1 (human retina pigmented epithelium),
NIH-3T3 (murine fibroblast) and BJ (human fibroblast). Supernumerary centrosomes
were initially generated using three different methods. DCB is an actin depolymerising
drug resulting in cytokinesis failure whereby the subsequent tetraploid cells contain
supernumerary centrosomes. Blebbistatin was also used to generate tetraploid cells
with supernumerary centrosomes by inhibiting myosin II (MyoII), which is required
for the formation of the cytokinetic furrow, also resulting in cytokinesis failure by
an independent mechanism to that of DCB. The CDK1 inhibitor R0-3306 (CDK1
inhibitor) was used to arrest cells at the end of G2 in the cell cycle, which results in
centrosome overduplication without DNA endoreplication (Steere et al. 2011).
Centrosome amplification was induced by either treating cells plated on glass cov-
erslips with 4µM DCB, or 50µM blebbistatin for 20 hours, or 5µM R0-3306 for 40
hours. The drugs were then washed off, and after 24 hours the cells were fixed for
analysis (Figure 3.1).
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Figure 3.1: Inducing centrosome amplification
Schematic of the 3 initial methods for generating supernumerary centrosomes. Cen-
trosome amplification was induced by either treating cells plated on glass coverslips
with 4µM DCB, or 50µM blebbistatin for 20 hours, or 5µM of the CDK1 inhibitor
R0-3306 for 40 hours. The drugs were then washed off, and after 24 hours the cells
were fixed for analysis. Both DCB and blebbistatin lead to cytokinesis failure, and
the resultant tetraploid cells have supernumerary centrosomes. The CDK1 inhibitor
arrests cells in G2 and leads to centrosome overduplication.
Cells were then antibody labelled for α-tubulin and centrin whilst DNA was stained
with Hoechst dye. Centrosome number per cell was quantified at metaphase using
2D immunofluorescence microscopy (identified by the mitotic spindle labelled by
α-tubulin), where cells with >4 centrioles (centrin labels individual centrioles, with 2
centrioles per centrosome) were identified as containing supernumerary centrosomes
(Figure 3.2). Centrosome number was quantified during mitosis to ensure that
the centrosome duplication had occurred, whereas if cells were quantified during
interphase centrosome duplication may not have occurred and the quantification of
centrosome number would have been inaccurate.
Generation of cells containing extra centrosomes can lead to cell cycle arrest in
normal cell lines (Holland et al. 2012). To overcome this, cells were released for
24 hours after each treatment into p38 inhibitor. p38 inhibition has been shown to
allow cells to overcome cell cycle arrest. Work by Zarubin and Han showed that the
stress of tetraploidy can lead to a p38 dependent cell cycle arrest (Zarubin & Han
2005). They showed that p38 is able to stabilise, phosphorylate and activate p53
which in turn drives cell cycle arrest. MCF10A seems to be the exception as it does
not arrest upon induction of extra centrosomes. Whilst MCF10A express both p38
and p53, they do not express p16 which is an inhibitor of cyclin dependent kinases
such as CDK4 and CDK6 which phosphorylate the retinoblastoma protein (pRB)
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Figure 3.2: Representation of mitotic cells with normal and supernumer-
ary centrosomes
Representative images of RPE-1 cells with normal centrosome number (left, iden-
tified by 2 centrin foci at each pole) and supernumerary centrosomes (middle and
right) where the cell contains >4 centrin foci. Cells were stained for centrioles
(centrin, green), microtubules (α-tubulin, red) and DNA (Hoescht, blue). Inset are
the centriole foci for each cell. Scale bars: 10µM
resulting in progression from G1 phase to S phase, which could be why they do not
arrest.
Centrosome amplification was quantified in all 6 cell lines with the different drug
treatments with the use of the p38 inhibitor. Centrosome amplification in control
cells was low at 8-20% of the cell population containing supernumerary centrosomes
(Figure 3.3). DCB treatment increased centrosome amplification to 40-75% of cells
containing supernumerary centrosomes. Blebbistatin resulted in 42-50% of cells with
supernumerary centrosomes. The CDK1 inhibitor had the highest levels of centrosome
amplification with 65-90% of cells with supernumerary centrosomes, however, the
CDK1 inhibitor in the RPE-1 cells resulted in the formation of micronuclei and cell
cycle arrest at G2, even with the addition of the p38 inhibitor, therefore as cells
did not enter mitosis centrosome amplification could not be quantified (Figure 3.3).
Therefore, all the conditions for generating supernumerary centrosomes resulted
in significantly higher levels of centrosome amplification in all cell lines, with the
exception of the RPE-1 with the CDK1 inhibitor which could not be quantified.
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Figure 3.3: Quantification of centrosome amplification
Quantification of centrosome amplification for the different methods utilised to
generate supernumerary centrosomes. Cells were treated with either 4µM DCB,
or 50µM Blebbistatin for 20 hours before being washed with fresh growth medium
and incubated with 10µM p38 inhibitor for 24 hours. For CDK1i treatment, 5µM
inhibitor was added for 40 hours, cells were then washed and incubated with 10µM
p38 inhibitor. ∗RPE-1 cells treated with CDK1 inhibitor for 40hrs arrested in
interphase with fragmented nuclei and could not be analysed. Data are mean ± SD
(standard deviation), n = 300 individual cells, 100 per experiment at metaphase.
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3.2 Clustering efficiency varies with cell type
Centrosome clustering was quantified in cells containing supernumerary centrosomes
(>4 centrioles) at both metaphase and cytokinesis. Multipolar cells were identified
at metaphase as having three or more poles, and at cytokinesis as dividing into
three or more daughter cells (Figure 3.4 A and C). Clustered cells were identified at
metaphase and cytokinesis as the cell dividing in a pseudo-bipolar manner, whereby
supernumerary centrosomes were clustered at one or both poles.
When comparing centrosome clustering between the different cell lines there was
no significant trend at metaphase, except for the BJ which were able to cluster
very efficiently compared to the other cells lines (~80% of cells with supernumerary
centrosomes) with both the DCB and Blebbistatin treatment, although this difference
was not seen with the CDK1 inhibitor (Figure 3.4 B). The remaining cell lines only
clustered in 20-40% of their cells with supernumerary centrosomes, with J3B1A
having particularly low efficiency of ~10% with the DCB and Blebbistatin treatment.
At cytokinesis, however, there was a clear trend, with the NIH-3T3, BJ and RPE-
1 cell lines all being able to cluster efficiently (~80% ) for all of the methods of
inducing supernumerary centrosomes, whilst the MCF10A, HaCaT and J3B1A
were less efficient with centrosome clustering only occurring in 10-40% of cells with
supernumerary centrosomes, showing little variation from metaphase in these three
lines (Figure 3.4 D).
These data suggest that centrosome clustering efficiency is cell line dependent,
with not all cell lines having the same efficiency to cluster their supernumerary
centrosomes. The level of centrosome clustering was lower at metaphase than at
cytokinesis, suggesting that at metaphase they are a mixed population of cells
that have clustered and those that are still in a multipolar configuration, and as a
consequence centrosome clustering is higher in cytokinesis For future experiments,
as metaphase was not a clear indicator of clustering efficiency cytokinesis was used.
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Figure 3.4: Centrosome clustering efficiency is cell type dependent
A Representative images of HaCaT cells with supernumerary centrosomes, gener-
ated by DCB treatment with p38 inhibitor, undergoing multipolar and clustered
metaphases. B Quantification of centrosome clustering in metaphase. Data are
mean ± SD, n = 300 individual cells, 100 per experiment. C Representative images
of HaCaT cells with supernumerary centrosomes, generated by DCB treatment with
p38 inhibitor, undergoing multipolar and clustered cytokinesis. D Quantification of
centrosome clustering in cytokinesis. Data are mean ± SD, n = 150 individual cells,
50 per experiment. *RPE-1 cells treated with CDK1 inhibitor for 40hrs arrested in
interphase with fragmented nuclei and could not be analysed. Scale bar = 10µM.
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3.3 p38 inhibitor does not affect centrosome
number or centrosome clustering
Because the cell lines were treated with p38 inhibitor, to assess whether this could
impact centrosome number and centrosome clustering MCF10A cells had supernu-
merary centrosomes induced by DCB treatment with and without the addition of
the p38 inhibitor. Centrosome amplification was then quantified (Figure 3.5 A).
No significant effect was observed in centrosome amplification upon the addition
of the p38 inhibitor, suggesting the hypothesis that the use of the p38 inhibitor
in the remaining cell lines would not affect centrosome amplification. Similarly,
no significant difference was observed in centrosome clustering with and without
the inhibitor, suggesting that the p38 inhibitor does not affect clustering efficiency
(Figure 3.5 B).
Figure 3.5: p38 inhibitor does not affect centrosome clustering
A Quantification of centrosome amplification in MCF10A cells with supernumerary
centrosomes induced by DCB treatment, with and without the addition of p38
inhibitor. No significant difference in centrosome amplification was observed upon
p38 treatment. B Quantification of centrosome clustering in MCF10A cells with
supernumerary centrosomes induced by DCB treatment, with and without the
addition of p38 inhibitor. No significant difference in centrosome clustering was
observed upon p38 treatment. Data are mean ± SD, n = 150 individual cells, 50 per
experiment at cytokinesis. Data analysed using Student’s t-test.
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3.4 Live cell imaging
To further confirm these results live cell imaging of tetraploid cells was performed.
MCF10A, HaCaT, RPE-1 and BJ cell lines expressing H2B-GFP (Histone 2B Green
Fluorescent Protein tagged) were generated via lentivirus infection. The H2B-GFP
construct allows DNA to be followed. The cell lines were then plated on glass
bottom microscopy dishes and supernumerary centrosomes were induced by DCB
treatment. Cells that failed cytokinesis, and therefore contained supernumerary
centrosomes, were easily identified by containing 2 nuclei (binucleated) (Figure 3.6 B,
time 0). These cells were then tracked through mitosis by live cell imaging and were
quantified as either undergoing a bipolar (as a proxy for clustered centrosomes) or
multipolar division (Figure 3.6 A). The results supported the observations observed
at cytokinesis in the fixed cell lines with the MCF10A and HaCaT not clustering
very efficiently (33 and 44%) whereas the RPE-1 and BJ cells cluster more efficiency
(>70%). These results support the observations made in the fixed cells and indicate
that quantification of clustering at cytokinesis is a better readout of clustering
efficiency.
Figure 3.6: Quantification of centrosome clustering by live cell imaging
A Quantification of centrosome clustering via live cell imaging in H2B-GFP expressing
cells where supernumerary centrosomes were generated by DCB treatment. B
Representative images of MCF10A H2B GFP tetraploid cells undergoing clustered
and multipolar cell divisions over time. Scale bar = 10µM.
93
Chapter 3. Results I: Centrosome clustering efficiency in different cell types
3.5 Centrosome amplification by PLK4
overexpression
In addition to drug treatments to induce supernumerary centrosomes, transient
overexpression of PLK4, the master regulator of centrosome duplication was also
used. PLK4 overexpression is an established method for generating supernumerary
centrosomes (Bettencourt-Dias et al., 2005; Habedanck et al., 2005; Kleylein-Sohn et
al., 2007; Basto et al., 2008). To ensure that PLK4 overexpression was transient,
it was controlled by a tetracycline repressor (TetR), this was necessary as it has
previously been shown that constitutive overexpression of PLK4 results in centrosome
amplification, which is then lost over time, whereas using a transient system allows
the analysis of supernumerary centrosomes when required. Cell lines expressing
the tetracycline repressor were generated by lentivirus, and subsequently infected
with lentivirus containing inducible PLK4. The tetracycline repressor binds to the
CMV/TO promoter, thereby inhibiting the expression of PLK4. Upon the addition
of Doxycycline hyclate (Dox) the repressor is suppressed and PLK4 overexpressed
enabling centrosome overduplication.
Centrosome amplification was quantified in the panel of cell lines upon the addition
of Dox in the PLK4 cell lines (Figure 3.7). Centrosome amplification went from
~20% to ~80% in the MCF10A, HaCaT, BJ and RPE-1 treated with doxycycline
hyclate. Centrosome amplification was not as efficient in the NIH-3T3 where 40% of
cells contained supernumerary centrosomes after Dox treatment (Figure 3.7).
Upon PLK4 overexpression there was little variation in centrosome clustering between
cell lines at metaphase, except for the NIH-3T3 which was more efficient at 60%
compared to ~30% in the other cell lines (Figure 3.8 A). At cytokinesis, the BJ and
NIH-3T3 cluster more efficiently at ~80% compared to the MCF10A, HaCaT and
RPE-1 which cluster ~60% of their cells with supernumerary centrosomes (Figure
3.8 B). This data is in contrast to the other methods of generating supernumerary
centrosomes, as both the MCF10A and HaCaT cell lines are more efficient (by
~20%) at clustering their supernumerary centrosomes with PLK4 overexpression,
whereas the NIH-3T3, BJ and RPE-1 have impaired centrosome clustering of ~15%.
Therefore, there was no specific trend observed.
To evaluate if Dox affects centrosome number, independently of PLK4 overexpression,
centrosome number in MCF10A cells with and without Dox was quantified. No signif-
icant difference in centrosome amplification was observed between control MCF10A
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Figure 3.7: Centrosome amplification by PLK4 overexpression
Quantification of centrosome amplification in the panel of cells lines expressing
TetR PLK4 with and without the addition of 2mg/ml doxycycline hyclate for 48
hours. Centrosome amplification is significantly increased upon PLK4 overexpression.
Data are mean ± SD, n = 150 individual cells, 50 per experiment at metaphase.
*J3B1A.TetR.PLK4 cells were not generated.
and those treated with Dox, this indicated that Dox does not affect centrosome
number directly, and any increase observed with the PLK4 cell lines is due to PLK4
overexpression (Figure 3.9 A). Similarly, to determine if Dox affects, or could explain
the variation between centrosome clustering observed with PLK4 overexpression
compared to the other methods of inducing supernumerary centrosomes, MCF10A
cells were treated with DCB to induce supernumerary centrosomes with and without
Dox for 48 hours. No significant change in centrosome clustering at cytokinesis was
observed, suggesting that Dox does not affect centrosome clustering, and therefore
does not explain the discrepancies observed in centrosome clustering between PLK4
overexpression and the other methods for generating supernumerary centrosomes
(Figure 3.9 B).
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Figure 3.8: Centrosome clustering in cell lines where supernumerary cen-
trosomes are generated by PLK4 overexpression
A Quantification of centrosome clustering in cell lines expressing TetR PLK4 with
supernumerary centrosomes induced upon PLK4 overexpression after the addition of
2mg/ml doxycycline hyclate at metaphase. B Quantification of centrosome clustering
at cytokinesis. Data are mean ± SD, n = 150 individual cells, 50 per experiment at
cytokinesis.
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Figure 3.9: Doxycycline hyclate does not affect centrosome amplification
or centrosome clustering
A Quantification of centrosome amplification in MCF10A with and without the
addition of 2mg/ml doxycycline hyclate for 48 hours. No significant difference was
observed in centrosome amplification with doxycycline hyclate. B Quantification of
centrosome clustering in MCF10A cells with supernumerary centrosomes induced
by DCB treatment, with and without the addition of 2mg/ml doxycycline hyclate.
No significant difference in centrosome clustering was observed upon doxycycline
hyclate treatment. Data are mean ± SD, n = 150 individual cells, 50 per experiment
at cytokinesis. Data analysed using Student’s t-test.
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3.5.1 TetR affects centrosome clustering
To understand if PLK4 overexpression was influencing centrosome clustering or
if it was the expression of the tetracycline repressor that was having an impact,
MCF10A overexpressing TetR alone, or in combination with PLK4, in the absence
of Dox, were treated with DCB to induce centrosome amplification. It was observed
that TetR overexpression alone, or in combination with PLK4, increased clustering
efficiency in tetraploid cells (Figure 3.10). These results suggest that the tetracycline
repressor itself is having an effect on centrosome clustering, independently of PLK4
overexpression, although it is unclear why the tetracycline repressor is affecting
clustering. Because of this effect the preferred method for most of the remaining
experiments was DCB treatment.
Figure 3.10: The tetracycline repressor affects centrosome clustering
Percentage of centrosome clustering at cytokinesis in MCF10A, MCF10A.TetR and
MCF10A.TetR.PLK4 in cells with supernumerary centrosomes which were generated
by DCB treatment. TetR expressing cells cluster more efficiently than control cells,
suggesting that TetR is having an effect on centrosome clustering. Data are mean
± SD, n = 150 individual cells, 50 per experiment. Data analysed using two-way
ANOVA with S̆idák post hoc test, **p<0.01, ***p<0.001.
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3.6 Discussion
Previous work suggests that cells have intrinsic mechanisms that facilitate centrosome
clustering, such as the spindle assembly checkpoint and the kinesin HSET, and thus
are unlikely to require adaptation to centrosome amplification (Reviewed in: Godinho
and Pellman, 2014). This was further supported by the fact that most cancer cell
lines with extra centrosomes seem to be able to cluster centrosomes efficiently (Ring,
Hubble and Kirschner, 1982; Quintyne et al., 2005; Kwon et al., 2008; Ganem,
Godinho and Pellman, 2009). However, a systematic analysis of clustering efficiency
in different cell types has never been performed.
Using three different and independent methods to generate supernumerary centro-
somes in a panel of six non-cancerous cell lines, it was interesting to observe that not
all cell lines had the same ability to efficiently cluster their supernumerary centro-
somes by cytokinesis. Cytokinesis was found to be a more reliable stage to quantify
centrosome clustering, as during metaphase cells may still be within a multipolar
configuration, which may ultimately cluster before the end of cell division. These
results were also confirmed by live cell imaging of tetraploid cells with supernumerary
centrosomes, supporting that fixed cell analysis was a sufficient method for reliably
analysing efficiency.
Interestingly, whilst PLK4 overexpression using a Tet-inducible system is widely
used within the field to generate supernumerary centrosomes, it was observed that
overexpression of the TetR alone or in combination with PLK4 increased clustering
efficiency in epithelial cells upon DCB treatment suggesting that TetR overexpression
is unexpectedly affecting this process. As a large amount of the research within the
field is done with PLK4 overexpression to generate supernumerary centrosomes, the
observation that the TetR may itself affect centrosome clustering efficiency may then
skew reported results of centrosome clustering. The mechanism through which the
TetR may be affecting centrosome clustering is unclear.
Because of the effect of the TetR on clustering efficiency, DCB treatment was used for
the majority of the remaining experiments for generating supernumerary centrosomes.
DCB results in cytokinesis failure through actin depolymerisation, with the resultant
tetraploid cells containing supernumerary centrosomes. Tetraploidy is often reported
in cancer, and may therefore be a mechanism for centrosome amplification. Therefore,
DCB treatment could be a representative model of centrosome amplification within
a tumour.
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The observation that not all cell types have the same ability to cluster their super-
numerary centrosomes raises the question that some cells might need to adapt for
centrosome clustering. Potential adaptation mechanisms include increased time in
mitosis or increased levels of the kinesin HSET allowing for centrosome clustering.
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4.1 Time in metaphase does not increase
centrosome clustering
The spindle assembly checkpoint has been shown to be important in centrosome
clustering, allowing cells time to cluster their supernumerary centrosomes prior to
anaphase onset (Basto et al., 2008; Yang et al., 2008). In support of this, cancer cells
with supernumerary centrosomes have been shown to have an increase in mitotic
index, the proportion of cells undergoing mitosis, which would suggest that cells with
supernumerary centrosomes take longer to go through mitosis, potentially giving
them time to cluster their centrosomes (Chan, 2011). To evaluate whether cells that
do not efficiently cluster supernumerary centrosomes, if given more time in mitosis
were then able to cluster more efficiently, MCF10A and HaCaT cells were treated
with 10µM of the proteasome inhibitor MG132 to block cells in metaphase (Kwon et
al., 2008). After 4 hours, the inhibitor was washed out, and the cells were allowed
to progress through mitosis for 1 hour (Figure 4.1 A). Under these conditions, no
significant difference in centrosome clustering was observed either at metaphase
or cytokinesis, suggesting that the low efficiency of centrosome clustering in the
MCF10A and HaCaT cell lines is not due to an insufficient time in metaphase, and
that there must be intrinsic differences that cannot be overcome by increasing time
in mitosis (Figure 4.1 B).
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Figure 4.1: Time in mitosis does not affect centrosome clustering
A) Schematic of the treatment of MCF10A and HaCaT cells using 10µM of the
proteasome inhibitor MG132 for 4 hours before washout and incubation at 37C for 1
hour. B) Quantification of MCF10A and HaCaT after MG132 treatment, showing
no significant difference between vehicle and MG132 treated. Data are mean ± SD,
n = 300 individual cells. Data analysed using two-way ANOVA with Šidák post-hoc
test.
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4.2 Levels of HSET do not correlate with
centrosome clustering
The kinesin HSET (KIFC1) is well established as an essential factor in centrosome
clustering (Basto et al., 2008; Kwon et al., 2008). To determine if there was a
correlation between HSET levels and clustering efficiency, the protein levels of HSET
were analysed using western blotting. HSET levels were consistent between the panel
of cell lines, suggesting that the differences in efficiency of centrosome clustering are
not due to HSET protein level variation (Figure 4.2).
Figure 4.2: HSET presence does not independently allow for efficient
centrosome clustering
Western blot analysis of HSET levels between the panel of 6 cell lines, showing
little variation in HSET abundance between cell lines. β-actin was used as a loading
control. Representative blot of 3 independent experiments.
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4.3 Cells expressing E-cadherin have an
impaired ability to cluster supernumerary
centrosomes
The RPE-1, BJ and 3T3 cell lines cluster supernumerary centrosomes considerably
more efficiently (~80% with DCB treatment) compared to the MCF10A, HaCaT and
J3B1A cell lines (~40% with DCB treatment). In trying to account for this difference,
it was noted that both the BJ and 3T3 cell lines were fibroblasts, and therefore do
not express E-cadherin. Similarly, whilst the RPE-1 cell line was originally derived
from epithelia, RPE-1 cells no longer express E-cadherin (Figure 4.3). This led to
the hypothesis that E-cadherin expression may be impairing centrosome clustering.
Figure 4.3: E-cadherin expression in the cell line panel
Western blot analysis of E-cadherin in the panel of 6 cell lines, showing that the
epithelial cells MCF10A, HaCaT and J3B1A express E-cadherin, whereas the 2
fibroblast cell lines BJ and NIH-3T3 do not express E-cadherin. RPE-1 cells, whilst
originally epithelial by origin, no longer express E-cadherin. β-actin was used as a
loading control. Representative of 3 independent experiments.
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4.3.1 siRNA knockdown of E-cadherin increases
centrosome clustering
To test the hypothesis that E-cadherin impairs centrosome clustering, small interfering
RNA (siRNA) was used to deplete E-cadherin protein levels. siRNA allows for the
short term (2-4 days) silencing of a particular protein of interest. The synthetic
double stranded RNA targets the mRNA of the protein of interest for degradation,
resulting in a loss of protein translation. MCF10A and HaCaT cells were transfected
either with siNegative, a non-targeting siRNA which controls for effects based on
transfection (but is designed not to target any mRNA), or on-target SMARTpool
for E-cadherin (gene name CDH1 ). The SMARTpool siRNAs are composed of 4
different siRNAs targeting the same gene, these sequences are designed to minimise
off-target effects. In addition, the sequences were designed to target different regions
within the gene transcript to maximise efficiency of protein knockdown. Cells were
analysed 72 hours post transfection. Knockdown with the SMARTpool siRNA was
highly efficient, as analysed by western blot (Figure 4.4 A). Centrosome clustering
in MCF10A and HaCaT cells, where supernumerary centrosomes were induced by
DCB treatment, increased with the knockdown of E-cadherin from ~40 to ~70%
(Figure 4.4 B). This supported the hypothesis that E-cadherin impairs centrosome
clustering.
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Figure 4.4: Knockdown of E-cadherin by siRNA increases centrosome
clustering
A) Western blot analysis of E-cadherin in MCF10A and HaCaT cells treated with
siNegative (control) and on-TARGET SMARTpool siRNA against E-cadherin (E-
cad). Cells were analysed at 72 hours post transfection. β-actin was used as a
loading control. Representative blot of 3 independent experiments. B) Centrosome
clustering increases upon knockdown of E-cadherin by siRNA. Data are mean ± SD,
n = 150 individual cells, 50 per experiment. Data analysed using two-way ANOVA
with Šidák post-hoc test, *** p<0.001, **** p<0.0001.
4.3.2 shRNA silencing of E-cadherin increases centrosome
clustering
In order to be able to examine the role of E-cadherin silencing for periods longer
than 72 hours, short hairpin RNA (shRNA) was used. shRNA differs from siRNA in
that instead of the RNA being directly transfected into the cells, they are encoded in
a DNA vector which is transfected via plasmid or viral transduction, enabling them
to silence proteins for the longer time period. Once inside the cell, the shRNA is
transcribed under the control of an RNA polymerase. The shRNA transcript consists
of a stem-loop structure, this is then transcribed in the nucleus and enters the RNA
interference (RNAi) pathway resulting in reduction in the translation of the protein
of interest. MCF10A.TetR.PLK4 cells expressing four different shRNA against
E-cadherin were generated by lentiviral transduction and selected using 10µg/ml
puromycin. To examine the silencing efficiency of the different shRNA, protein levels
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Figure 4.5: shRNA silencing of E-cadherin increases centrosome cluster-
ing
A) Western blot analysis of E-cadherin levels in MCF10A TetR PLK4 with 4 different
shRNA against CDH1. Silencing was most efficient with shRNAs 9 and 10, whereas
sequences 8 and 11 did not alter E-cadherin protein levels. β-actin was used as a
loading control. Representative blot of 3 independent experiments B) Centrosome
clustering increases upon silencing of E-cadherin by shRNA. Data are mean ± SD, n
= 150 quantified at cytokinesis. Data analysed using one-way ANOVA with Tukey
post-hoc test, * p<0.05, ** p<0.01.
were analysed by western blotting (Figure 4.5 A). Sequences 9 and 10 were the
most efficient at silencing E-cadherin, whereas sequences 8 and 11 did not affect
E-cadherin levels. Therefore, shRNA number 9 and 10 were used for the remaining
analysis. Although TetR.PLK4 cells have already improved clustering efficiency due
to the TetR expression (see Section 3.5.1), it was still possible to observe that when
E-cadherin was silenced by shRNA, centrosome clustering increased by ~20% (Figure
4.5 B). This supports the data observed with siRNA that loss of E-cadherin can
improve centrosome clustering in epithelial cells.
4.3.3 CRISPR-Cas9 knockout of E-cadherin increases
centrosome clustering
To further evaluate the role of E-cadherin in impairing efficient clustering, knockout
of E-cadherin by CRISPR-Cas9 technology was performed.
To maximise the effect of each CRISPR-Cas9 reaction, all sequences were designed
to target within the first exon of E-cadherin. This ensures that if a truncation
occurs, that the protein expressed should have the least likelihood of being active.
Lentiviral vectors were generated as described in Section 2.3.5. To further increase
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Figure 4.6: CRISPR-Cas9 efficiency in MCF10A and HaCaT
Western blots of CRISPR-Ca9 efficiency in A) MCF10A and B) HaCaT cell lines
co-infected with multiple guide RNAs against E-cadherin. In both cell lines gRNAs 2
and 5 when co-infected had the greatest loss of E-cadherin in the mixed populations,
suggesting the greatest percentage of knockout. β-actin was used as a loading control.
the likelihood of successful gene knockout, multiple lentiviruses using two or more
gRNA were co-infected into the MCF10A and HaCaT cell lines. After two weeks of
selection using 1-5µg/ml puromycin, E-cadherin levels in the mixed cell populations
were analysed by western blot analysis (Figure 4.6). In both the MCF10A and
HaCaT cell lines, co-infection with lentivirus with gRNA sequences 2 and 5 showed
the lowest levels of E-cadherin, suggesting the highest percentage of gene knockout
occurred in these populations.
Having identified the polyclonal populations with the highest levels of E-cadherin
knockout, these cell lines were then used for clonal selection. 100 cells were plated in
a 15cm dish and incubated for 10 days to allow colonies to form from single cells.
Colonies were then selected using a clonal selection column and trypsinisation. The
individual colonies were then amplified, and once expanded to a large enough popula-
tion, the protein expression of E-cadherin was analysed. For both the MCF10A and
HaCaT cell lines, multiple clones of E-cadherin knockout were identified (Figure 4.7 A
and C). In both cell lines, where supernumerary centrosomes were generated by DCB
treatment, loss of E-cadherin resulted in increased centrosome clustering, whereas
the control clones where the gene knockout was unsuccessful had no significant effect
on centrosome clustering (Figure 4.7 B and D). Therefore, supporting the results
observed with both siRNA and shRNA.
To mitigate any effect due to clonality of the knockout cell lines, an equal mix of
the knockout clones were made for both the MCF10A and HaCaT, generating a
polyclonal population of E-cadherin cell lines, referred to as MCF10A CDH1-/- and
HaCaT CDH1-/- respectively. E-cadherin knockout in the polyclonal populations was
re-confirmed by both western blot and 2D immunofluorescence microscopy (Figure
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Figure 4.7: Loss of E-cadherin in clonal populations increases centrosome
clustering
Western blot analysis of MCF10A and HaCaT cell lines showing E-cadherin levels
in individual clonal populations (A and C) where β-actin is used as a loading
control. Representative blot of 3 independent experiments. Centrosome clustering
increases in the clones where E-cadherin has been successfully knocked out, but
remains unchanged in the control clones (B and D). Supernumerary centrosomes
were generated by DCB treatment. Data are mean ± SD, n = 150 individual cells,
50 per experiment, quantified at cytokinesis.
4.8 A and B) These polyclonal populations of CDH1-/- cells were able to cluster their
supernumerary centrosomes significantly more efficiently than control E-cadherin
expressing cells from ~40 to ~80% (Figure 4.8 C).
As well as examining the effect of loss of E-cadherin on non-cancerous cell lines,
comparison of the A431 human epidermoid carcinoma cell lines was also performed.
A431 CDH1-/- cells were generated by Takuya Kato in the lab of Erik Sahai at
the Francis Crick Institute. A431 normally express E-cadherin, and have a ~15%
population of cells containing supernumerary centrosomes (Supplementary Table
7.1). After treatment with DCB, A431 cells behave similarly to other epithelial
cell lines, with only ~30% of cells clustering at cytokinesis (Figure 4.9 C). Upon
loss of E-cadherin by CRISPR-Cas9, as confirmed by western blot analysis and
2D immunofluorescence microscopy (Figure 4.9 A and B), ~55% of A431 CDH1-/-
cells can cluster their supernumerary centrosomes at cytokinesis (Figure 4.9 C). No
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Figure 4.8: Gene knockout of E-cadherin increases centrosome clustering
A) Western blot analysis of E-cadherin levels after an equal combination of E-cadherin
knockout clones were mixed for the MCF10A and HaCaT cell lines, generating
polyclonal populations. B) 2D immunofluorescence microscopy images of both
WT and CDH1-/- MCF10A and HaCaT cell lines, confirming E-cadherin loss. C)
Centrosome clustering increases with loss of E-cadherin in cells where supernumerary
centrosomes are generated by DCB. Data are mean ± SD, n = 150 individual cells,
50 per experiment, quantified at cytokinesis. Data analysed using a two-way ANOVA
with Šidák post-hoc test, *** p<0.001. Scale bar = 10µM.
significant difference was observed at metaphase, supporting the previous results,
that metaphase is not an adequate measure of clustering efficiency (Figure 4.9 C).
In turn, this supports the conclusion that in cancer cells, as well as in non-cancer
cell lines, loss of E-cadherin is sufficient to improve centrosome clustering efficiency.
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Figure 4.9: Loss of E-cadherin in A431 human epidermoid carcinoma
cells increases centrosome clustering
A) Western blot analysis in the A431 human epidermoid carcinoma cell line, and
A431 CDH1-/- given by Erik Sahai. B) 2D Immunofluorescence images of A431 and
A431 CDH1-/- confirming loss of E-cadherin. C) Centrosome clustering increases
with loss of E-cadherin in cells where supernumerary centrosomes are generated by
DCB, quantified at cytokinesis. No significant change was observed at metaphase.
Data are mean ± SD, n = 150 individual cells, 50 per experiment. Data analysed
using two-way ANOVA with Šidák post-hoc test. ***p<0.001. Scale bar = 10µM.
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4.3.4 Expressing E-cadherin in RPE-1 impairs centrosome
clustering
To explore if expression of E-cadherin affects centrosome clustering in a cell line that
does not normally express it, RPE-1 cells that expressed full length E-cadherin were
generated. To control for a lentiviral infection RPE-1 cells expressing a truncated
form that only contained the intracellular domains (E-cadDN) were also generated.
Western blot analysis was performed confirming both E-cadherin and E-cadDN
protein expression at the correct sizes 120 and ~50kDa respectively (Figure 4.10
A). 2D immunofluorescence microscopy was used to determine that the localisation
of the two constructs was correct, with the full-length E-cadherin being membrane
bound, whereas the truncated form localised to the cytoplasm (Figure 4.10 B). RPE-1
cells in which supernumerary centrosomes are induced by DCB treatment cluster
supernumerary centrosomes efficiently (~90%), however after expressing full length
E-cadherin, centrosome clustering was impaired to a level that is comparable to
the centrosome clustering efficiency in the MCF10A, HaCaT and J3B1A epithelial
cell lines at ~40% (Figure 4.10 C). Expression of the truncated E-cadDN had no
significant effect on centrosome clustering (Figure 4.10 C). These data further support
the hypothesis that E-cadherin loss is both required and sufficient to enable efficient
clustering supernumerary centrosomes in epithelial cells.
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Figure 4.10: Expression of full length E-cadherin in RPE-1 cells impairs
centrosome clustering
A) Western blot analysis of E-cadherin protein levels in RPE-1 control cells, RPE-1
cells expressing full length E-cadherin (+E-cad), and a truncated form of E-cadherin
which only contains the intracellular domain (+E-cad DN). B) 2D immunofluores-
cence microscopy images to show localisation of E-cadherin in RPE-1 cells, and the
full and truncated forms of E-cadherin. Scale bar = 10µM. C) Centrosome clustering
decreases with full length expression of E-cadherin in cells where supernumerary
centrosomes are generated by DCB. No significant effect on centrosome clustering
was observed with the truncated form of E-cadherin. Data are mean ± SD, n =
150 individual cells, 50 per experiment, at cytokinesis. Data analysed using one-way
ANOVA with Tukey post-hoc test. *** p<0.001.
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4.4 Change in centrosome clustering is not due
to epithelial to mesenchymal transition
Loss of E-cadherin is associated with epithelial to mesenchymal transition (EMT).
However, previous work by Chen et al. has stated that loss of E-cadherin in MCF10A
is not sufficient to drive this transition (Chen et al., 2014). To test if EMT had
occurred in the CDH1-/- cell lines, N-cadherin and vimentin protein levels were
analysed. If EMT had occurred N-cadherin and vimentin levels would increase.
In both the MCF10A CDH1-/- and HaCaT CDH1-/- cell lines, no increase in N-
cadherin or vimentin levels were observed, suggesting that EMT had not occurred
(Figure 4.11). Therefore, changes in centrosome clustering are not due to effects of
EMT, but rather the loss of E-cadherin itself.
Figure 4.11: Knockout of E-cadherin in MCF10A and HaCaT cell lines
is not sufficient to drive epithelial to mesenchymal transition
Western blot analysis of the protein level of two EMT markers – N-cadherin (N-cad)
and vimentin in MCF10A and HaCaT cell lines. No change in protein expression is
observed after knockout of E-cadherin, suggesting EMT has not occurred. β-actin
was used as a loading control.
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4.5 Change in centrosome clustering is not due
to centrosome inactivation
The efficiency of different cells to divide in a bipolar fashion with supernumerary
centrosomes has previously been observed in Drosophila (Sabino et al., 2015). Neu-
roblasts were observed to undergo bipolar divisions compared to epithelial cells
within the developing wing disks when centrosome amplification was generated by
SAK/PLK4 overexpression (Basto et al., 2008; Sabino et al., 2015). These increases
in bipolar divisions were not due to increased centrosome clustering, but due to
centrosome inactivation which is characterised by low centrosomal levels of γ-tubulin
and pericentrin, see Section 1.2.4 (Basto et al., 2008; Sabino et al., 2015). Sabino
et al. reported that overexpression of moesin, the sole member of the conserved
ezrin-radixin-moesin (ERM) family of proteins found in Drosophila, compromised
centrosome inactivation within the wing disks, resulting in increased multipolar cell
divisions (Sabino et al., 2015). To confirm that centrosome inactivation was not
occurring in the cell lines observed centrosomal localisation of γ-tubulin and pericen-
trin was analysed (Figure 4.12 A and B). No evidence of centrosome inactivation was
observed, all extra centrosomes in both multipolar and clustered spindles showed
similar levels of both γ-tubulin and pericentrin (Figure 4.12 A and B). In addition,
no change was observed in the levels of ERM proteins in the epithelial cells with
and without E-cadherin (Figure 4.12 C).
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Figure 4.12: E-cadherin loss does not lead to centrosome inactivation
A and B) Representative 2D immunofluorescence microscopy images of
MCF10A.CDH1-/-.centrin-GFP cell lines, co-stained with γ-tubulin (A) and peri-
centrin (B). All supernumerary centrosomes showed similar levels of γ-tubulin and
pericentrin, suggesting that centrosome inactivation does not occur within these
cells. 150 individual cells were analysed for each condition. Scale bar = 10µM. C)
Western blot analysis of ERM levels in MCF10A and HaCaT cell lines with and
without E-cadherin. No change in ERM protein level was observed. β-actin was used
as a loading control. Representative image of 3 independent experiments.
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4.6 Loss of E-cadherin leads to increased cell
viability in the presence of supernumerary
centrosomes
To determine if the increase in centrosome clustering as a result of loss of E-cadherin
provided a survival benefit in the presence of supernumerary centrosomes cell viability
assays were carried out.
4.6.1 Colony formation assay
Colony formation assays were used for MCF10A.TetR.PLK4 cells expressing shCDH1,
as described in Section 2.6. Supernumerary centrosomes were induced by PLK4
overexpression, by the addition of Dox for 48 hours; after which 100 cells were plated
per 6cm dish and incubated for 7 days. Colonies were fixed and stained using crystal
violet, images were taken and the number of colonies was counted and analysed.
Alongside this, to control for colony size, colonies were dissolved in 0.05% v/v
Triton-X 100 in PBS overnight and absorbance read on a plate photospectrometer
at 560nm and 405nm and normalised to the control for each cell line where Dox
had not been added. Both colony number, and absorbance methods gave similar
results (Figure 4.13). For MCF10A.TetR.PLK4 cells expressing E-cadherin, addition
of doxycycline and the resultant centrosome amplification resulted in a loss of ~40%
viability (Figure 4.13). Cells expressing shCDH1 #9, which had the lowest protein
expression of E-cadherin, had no significant difference between the control cells, and
those containing supernumerary centrosomes, and the shCDH1 #10 expressing cells
had a loss of ~20% viability compared to controls (Figure 4.13). Therefore, loss of
E-cadherin and the subsequent increase in centrosome clustering, enables cells to
survive better in the presence of supernumerary centrosomes.
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Figure 4.13: Knockdown of E-cadherin by shRNA increases cell viability
in MCF10A.TetR.PLK4 cells with supernumerary centrosomes
A) Representative images of 3 independent experiments (3 plates per condition,
per experiment) of MCF10A TetR PLK4, and shCDH1 treated colonies where
supernumerary centrosomes were induced by the addition of doxycycline (+Dox).
Cells were incubated for 7 days to allow for colony growth. B) Quantification
of number of colonies after 7 days incubation. C) Quantification after colonies
were dissolved in 0.05% Triton-X 100 in PBS overnight. Knockdown of E-cadherin
increases colony number in the presence of supernumerary centrosomes. Absorbance
was measured at 560nm and a background absorbance of 405nm was deducted. Data
was normalised to the control for cell line. Data are mean ± SD, n = 3. Data
analysed using two-way ANOVA with Šidák post-hoc test. * p<0.05, ** p <0.01,
*** p<0.001.
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4.6.2 IncuCyte
To investigate cell viability in the E-cadherin CRISPR knockout cells, the IncuCyte
system was used. The IncuCyte is a live cell imaging system built within a cell
culture incubator, allowing for long term live cell imaging. By generating cells
expressing histone H2B-GFP which enables the tracking of DNA, a mask could be
applied to accurately count cell number. This system meant that DCB treatment
could not be used, as the resultant tetraploid cells would show two nuclei per cell,
giving incorrect measurements of cell number. Therefore CDH1-/- cells expressing
TetR.PLK4.H2B-GFP were generated. To quantify if the E-cadherin knockout cell
lines clustered efficiently upon PLK4 overexpression and with H2B-GFP expression,
centrosome clustering was analysed. Both the MCF10A and HaCaT cell lines had
~80% of their cells containing supernumerary centrosomes after PLK4 overexpression
(+Dox) (Figure 4.14 A). The CDH1-/- cells could cluster these supernumerary
centrosomes more efficiently at both metaphase and cytokinesis (Figure 4.14 B),
supporting the previous data shown using DCB treatment in the CDH1 -/- cell lines.
Figure 4.14: Generation of cell lines for IncuCyte viability
A) MCF10A and HaCaT cell lines expressing TetR PLK4 H2B-GFP had ~80% of
their cells containing supernumerary centrosomes after induction of PLK4 overex-
pression by doxycycline. B) Centrosome clustering was more efficient in the CDH1-/-
cells at both metaphase and cytokinesis. Data are mean ± SD, n = 150. Data
analysed using two-way ANOVA with Šidák post-hoc test compared to WT cells **
p<0.01, *** p<0.001.
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After 48 hours of PLK4 overexpression, cells were plated in 12 well plates and placed
into the IncuCyte. Images were recorded every hour at 4 locations per well. After 7
days, the images were analysed using the IncuCyte software. Masks were created
for each experiment using the “top-hat” mask, ensuring that the thresholds were
appropriate for the H2B-GFP to be identified, and that no background was included
within the cell count (Figure 4.15).
Cell counts were then calculated using the mask, with an average of the four images
per well being used to generate an average cell count for each condition. In both
the MCF10A and HaCaT samples there was significantly impaired cell growth
between the control cells (-Dox), and those with supernumerary centrosomes (+Dox)
(Figure 4.16). In the E-cadherin knockout cells, there was a smaller reduction in cell
viability between the cells with and without supernumerary centrosomes (Figure
4.16). Suggesting that loss of E-cadherin enables cells to survive in the presence of
extra centrosomes.
Figure 4.15: IncuCyte masks for H2B-GFP
Cell counts were calculated based on masks for individual H2B-GFP labelled nuclei
within the cells. These were re-calculated for each experiment and thresholds set
to ensure each nuclei was included with no background. These are representative
images of 3 independent experiments for the MCF10 and HaCaT cells expressing
TetR.PLK4.H2B-GFP with and without doxycycline overexpression. Control = -Dox,
PLK4 OE = +Dox. Purple represents masked H2B-GFP.
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Figure 4.16: E-cadherin knockout increases cell viability in the presence
of supernumerary centrosomes
Analysis of survival curves in control and CDH1-/- cells upon induction of centrosome
amplification. Data are mean ± SD of repeated measurements, n = 3. Data analysed
using two-way ANOVA with Šidák post-hoc test based on area under the curve. **
p p<0.01, *** p<0.001.
4.7 DDR1 localises to adherens junctions
E-cadherin has previously been shown to play a role in inhibiting cortical contractility
at the adherens junctions. Research by Hidalgo-Carcedo et al. in interphase cells
showed that E-cadherin can recruit DDR1 to the adherens junctions, through a
not fully elucidated mechanism (Hidalgo-Carcedo et al., 2011). They reported that
DDR1 through Par3 and Par6 controls the localisation of RhoE to cell-cell contacts,
where it antagonises ROCK-driven actomyosin contractility. Cortical contractility
had previously been shown to play a role in centrosome clustering (Kwon et al.,
2008). It was hypothesised that the low levels of clustering efficiency in epithelial cells
may result from the lower levels of contractility. To test if E-cadherin’s recruitment
of DDR1 was preventing efficient clustering of supernumerary centrosomes, DDR1
localisation at cell-cell contacts was first confirmed using 2D immunofluorescence
microscopy (Figure 4.17).
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Figure 4.17: DDR1 localises to cell-cell contacts
2D immunofluorescence confirming that DDR1 localises to cell-cell contacts in
MCF10A, but does not localise where cells are not in contact. DDR1 shown in green,
f-actin in red (Phalloidin Alex Fluor 568), DNA in blue. Scale bar = 10µM.
4.7.1 DDR1 localisation is maintained during mitotic
rounding
If DDR1 was playing a role in impairing centrosome clustering, it was hypothesised
that its localisation must be maintained during mitosis. DDR1 localisation was
analysed by 2D immunofluorescence microscopy, which showed that its localisation
is maintained to cell-cell contacts during mitosis, including through to telophase
(Figure 4.18). This suggested that DDR1 could regulate cortical contractility in
mitosis.
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Figure 4.18: DDR1 localisation to cell-cell contacts is maintained during
mitosis
2D immunofluorescence confirming that DDR1 localises to cell-cell contacts in
MCF10A during the different stages of mitosis. DDR1 shown in green, f-actin in
red, DNA in blue. Scale bar = 10µM.
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4.8 Loss of DDR1 correlates with increased
centrosome clustering efficiency
When examining DDR1 protein expression in the panel of cell-lines, none of the
cell lines that were efficient at clustering their supernumerary centrosomes (RPE-1,
NIH-3T3 and BJ) expressed DDR1 as seen by western blot, whereas the cell lines
that did not cluster efficiently (MC10A, HaCaT and J3B1A) did (Figure 4.19). The
lower band is a high-mannose immature form of DDR1 (Noordeen et al., 2006).
Figure 4.19: Expression of DDR1 correlates with impaired centrosome
clustering efficiency
Western blot analysis of DDR1 protein level in a panel of cell lines. The cell
lines expressing DDR1 - MCF10A, HaCaT and J3B1A cluster ~40% in cells with
supernumerary centrosomes generated by DCB, whereas those not expressing DDR1,
the RPE-1, NIH-3T3 and BJ all cluster ~80%. β-actin was used as a loading control.
* refers to a high-mannose immature form of DDR1.
4.8.1 Knockdown of DDR1 by siRNA increases
centrosome clustering
To investigate if loss of DDR1 increased clustering efficiency in the MCF10A and
HaCaT cell lines, cells were treated with on-target SMART-pool siRNA against
DDR1, as described for E-cadherin in Section 4.3.1. Knockdown efficiency of
DDR1 was analysed by western blot (Figure 4.20 A and B). In both the MCF10A
and HaCaT cells DDR1 was efficiently depleted and this resulted in a significant
improvement in centrosome clustering (Figure 4.20 A and B). To ensure that siRNA
treatment against DDR1 did not result in loss of E-cadherin which could explain
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the improved clustering phenotype, E-cadherin levels were also assessed. E-cadherin
levels remained unchanged with loss of DDR1 as shown by western blot analysis,
and 2D immunofluorescence microscopy (Figure 4.20). These data therefore support
the hypothesis that DDR1 impairs centrosome clustering, downstream of E-cadherin.
Figure 4.20: Knockdown of DDR1 by siRNA increases centrosome clus-
tering
Aand B) Western blot analysis of DDR1 and E-cadherin in siRNA against DDR1
treated cells in MCF10A (A) and HaCaT (B). β-actin was used as a loading control.
Representative blot of 3 independent experiments. Alongside each is quantification
of centrosome clustering in the control and DDR1 treated cells, where knockdown of
DDR1 increases centrosome clustering. Data are mean ± SD, n = 150 individual
cells, 50 per experiment at cytokinesis. Data analysed using Student’s t-test. ***
p<0.001. C) 2D immunofluorescence of E-cadherin in control and DDR1 siRNA
treated MCF10A mitotic cells at metaphase, showing that E-cadherin level and
localisation is maintained upon knockdown of DDR1. Scale bar = 10µM.
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4.8.2 Unsuccessful attempt to CRISPR knockout DDR1
To further confirm the siRNA results and examine cell lines with knockout of DDR1,
CRISPR-Cas9 was used as described in Section 2.3.5 in HaCaT cells. Three different
gRNA were co-infected via lentivirus into HaCaT cells, however despite selecting
100 clones, no full knockout clone was identified, although some clones displayed
partial knockout (Figure 4.21). Due to time restrictions, further work to generate a
successful oomplete DDR1 knockout clone was not carried out.
Figure 4.21: Unsuccessfully attempted to gene knockout DDR1 in HaCaT
cells
Representative western blot of 12 out of 100 clones analysed showing no positive
gene knockout for DDR1 in HaCaT cell lines. β-actin is used as a loading control.
4.9 DDR1 levels are regulated by E-cadherin
expression
The work of Hidalgo-Carcedo et al. reported that E-cadherin localises DDR1 to the
adherens junctions (Hidalgo-Carcedo et al., 2011). However, having observed that
DDR1 is only present in epithelial cells, it was hypothesised that E-cadherin may
play a role in DDR1 stabilisation and not just localisation. Western blot analysis
of DDR1 levels showed that DDR1 was lost in the E-cadherin CDH1-/- cell lines
(Figure 4.22 A). Analysis of mRNA for DDR1 was also performed, and no significant
difference was observed between the control and CDH1-/- cell lines, suggesting that
E-cadherin regulates DDR1 protein levels but not mRNA expression (Figure 4.22
B). Similar results were observed in the A431 CDH1-/- cell line, where DDR1 is
not observed after loss of E-cadherin, as seen by 2D immunofluorescence microscopy
(Figure 4.22 C).
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Figure 4.22: E-cadherin stabilises DDR1 at protein level
A) Western blot analysis of DDR1 in MCF10A CDH1-/- and HaCaT CDH1-/- cell
lines. DDR1 is lost in the cell lines where E-cadherin has been knocked out. * refers
to a high-mannose immature form of DDR1. β-actin is used as a loading control.
Representative of 3 independent experiments B) qRT-PCR analysis of DDR1 mRNA
levels in MCF10A CDH1-/- and HaCaT CDH1-/- cell lines compared to controls.
Data has been normalised to GAPDH. Data are mean ± SD, n = 3. Data analysed
using two-way ANOVA with Šidák post-hoc test. No significant difference was
observed between control and knockout cells. C) 2D immunofluorescence microscopy
of A431 and A431 CDH1-/- cells with f-actin stained in red, DDR1 in green and
DNA in blue. The CDH1-/- cells do not express DDR1, supporting that E-cadherin
stabilises DDR1 levels. Scale bar = 10µM.
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4.9.1 RPE-1 cells expressing E-cadherin express DDR1
Conversely, when examining DDR1 levels by western blot in the RPE-1 cell line
expressing E-cadherin, DDR1 protein was observed, whilst it was not seen in the
EcadDN line. (Figure 4.23 A). This therefore supported that E-cadherin may play
a role in stabilising DDR1, and not just localisation of the protein. Furthermore,
when the RPE-1 E-cadherin expressing cells were treated with siRNA against DDR1,
centrosome clustering significantly increased (Figure 4.23 B). This suggests that
DDR1 impairs centrosome clustering, and requires E-cadherin to be stabilised.
Figure 4.23: Knockdown of DDR1 in RPE-1 E-cadherin cells increases
centrosome clustering
A) Western blot analysis of DDR1 levels in RPE-1 cells expressing E-cadherin and
truncated E-cadherin compared to controls. Expression of full length E-cadherin
results in DDR1 protein expression, suggesting E-cadherin stabilises DDR1. β-actin
is used as a loading control. Representative blot of 3 independent experiments.
* refers to a high-mannose immature form of DDR1. B) Quantification of RPE-
1 E-cadherin expressing cells treated with DDR1 siRNA, showing an increase in
centrosome clustering upon knockdown of DDR1. Data are mean ± SD, n = 150
individual cells, 50 per experiment at cytokinesis. Data analysed using one way
ANOVA with Tukey post-hoc test. *** p<0.001.
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4.10 Increased centrosome clustering upon
depletion of DDR1 is not due to loss of
kinase function
The primary function of DDR1 within a cell is as a collagen activated tyrosine kinase,
that has a number of downstream functions including cell proliferation, survival,
adhesion and migration. DDR1 is activated upon binding to collagen where it is
then autophosphorylated, through a mechanism that has yet to be fully elucidated
(Reviewed in: Leitinger, 2011) (Figure 4.24 A). However, DDR1 localisation to
adherens junctions and the signalling cascade which leads to antagonism of ROCK1
mediated actoymyosin contractility is reported to be independent of the collagen
activated tyrosine kinase function (Hidalgo-Carcedo et al., 2011). To determine if the
resultant increase in clustering was due to a loss of DDR1, or the loss of the tyrosine
kinase signalling, the DDR1 tyrosine kinase inhibitor DDR1-IN-1 was used. MCF10A
cells were pre-treated with 0 – 15mM DDR1-IN-1 for 1 hour. The medium was then
removed and replaced with medium containing 10µg/ml of collagen and DDR1-IN-1
for 2 hours. Western blot analysis showed that upon addition of collagen DDR1 was
phosphorylated, as observed by a phospho-shift in the protein size (Figure 4.24 B,
lane 1). After addition of inhibitor the phospho-shift was no longer observed at 10
and 15mM concentration of inhibitor (Figure 4.24 B). As the growth medium does
not contain collagen in normal tissue culture conditions, DDR1 is not phosphorylated
under normal growth conditions (Figure 4.24 B, lane 5). Quantification of centrosome
clustering at both metaphase and cytokinesis in the presence of 15mM DDR1-IN-1
shows no significant difference in centrosome clustering (Figure 4.24 C). These data
confirm that the increase in centrosome clustering observed upon loss of DDR1 is
not due to the loss of the tyrosine kinase function.
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Figure 4.24: Increased centrosome clustering upon knockdown of DDR1
is not due to loss of tyrosine kinase function
A) Schematic of DDR1 which upon binding to collagen, autophosphorylates and
becomes activated. DS represents Discoidin domain. B) Western blot analysis of
MCF10A cells treated with 0-15mM of the DDR1 inhibitor DDR1-IN-1, with and
without addition of 10µM collagen. Addition of collagen results in activation of
DDR1 as seen by a phospho-shift in size (where the red line is placed to show normal
DDR1 size), which is lost upon addition of 10-15mM DDR1-IN-1. C) Quantification
of centrosome amplification in MCF10A cells with 10µM collagen, with and without
15mM DDR1-IN-1, showing no significant effect on centrosome clustering. Data
are mean ± SD, n = 150 individual cells, 50 per experiment. Data analysed using
two-way ANOVA with Šidák post-hoc test. *** p<0.001.
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4.11 RhoA negative regulators do not affect
centrosome clustering
During interphase, it has been shown that DDR1 regulation of contractility is medi-
ated by recruitment of p190RhoGAP, which inhibits RhoA activity (Hidalgo-Carcedo
et al., 2011). Therefore, to test if p190RhoGAP was affecting centrosome clustering,
p190RhoGAP was depleted by siRNA. The knockdown of p190RhoGAP was very
efficient as analysed by western blot, but no significant effect on centrosome clustering
were observed (Figure 4.25). This suggests that p190RhoGAP is not involved in the
E-cadherin/DDR1 signalling cascade that impairs centrosome clustering.
Figure 4.25: Loss of p190RhoGAP does not affect centrosome clustering
A) Western blot analysis of p190RhoGAP in MCF10A and HaCaT cells treated with
siNegative (control) and on-TARGET SMARTpool siRNA against p190RhoGAP
(p190). Cells were analysed at 72 hours post transfection. β-actin was used as a
loading control. Representative blot of 3 independent experiments B) Centrosome
clustering is not significantly affected upon knockdown of p190RhoGAP by siRNA.
Data are mean ± SD, n = 150. Data analysed using two-way ANOVA with Šidák
post-hoc test.
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DLC3, another regulator of RhoA at adherens junctions, was also depleted by
siRNA (Hendrick et al., 2016). Similarly to p190RhoGAP, no effect was observed
with knockdown of DLC3, suggesting that the regulation of cortical contractility in
epithelial mitotic cells may not mediated through RhoA (Figure 4.26).
Figure 4.26: Loss of DLC3 does not affect centrosome clustering
A) Western blot analysis of DLC3 in MCF10A and HaCaT cells treated with
siNegative (control) and on-TARGET SMARTpool siRNA against DLC3. Cells
were analysed at 72 hours post transfection. β-actin was used as a loading control.
Representative blot of 3 independent experiments. B) Centrosome clustering is not
significantly affected upon knockdown of DLC3 by siRNA. Data are mean ± SD,
n = 150 individual cells, 50 per experiment at cytokinesis. Data analysed using
two-way ANOVA with with Šidák post-hoc test.
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4.12 Loss of RhoE increases centrosome
clustering
4.12.1 RhoE siRNA
It is known that RhoE, a small GTPase, which is recruited to the adherens junctions
in a DDR1-dependent manner, can negatively regulate actomyosin contractility by
directly inhibiting ROCK1 activity, downstream of RhoA (Riento et al., 2003; Hidalgo-
Carcedo et al., 2011). To test whether downregulation of contractility by RhoE
was affecting centrosome clustering, RhoE was depleted by siRNA. Unexpectedly,
depletion of RhoE decreased centrosome clustering efficiency in HaCaT cell lines
(Figure 4.27). The siRNA for RhoE used did not result in RhoE depletion in MCF10A
(Figure 4.27 C).
4.12.1.1 RhoE siRNA affects Mad2 levels
During quantification of the RhoE depleted HaCaT cells, it was observed that the in-
crease in multipolar mitosis was accompanied by an increase in lagging chromosomes,
identified during anaphase (Figure 4.28).
This suggested that RhoE depletion may also have been affecting the spindle assembly
checkpoint (SAC), which prevents efficient clustering, as described in Section 1.2.5.
This would have been a novel role for RhoE as a regulator of the SAC. However,
work by Sigoillot et al. using a bioinformatics approach suggested that Mad2, a
known regulator of the SAC can be prominently affected as an off target effect by
other siRNA (Sigoillot et al., 2012). To test whether Mad2 levels were being affected
by the RhoE siRNA, Mad2 protein levels were analysed by western blotting. The
western blot showed that Mad2 was being depleted upon treatment of RhoE siRNA
(Figure 4.29). These data therefore suggested that the effect observed on the decrease
in centrosome clustering, and increase in lagging chromosomes is due to decreased
levels of Mad2, which in turn leads to premature anaphase onset from an absence of
the SAC.
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Figure 4.27: RhoE depletion by siRNA results in an increase of multipo-
lar divisions
A) Western blot analysis of RhoE in HaCaT cells treated with siNegative (control)
and on-TARGET SMARTpool siRNA against RhoE. Cells were analysed at 72
hours post transfection. β-actin was used as a loading control. Representative
blot of 3 independent experiments. B) Centrosome clustering is impaired upon
knockdown of RhoE by siRNA. Data are mean ± SD, n = 150 individual cells, 50
per experiment at cytokinesis. Data analysed using Student’s t-tests. *** p<0.001.
C) Western blot analysis of RhoE in MCF10A cells treated with siNegative (control)
and on-TARGET SMARTpool siRNA against RhoE. Cells were analysed at 72 hours
post transfection. β-actin was used as a loading control. Representative blot of 3
independent experiments.
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Figure 4.28: RhoE depletion by siRNA results in an increased number
of lagging chromosomes
Quantification of percentage of cells with lagging chromosomes in HaCaT cells upon
depletion of RhoE by siRNA. Data are mean ± SD, n = 150 individual cells, 50 per
experiment at anaphase. Data analysed using Student’s t-test. ** p<0.01.
Figure 4.29: RhoE siRNA results in a decrease in Mad2 protein levels
Western blot analysis of Mad2 protein levels in HaCaT cells with RhoE siRNA,
showing a depletion of Mad2. β-actin was used as a loading control. Representative
blot of 3 independent experiments.
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4.12.1.2 MG132 enables increased centrosome clustering in
the absence of RhoE
Mad2 depletion prevents efficient centrosome clustering by affecting the SAC resulting
in too short a time in mitosis to enable clustering. To overcome the effect of Mad2
knockdown on the SAC, MG132 was used to prolong metaphase in RhoE depleted cells.
In this condition centrosome clustering improved upon RhoE depletion with MG132
treatment (Figure 4.30). Taken together, these results suggest that downregulation
of RhoE prevents efficient centrosome clustering in epithelial cells. This data also
supports previously published data that cells require sufficient time in mitosis to
cluster efficiently, and that reduced time in mitosis can impair efficient centrosome
clustering (Basto et al., 2008; Kwon et al., 2008; Yang et al., 2008).
Figure 4.30: MG132 treatment in RhoE siRNA treated cells increases
centrosome clustering
Quantification of centrosome clustering in HaCaT cells treated with siRNA targeting
RhoE. Cells were treated with 10µM MG132 to prolong metaphase for 4 hours, and
released for 1 hour. RhoE cells with MG132 treatment clustered their supernumerary
centrosomes significantly more efficiently than control cells. Data are mean ± SD,
n = 150 individual cells, 50 per experiment at cytokinesis. Data analysed using
two-way ANOVA with Šidák post-hoc test. *** p<0.001.
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4.12.2 Single target siRNA against RhoE increases
centrosome clustering
Having identified that the initial siRNA targeting RhoE was also decreasing Mad2,
which was in turn affecting centrosome clustering, a different single siRNA targeting
RhoE was used. Depletion of RhoE by this single siRNA did not affect Mad2 levels,
whilst remaining efficient at depleting RhoE levels, as shown by western blot (Figure
4.31 A). Quantification of centrosome clustering showed that depletion of RhoE
increases centrosome clustering, as initially expected (Figure 4.31 B). This suggests
that the downregulation of contractility by RhoE impairs centrosome clustering.
Figure 4.31: Single target siRNA against RhoE increases centrosome
clustering
A) Western blot analysis of RhoE in HaCaT cells treated with siNegative (control)
and on-TARGET plus single siRNA against RhoE. Cells were analysed at 72 hours
post transfection. β-actin was used as a loading control. Representative blot of
3 independent experiments. Mad2 levels were unaffected with this siRNA. B)
Centrosome clustering is improved upon knockdown of RhoE by siRNA. Data are
mean ± SD, n = 150 individual cells, 50 per experiment at cytokinesis. Data analysed
using Student’s t-tests. *** p<0.001.
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4.13 Loss of E-cadherin and DDR1 correlates
with centrosome amplification in a panel of
breast cancer cell lines
Many solid tumours of an epithelial origin have been shown to contain supernu-
merary centrosomes (Reviewed in:Zyss and Gergely, 2009; Chan, 2011). However,
the previous data suggest that epithelial cells have a low efficiency of clustering
supernumerary centrosomes, resulting in poor survival. Therefore, it is possible that
cancer cells from an epithelial origin need to adapt in order to survive in the presence
of extra centrosomes, and loss of E-cadherin and DDR1 may be part of this adapta-
tion mechanism. To test this, centrosome amplification was analysed in a panel of
15 breast cancer cell lines along with E-cadherin and DDR1 protein levels (Figure
4.32 A and B). Six cell lines were identified which had high levels of centrosome
amplification (>30% of cells contain supernumerary centrosomes). When E-cadherin
protein levels were examined in these cell lines, all 6 did not express E-cadherin
(Figure 4.32 B). In support of the data suggesting that E-cadherin is important for
the stabilisation of DDR1, all 6 cell lines did also not express DDR1 (Figure 4.32
B). When looking at HSET protein expression, all cell lines expressed HSET, and
there was no observable trend with HSET level and clustering efficiency, supporting
the hypothesis that HSET alone is not sufficient to enable centrosome clustering.
As expected, all of the cell lines with high levels of centrosome amplification were
able to cluster their supernumerary centrosomes effectively (>80%) by cytokinesis
(Figure 4.32 C), independently of breast cancer subtype, although higher levels of
centrosome amplification have been reported in basal cell lines (D’Assoro et al., 2002;
Denu et al., 2016).
Similarly to the CDH1-/- cell lines, ERM protein expression was analysed by western
blot, and no correlation between ERM protein level and centrosome amplification
was observed (Figure 4.33). This supported that centrosome inactivation does not
occur within these cell lines.
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Figure 4.32: Loss of E-cadherin and DDR1 correlates with high levels of
centrosome amplification in breast cancer
A) Quantification of centrosome amplification in a panel of 15 breast cancer cell
lines. Cell lines with >30% of their cells containing supernumerary centrosomes are
classed as having high levels of centrosome amplification. Data are mean ± SD,
n = 150 at metaphase. B) Western blot analysis of E-cadherin and DDR1 in the
breast cancer panel. * denotes cell lines with high levels of centrosome amplification,
which correlates with loss of E-cadherin and DDR1. C) Quantification of centrosome
amplification in the 6 cell lines with high levels of centrosome amplification. All cell
lines are efficient are clustering their supernumerary centrosomes (>80%). Data are
mean ± SD, n = 150 individual cells, 50 per experiment at cytokinesis.
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Figure 4.33: Centrosome amplification in a panel of breast cancer cell
lines does not correlate with ERM protein expression
Western blot analysis of ERM levels in the panel of 15 breast cancer cell lines. No
correlation between ERM protein level and level of centrosome amplification was
observed. β-actin was used as a loading control. * represents high levels of centrosome
amplification (>30% of cells). Representative image of 3 independent experiments.
4.14 Discussion
Having shown that not all cell types are inherently able to cluster their supernu-
merary centrosomes efficiently, it was important to try and understand the intrinsic
mechanisms which enabled the NIH-3T3, BJ and RPE-1 to cluster their centrosomes
efficiently, which was not occurring in the remaining cell lines.
Previous work showed that time spent in metaphase as well as the kinesin HSET are
important for centrosome clustering. However, when given more time in metaphase
using the proteasome inhibitor MG132, centrosome clustering was not improved in
the MCF10A and HaCaT cell lines. In addition, the levels of HSET were consistent
in all six cell lines analysed, suggesting that HSET is not a limiting factor for
centrosome clustering efficiency, although the localisation of HSET was not explored.
Having ruled out two potential mechanisms which might have accounted for the
variation in centrosome clustering efficiency between the two groups of cells, the
background of the cell lines in the panel was explored more deeply to try and identify
a potential cause for the differences observed. It was noted that the MCF10A,
HaCaT and J3B1A were all of epithelial origin and expressed E-cadherin, the BJ
and NIH-3T3 were both fibroblasts, and interestingly the RPE-1 cell lines whilst of
epithelial origin has subsequently lost E-cadherin expression. Based on this it was
hypothesised that the presence of E-cadherin may impair centrosome clustering.
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Using siRNA, shRNA and CRISPR-Cas9 in the MCF10A and HaCaT cell lines, it
was found that depletion of E-cadherin significantly increased centrosome clustering
efficiency from ~40% to ~80%. These results strongly support a role for E-cadherin
in preventing efficient clustering in epithelial cell lines. Comparable results were
observed in cell lines where supernumerary centrosomes were generated by PLK4
overexpression. Increased centrosome clustering was also observed in the A431 skin
cancer cell line upon knockout of E-cadherin, suggesting that loss of E-cadherin
could be a mechanism of adaptation for cancers with supernumerary centrosomes. It
is unclear however if E-cadherin loss may facilitate the preservation of centrosome
amplification, or if centrosome amplification may drive the loss of E-cadherin for cell
survival.
Conversely, overexpression of E-cadherin in the E-cadherin deficient cell line RPE-
1 impaired centrosome clustering efficiency, comparable to the MCF10A, HaCaT
and J3B1A. These data further support that the expression of E-cadherin impairs
centrosome clustering, and that loss of E-cadherin may be a mechanism of adaptation
for cells with supernumerary centrosomes.
Adaptation to centrosome clustering has always been assumed to be important for
cell survival, with multipolar cell divisions leading to severe levels of aneuploidy
which are poorly tolerated leading to cell death. Loss of E-cadherin was shown to
increase cell survival/viability in both colony formation and cell growth assays. These
data confirm that adaptation to centrosome amplification by centrosome clustering
enables cells to adapt to, and maintain prolonged survival.
It was found that DDR1 depletion, which controls cortical contractility downstream
of E-cadherin was able to increase centrosome clustering in epithelial cells, therefore
suggesting that DDR1 can impair centrosome clustering. Use of a DDR1 tyrosine
kinase inhibitor did not affect centrosome clustering, therefore supporting that the
observed change in centrosome clustering is due to the loss of the E-cadherin-DDR1
pathway, which is independent of DDR1’s tyrosine kinase function rather than
through DDR1 tyrosine kinase receptor signalling.
Regulation of cortical contractility by DDR1 has been reported to involve the RhoA
negative regulator p190RhoGAP, which acts downstream of DDR1 to prevent cortical
contractility (Hidalgo-Carcedo et al., 2011). However, p190RhoGAP depletion has
no role on centrosome clustering suggesting that RhoA activity might be dispensable.
Similarly, depletion of DLC3, another negative of RhoA had no effect on centrosome
clustering. In contrast, depletion of RhoE, which can directly bind and inhibit ROCK
to prevent cortical contractility, led to efficient clustering. These data therefore
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suggest that RhoE may directly impair centrosome clustering rather than through
RhoA signalling, although depletion of RhoA was not tested.
Taken together, these results suggest that loss of E-cadherin and/or DDR1 could
play a role in the adaptation to supernumerary centrosomes in cancer. The findings
in the panel of 16 breast cancer cell lines further supports the idea that loss of
E-cadherin/DDR1 could be part of an adaptation mechanism to centrosome ampli-
fication in cancer. This mechanism is suggested to be through control of cortical




Results III: Elucidating the role of
cortical contractility in centrosome
clustering
5.1 E-cadherin knockout cells have increased
cortical tension
Having identified that loss of E-cadherin and DDR1 results in increased centrosome
clustering, it was hypothesised that this may be due to increased cortical contractility.
To test the hypothesis that loss of E-cadherin could result in increased cortical
contractility, atomic force microscopy (AFM) was used to measure cortical tension
(Figure 5.1). Cortical tension has been shown to be dependent upon actomyosin
contractility, and therefore can be regarded as a surrogate measure of cortical
contractility (Harris, Daeden and Charras, 2014). AFM works by a cantilever being
lowered with a known force onto a cell, and a laser beam is aimed down the cantilever
which then measures the deflection of the cantilever upon contact with the cell. Based
on the recorded changes of the cantilever, the cortical tension can be calculated
based on the Sneddon model of elasticity (Sneddon, 1965).
Cells were plated on glass-bottom tissue culture dishes, when they reached 70%
confluency they were treated with 10µM MG132 to increase the number of mitotic
cells for analysis. The AFM experiments were kindly performed and analysed by
Malti Vaghela in the laboratory of Guillaume Charras at University College London.
Measurement of cortical tension/elasticity was recorded in mitotic cells in a monolayer
(Figure 5.2 B). Measurement of cortical tension/elasticity in both the MCF10A and
HaCaT cell lines increased significantly in the E-cadherin knockout cell lines (Figure
5.2 A). This confirmed that loss of E-cadherin was sufficient to increase cortical
contractility as expected.
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Figure 5.1: Atomic force microscopy
Schematic of atomic force microscopy. A cantilever is lowered with a known force
onto a mitotic cell. A laser aimed down the cantilever then detects deflection of the
cantilever upon contact with the cell. From the deflection, the cortical tension can
be calculated based upon the Sneddon model of elasticity.
Figure 5.2: Loss of E-cadherin increases cortical tension/stiffness in a
monolayer
A) Quantification of cortical elasticity/tension based on the Sneddon model in
MCF10A and HaCaT control and CDH1-/- cell lines in a 70% confluency monolayer.
Cells were treated with 10µM MG132 for 2 hours prior to analysis. Loss of E-cadherin
increases cortical stiffness/tension. Data are 25-75th percentile with the median,
where the whiskers represent minimum and maximum measurements. N = 14
individual cells, with 4 measurements per cell. Data analysed using two-way ANOVA
with Šidák post-hoc test. *** p<0.001. B) Representative images of MCF10A and
MCF10A CDH1-/- cell lines within the AFM. Measurements were taken of mitotic
cells. The cantilever can be observed on the left-hand side of each image, this was
then located over the cell to be quantified.
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As the proposed hypothesis relies on E-cadherin at cell-cell junctions, it was therefore
predicted that in single cells where E-cadherin does not localise, the tension/elasticity
would not vary between the control and CDH1-/- cell lines. To test this, AFM
was performed on single cells. As expected, no significant difference was observed
between the two conditions (Figure 5.3). This supported that there is an increase in
cortical tension due to a loss of E-cadherin at the cell cortex.
Figure 5.3: Loss of E-cadherin does not increase cortical tension/stiffness
in single cells
A) Quantification of cortical tension/elasticity based on the Sneddon model in HaCaT
control and CDH1-/- cell lines single mitotic cells. Cells were treated with 10µM
MG132 for 2 hours prior to analysis. No significant difference is observed between
E-cadherin proficient and knockout cell lines. Data are 25-75th percentile with the
median, where the whiskers represent minimum and maximum measurements. N
= 14 individual cells, with 4 measurements per cell. Data analysed using Student’s
t-test. B) Representative images of HaCaT and HaCaT CDH1-/- cells within the
AFM. Single cells during metaphase, as identified by the metaphase plate were
measured.
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5.2 Change in centrosome clustering is not due
to change in cell rounding
Having identified that E-cadherin loss increases cortical tension/contractility, to test
that these changes did not affect cell rounding, which may have played a role on
the centrosome clustering efficiency, the ratio of length vs width was measured in
mitotic cells (Figure 5.4). No change in mitotic rounding was identified upon loss of
E-cadherin in both the MCF10A and HaCaT cell lines, suggesting that the increase
in centrosome clustering efficiency is not due to cell rounding changes (Figure 5.4).
Figure 5.4: Knockout of E-cadherin does not affect cell rounding in mi-
tosis
Cell rounding was quantified by measuring the ratio of the length (h) over width
(w) in mitotic cells, identified by a metaphase plate by brightfield microscopy. No
significant differences were identified after E-cadherin knockout in MCF10A and
HaCaT cell lines. Data are mean ± SD, n = 30 individual cells. Data analysed using
two-way ANOVA with Šidák post-hoc test.
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5.3 Perturbing cortical contractility impairs
centrosome clustering
To test if efficient centrosome clustering requires cortical contractility, a number of
different drug treatments were used to alter contractility.
5.3.1 Blebbistatin inhibition of cortical contractility
impairs centrosome clustering
Blebbistatin is a MyoII inhibitor resulting in decreased cortical contractility. Cells
were treated with 50µM blebbistatin for 4 hours prior to fixation. As blebbistatin
inhibits MyoII, which is required for the formation of the cytokinetic furrow, cells were
unable to enter cytokinesis and were therefore analysed at telophase (Figure 5.5 A).
In all of the cell lines treated with blebbistatin, centrosome clustering was impaired,
resulting in ~30% of cells being able to cluster (Figure 5.5 B). Any advantage that
loss of E-cadherin gave to MCF10A and HaCaT cells in clustering supernumerary
centrosomes was lost upon inhibition of cortical contractility, supporting that this
additional contractility is a key driver in centrosome clustering.
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Figure 5.5: Blebbistatin inhibition of cortical contractility impairs cen-
trosome clustering
A) 2D immunofluorescence microscopy images of MCF10A cells treated with 50µM
blebbistatin for 4 hours. Cells were quantified at telophase as blebbistatin impairs
the formation of the cytokinetic furrow. B) Quantification of centrosome clustering
in cells treated with 50µM blebbistatin for 4 hours pre-fixation in cells where su-
pernumerary centrosomes were generated by DCB treatment. Blebbistatin resulted
in significant decrease of centrosome clustering to a basal level of ~30%. Data are
mean ± SD, n = 150 individual cells, 50 per experiment at telophase. Data analysed
using two way ANOVA with Šidák post-hoc test.. ** p<0.01, *** p<0.001. Scale
bar = 10µM.
5.3.2 ROCK1 inhibition impairs centrosome clustering
To further confirm the importance of cortical contractility on centrosome clustering,
the ROCK1 inhibitor Y-27632 dihydrochloride was used. Cells were treated with
10µM Y-27632 dihydrochloride for 4 hours before fixation and quantified at telophase
as per the blebbistatin treated cells. Supporting the blebbistatin results, there was a
significant reduction of centrosome clustering to the basal level of ~30% in all cell
lines tested (Figure 5.6). This basal level of centrosome clustering suggested that
there are other mechanisms independent of cortical contractility that enable cells to
cluster, however cortical contractility is important in enabling a large proportion of
cells to cluster efficiently.
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Figure 5.6: ROCK1 inhibition impairs centrosome clustering
Quantification of centrosome clustering in cells treated with 10µM Y-27632 dihy-
drochloride for 4 hours pre-fixation in cells where supernumerary centrosomes were
generated by DCB treatment. Y-27632 dihydrochloride resulted in a significant
decrease of centrosome clustering to a basal level of ~30%. Data are mean ± SD, n
= 150 individual cells, 50 per experiment at telophase. Data analysed using two way
ANOVA with Šidák post-hoc test. ** p<0.01, *** p<0.001.
149
Chapter 5. Results III: Elucidating the role of cortical contractility in centrosome
clustering
5.3.3 Calyculin-A treatment increases centrosome
clustering in epithelial cells
In contrast to the blebbistatin and Y-27632 dihydrochloride treatment, which impairs
cortical contractility, Calyculin-A was used to determine if increasing cortical con-
tractility in epithelial cells would enable them to cluster supernumerary centrosomes
more efficiently. Calyculin-A is a natural product which was originally isolated from
the marine sponge Discodermia calyx (Ishihara et al., 1989). Calyculin-A is a potent
phosphatase inhibitor and therefore increases the levels of phosphorylated proteins,
including the accumulation of p-MLC (phosphorylated myosin light chain) which is
involved in increasing cortical contractility. MCF10A and HaCaT cells were treated
with 1µM Calyculin-A for 2 hours. Both cell lines showed significantly increased
centrosome clustering after Calyculin-A treatment (Figure 5.7). This data combined
with the blebbistatin and Y-27632 dihydrochloride data suggests that an increase in
cortical contractility is sufficient to increase centrosome clustering efficiency within
epithelial cells. This observation that increased corticial contracility improves centro-
some clustering supports the hypothesis that that low cortical contractility observed
in epithelial cells compromises efficient clustering.
Figure 5.7: Calyculin-A treatment increases centrosome clustering in
epithelial cells
Quantification of centrosome clustering in cells treated with 1µM Calyculin-A for 2
hours pre-fixation in epithelial cells where supernumerary centrosomes were generated
by DCB treatment. Calyculin-A treatment results in an increase in centrosome
clustering. Data are mean ± SD, n = 150 individual cells, 50 per experiment at
telophase. Data analysed using two-way ANOVA with Šidák post-hoc test. **
p<0.01, *** p<0.001.
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5.4 Increased cortical contractility results in
closer centrosomes at metaphase
After demonstrating that cortical contractility is important for centrosome clustering,
it was hypothesised that increased cortical contractility brings centrosomes in closer
proximity, which then enables clustering. To test this hypothesis, the angle between
the closest centrosomes in tripolar metaphase spindles were measured in MCF10A
and HaCaT cells, with and without E-cadherin (Figure 5.8 A). The rosette plots are
a graphical representation of the number of cells with a certain angle from 0-120°
(Figure 5.8 B and C). In epithelial cells without E-cadherin the centrosomes are
closer together than in E-cadherin expressing cells (Figure 5.8 B and C, top). This
difference in proximity is lost upon the addition of blebbistatin which perturbs MyoII
contractility, supporting the hypothesis that contractility is required for centrosomes
to be within closer proximity and that this proximity allows them to be clustered
(Figure 5.8 B and C).
To further test the importance of cortical contractility on the proximity of supernu-
merary centrosomes in tripolar metaphase spindles, the ROCK1 inhibitor, Y-27632
dihydrochloride (ROCKi) was used. Similarly to blebbistatin treatment, perturbing
ROCK1-mediated contractility resulted in centrosomes being further apart, in both
the MCF10A CDH1-/- and HaCaT CDH1-/- cell lines (Figure 5.9 A). Conversely, to
test if increased cortical contractility could bring centrosomes together in epithelial
cells, Calyculin A treatment was used. Increased cortical contractility resulted in the
centrosomes being in closer proximity, as analysed by the angles between extra cen-
trosomes in both the MCF10A and HaCaT cell lines (Figure 5.9 B). Altogether these
data suggest that cortical contractility is required to bring centrosomes into closer
proximity, and it is the increased cortical contractility which enables to centrosomes
to cluster in the absence of E-cadherin.
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Figure 5.8: E-cadherin loss in epithelial cells results in closer proximity
centrosomes, which requires cortical contractility
A) Representative 2D immunofluorescence microscopy image of a MCF10A cell
undergoing a tripolar division with supernumerary centrosomes induced by DCB
treatment. Overlaid is a representation of how angles were measured between the
closest centrosomes. Scale bar = 10µM. B) and C) Quantification of the number
of cells in MCF10A (B) and HaCaT (C) with angles measured between the closest
centrosomes in tripolar metaphases from 0-120°, each bar represents a division of 5°. n
= 150 individual cells, 50 per experiment, overlaid black bar = mean. Supernumerary
centrosomes were induced by DCB treatment. Red bars represent control cells, green
bars represent 4 hours 50µM blebbistatin treatment pre-fixation. CDH1-/- cells have
closer proximity centrosomes than E-cadherin expressing cells, this observation is
lost upon the perturbation of MyoII contractility by blebbistatin.
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Figure 5.9: Cortical contractility is required to bring centrosomes into
closer proximity
A) Quantification of the number of cells in MCF10A and HaCaT cell lines with
angles measured between the closest centrosomes in tripolar metaphases from 0-120°,
each bar represents a division of 5°. Supernumerary centrosomes were induced by
DCB treatment. Red bars represent control cells, green bars represent 4 hours
treatment with 10µM ROCK1 inhibitor (ROCKi) pre-fixation. CDH1-/- cells have
closer proximity centrosomes than E-cadherin expressing cells, this observation is
lost upon the perturbation of contractility by ROCKi. B) Quantification of angles
in tripolar metaphases in MCF10A and HaCaT cells treated with 1µM Calyculin-A.
Increase of contractility by the addition of Calyculin-A leads to closer proximity
supernumerary centrosomes. n = 150 individual cells, 50 per experiment, overlaid
black bar = mean.
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5.5 Astral microtubules are important for
centrosome clustering
It has previously been shown that cortical forces are transmitted to the centrosomes
via astral microtubules (Rosenblatt et al., 2004; Théry et al., 2005). Alongside this
astral microtubules have previously been implicated in centrosome clustering, but the
mechanism has not been explored (Kwon et al., 2008). It was therefore hypothesised
that astral microtubules play a role in translating the cortical contractility in CDH1-
/- cells to facilitate centrosome clustering. To test this low doses of nocodazole
(5nM), which depolymerise astral microtubules whilst allowing for the formation
of the mitotic spindle, were used for 3 hours prior to fixation. EB1 staining which
identifies the ends of growing microtubules, suggests a depletion in astral microtubules
upon nocodazole treatment (Figure 5.10 A). Upon addition of nocodazole and the
disruption of astral microtubules, centrosome clustering was significantly impaired in
the MCF10A and HaCaT cells lines, both with and without E-cadherin (Figure 5.10
B). The cells clustered to the basal level of ~30%, similar to the results observed upon
addition of blebbistatin or the ROCK1 inhibitor. When examining the distance of
the closest centrosomes in tripolar metaphases, depletion of the astral microtubules
impaired centrosomes moving closer in the CDH1-/- cell lines (Figure 5.10 C). These
data suggest that astral microtubules play a role in translating the cortical forces to
the centrosomes, allowing them to move in closer proximity.
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Figure 5.10: Astral microtubules transmit cortical forces to the centro-
somes
A) 2D immunofluorescence microscopy in HaCaT cells. Left panel shows growing
astral microtubules as visualised by EB1 staining. Right panel shows cells after 3
hours treatment with 5nM nocodazole, resulting in a loss of astral microtubules,
shown by a depletion of EB1 at the spindle poles (identified by the arrows) Scale
bar = 10µM. B) Quantification of centrosome clustering, which decreases upon loss
of astral microtubules in nocodazole treated cells. Supernumerary centrosomes were
generated by DCB treatment. Data are mean ± SD, n = 150 individual cells, 50
per experiment. Data analysed using two way ANOVA with Šidák post-hoc test., *
p<0.05, ** p<0.01, ** p<0.001. C) Quantification of angles in tripolar metaphase
spindles in MCF10A and HaCaT cells treated with 5nM nocodazole. Loss of astral
microtubules results in a reduction in closer proximity supernumerary centrosomes.
n = 150 individual cells, 50 per experiment, overlaid black bar = mean smallest
angle in tripolar metaphases.
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5.6 HSET is important for centrosome
clustering independently of E-cadherin loss
As the kinesin HSET, a minus-end directed microtubule motor has already been
identified as a requirement for centrosome clustering (Basto et al., 2008; Kwon et
al., 2008), it was hypothesised that the closer proximity of centrosomes, facilitated
by the increase in cortical contractility, could then allow for HSET to be able to
cluster them. To confirm that HSET was required for centrosome clustering, HSET
was knocked down by siRNA in control and CDH1-/- MCF10A and HaCaT cell
lines (Figure 5.11 B). The analysis of centrosome clustering showed that depletion of
HSET prevented centrosome clustering in all cell lines, independently of E-cadherin
expression, leading to a basal level of ~10%, the lowest level of centrosome clustering
observed (Figure 5.11 A).
Figure 5.11: The kinesin is required for centrosome clustering, indepen-
dently of E-cadherin expression
A) Centrosome clustering is impaired upon depletion of HSET by siRNA, inde-
pendently of E-cadherin levels. Supernumerary centrosomes were induced by DCB
treatment. Data are mean ± SD, n = 150 individual cells, 50 per experiment at
cytokinesis. Data analysed using two way ANOVA with Šidák post-hoc test, ***
p<0.001. B) Western blot analysis of cells treated with siNegative (control) and
on-TARGET SMARTpool siRNA against HSET. Cells were analysed at 72 hours
post transfection. β-actin was used as a loading control.
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When examining the effect of knockdown of HSET by siRNA on the proximity of
supernumerary centrosomes, no change on the smallest angle distribution in tripolar
metaphases was observed, unlike with changes in contractility (Figure 5.12). This
suggests that through the increased cortical contractility centrosomes are still able
to move closer to each other, but due to the lack of HSET, these centrosomes cannot
be clustered. This could explain why the presence of HSET is not by itself enough
to enable supernumerary centrosomes to cluster efficiently.
Figure 5.12: Knockdown of HSET does not affect centrosome proximity
in tripolar metaphases
Quantification of the number of cells in MCF10A and HaCaT cell lines with angles
measured between the closest centrosomes in tripolar metaphases from 0-120°, each
bar represents a division of 5°. n = 150, overlaid black bar = mean. Supernumerary
centrosomes were induced by DCB treatment. Red bars represent control cells,
green bars represent HSET knockdown by siRNA. HSET deletion does not affect
the smallest angle distribution in tripolar metaphases.
5.7 High centrosome number per cell increases
centrosome clustering efficiency
Based on these observations, it was proposed that the cortical contractility is
required for bringing centrosomes close enough together for HSET to then enable the
clustering. From this model, it was then suggested that if there was a large number
of supernumerary centrosomes, which were then in close proximity, centrosome
clustering would be efficient, independent of cortical contractility. In order to
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investigate this hypothesis, supernumerary centrosomes were generated by PLK4
overexpression controlled by the pInducer vector, which generates a larger number
of supernumerary centrosomes per cell. pInducer is a tetracycline-inducible system
similar to that of the tetracycline repressor (Meerbrey et al., 2011). MCF10A cells
were transfected with lentivirus expressing pInducer.PLK4. Positively transfected
cells were identified by cell sorting for GFP, expressed as part of the pInducer
vector. To determine if the pInducer may be altering centrosome clustering efficiency,
centrosome clustering was measured after generation of supernumerary centrosomes
by DCB treatment in MCF10A, MCF10A.TetR.PLK4 and MCF10A.pInducer.PLK4
in the absence of Dox. Unlike the TetR cell line, the pInducer cell line behaved as
per the control, suggesting that the pInducer does not affect centrosome clustering
(Figure 5.13).
Having identified that the pInducer expression does not affect centrosome clustering
in the same way as the tetracycline repressor (Section 3.5.1, Figure 3.10), centrosome
clustering was quantified after PLK4 overexpression. MCF10A.pInducer.PLK4 cells
were treated with 2µg/ml Dox for 48 hours. As hypothesised, these cells were able
to cluster their supernumerary centrosomes with high efficiency (~90%), compared
to ~40% with DCB treatment, and ~60% with TetR.PLK4 (Figure 5.14 A). This
correlated with the large level of centrosome amplification per cell (Figure 5.14 B).
Quantification of centriole number per cell showed that in DCB treated cells the
mean number of centrioles measured at metaphase was ~6, whereas this increased to
~18 in the pInducer.PLK4 cells, with the TetR.PLK4 having ~12 (Figure 5.14 B).
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Figure 5.13: pInducer expression does not affect centrosome clustering
Quantification of centrosome clustering measured after generation of supernumer-
ary centrosomes by DCB treatment in MCF10A, MCF10A.TetR.PLK4 (TetR) and
MCF10A.pInducer.PLK4 (pInducer) in the absence of doxycycline. Without doxycy-
cline, the TetR expressing cells are more efficient at clustering their supernumerary
centrosomes compared to controls, there is no significant difference observed between
pInducer PLK4 cells and controls. Data are mean ± SD, n = 150 individual cells,
50 per experiment at cytokinesis. Data analysed using one way ANOVA with Tukey
post-hoc test, ** p<0.01.
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Figure 5.14: Centrosome clustering and centrosome number increase in
pInducer.PLK4 cells
A) Quantification of centrosome clustering in MCF10A after DCB treatment, and
MCF10A.TetR.PLK4 and MCF10A.pInducer.PLK4 are treatment with 2µg/ml Dox
for 48 hours. Data are mean ± SD, n = 150 individual cells, 50 per experiment
at cytokinesis. B) Centriole number quantified in MCF10A after DCB treatment,
and MCF10A.TetR.PLK4 and MCF10A.pInducer.PLK4 are treatment with 2µg/ml
doxycycline for 48 hours. Data are mean ± SD, n = 150 individual cells, 50 per
experiment at metaphase. Data analysed using one way ANOVA with Tukey post-hoc
test, * p<0.05, ** p<0.01, *** p<0.001.
To try and reduce the efficiency of generating supernumerary centrosomes, the level
of Dox was titrated. MCF10A.pInducer.PLK4 cells were treated with 0.5-2µg/ml
Dox for 48 hours, the Dox was then washed out for 24-72 hours and centriole number
quantified. Even at the lowest dosage of Dox (0.5µg/ml) and 72 hours post washout
the high level of centrosome number was still observed, therefore variation of Dox
was not sufficient to control the level of centrosome number (Figure 5.15).
Whilst the attempted titration of Dox did not significantly reduce centrosome num-
ber, an alternative method of using SAS-6 siRNA to reduce centrosome number
was used. SAS-6 is required for centrosome duplication, and has previously been
described to abrogate centrosome overduplication (Leidel et al., 2005). Supernumer-
ary centrosomes were generated in MCF10A.pInducer.PLK4 cells upon treatment
with 2µg/ml of Dox for 48 hours, cells were then treated with SAS-6 siRNA for 72
hours. Quantification of centrosome number showed that under these conditions
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Figure 5.15: Titration of doxycycline does not significantly affect centro-
some number in pInducer.PLK4 cells
Centriole number quantified in MCF10A.pInducer.PLK4 after treatment with 0.5-
2µg/ml doxycycline for 48 hours. Doxycycline was washed out, and cells were
incubated for 24-72 hours. Data are mean ± SD, n = 150 individual cells, 50
per experiment at metaphase. Data analysed using one way ANOVA with Tukey
post-hoc test.
centrosome number reduces to ~6, the same as under DCB treatment (Figure 5.16
A and B). Analysis of centrosome clustering further showed that under these condi-
tions centrosome clustering reflects the low level of centrosome clustering efficiency
observed with DCB treatment at ~40% (Figure 5.16 C). These data support that
the increased clustering efficiency in the MCF10A.pInducer.PLK4 observed is due to
the high levels of centrosome amplification, but when centrosome number is lower,
centrosome clustering is similar to the clustering efficiency observed in DCB treated
cells, this is hypothesised to be due to the proximity of the centrosomes, enabling
HSET to facilitate centrosome clustering.
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Figure 5.16: Lower levels of centrosome amplification in
MCF10A.pInducer.PLK4 leads to lower efficiency of centrosome
clustering
A) Immunofluorescence images depicting examples of MCF10A.pInduer.PLK4
after 48h Dox treatment showing high levels of centrosome amplification. Top
– merge, Bottom – α-tubulin. Scale bar = 10µM. B) Quantification of centriole
number in MCF10A with DCB treatment and MCF10A.pInducer.PLK4 with 2µg
doxycycline, with and without 72 hours SAS-6 siRNA treatment. SAS-6 siRNA
treatment reflects the centrosome number observed with DCB treatment. Data
are mean ± SD, n = 150 individual cells, 50 per experiment at metaphase. C)
Quantification of centrosome clustering in MCF10A with DCB treatment and
MCF10A.pInducer.PLK4 with 2µg doxycycline, with and without 72 hours SAS-6
siRNA treatment. SAS-6 siRNA treatment reflects the centrosome clustering
efficiency observed with DCB treatment. Data are mean ± SD, n = 150 individual
cells, 50 per experiment at cytokinesis. Data analysed using one way ANOVA with
Tukey post-hoc test. *** p<0.001.
162
Chapter 5. Results III: Elucidating the role of cortical contractility in centrosome
clustering
5.8 Discussion
In epithelial cells, downregulation of cortical contractility is achieved via inhibition
of the RhoA-ROCK pathway downstream of E-cadherin (Hidalgo-Carcedo et al.,
2011). Because E-cadherin cell junctions are maintained during mitosis and play a
role in the orientation of the mitotic spindle (Baker and Garrod, 1993; den Elzen et
al., 2009), it was hypothesised that decreased cortical contractility impairs efficient
clustering in epithelial cells. To test this atomic force microscopy (AFM) was used to
measure cortical elasticity, which acts as a proxy for tension and stiffness. CDH1-/-
cells were shown to have significantly higher cortical contractility than the E-cadherin
control cells in a monolayer in both the MCF10A and HaCaT cell lines. Interestingly,
this effect is lost when individual cells are quantified, suggesting that the formation
of adherens junctions is required to decrease contractility, a process that depends on
E-cadherin and DDR1.
Inhibition of cortical contractility through blebbistatin (a MyoII inhibitor) or a
ROCK1 inhibitor treatments impaired centrosome clustering, particularly in cells
that do not have E-cadherin, supporting a role for cortical contractility in driving
efficient centrosome clustering. Similarly use of the broad phosphatase inhibitor
Calyculin-A which results in increased p-MLC and therefore increased actomyosin
contractility resulted in more efficient centrosome clustering.
The observation that the supernumerary centrosomes are closer in tripolar metaphases
in CDH1-/- cells suggested that cortical contractility enables centrosomes to move
in closer proximity, which then enables more efficient centrosome clustering. It is
unclear how contractility promotes centrosome movement. One possibility is by
regulating microtubule stability at the cortex. For example, RhoA, ROCK and
myosin-dependent contractility were shown to promote microtubule destabilisation in
different contexts (Palazzo et al., 2001; Even-Ram et al., 2007; Takesono et al., 2010).
Thus, it is possible that in epithelial cells, low contractility leads to increased astral
microtubule stability thereby preventing centrosome movement. However, even in
the absence of cortical contractility there is still a 30-40% chance that centrosomes
can cluster, suggesting that in these cells the centrosomes are then close enough for
clustering to occur independently of actoymyosin contractility.
A role for astral microtubules supporting centrosome clustering has previously
been described, but the mechanism was not elucidated (Kwon et al., 2008). The
depletion of astral microtubules by low doses of nocodazole resulted in impaired
centrosome clustering regardless of E-cadherin status, therefore indicating that
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astral microtubules are important for translating the actomyosin contractility to the
centrosomes enabling them to be within the closer proximity.
Depletion of HSET by siRNA results in a loss of centrosome clustering in both
control and CDH1-/- cell lines, but does not affect the proximity of centrosomes in
tripolar metaphases. These data suggest that HSET is still fundamentally required
for centrosome clustering, however cortical contractility is required to bring the
centrosomes within close enough proximity for HSET to facilitate the clustering.
Therefore, whilst cells have the intrinsic mechanisms for centrosome clustering,
adaptation is required to enable those mechanisms to work efficiently.
The data suggest that the role of cortical contractility in bringing centrosomes
close enough together for HSET to cluster is the most fundamental part in cellular
adaptation to supernumerary centrosomes. In the MCF10A.pInducer.PLK4 cell lines
where high levels of centrosome amplification per cell were generated, these cells
were able to cluster very efficiently regardless of their E-cadherin status. This would
suggest that because there are so many centrosomes within the cell, they are already
within proximity for HSET to then cluster them together. This was supported by
use of SAS-6 siRNA to deplete centrosome number which confirmed that centrosome
clustering can also be correlated to the level of supernumerary centrosomes per cell,
with very high numbers, where they are in closer proximity clustering efficiently,
whereas those with lower numbers and therefore further apart being less efficient.
How the orientation and direction of this clustering occurs when there are so many
supernumerary centrosomes is unknown. In these latter cases where centrosome
number per cell is not as high it is then expected that cortical contractility is required




Whilst the mechanisms for centrosome clustering have previously been explored,
these data show for the first time in human cells that not all cell types are inherently
able to cluster. In particular, cells from an epithelial origin have inefficient clustering
mechanisms and need to adapt to centrosome amplification in order to survive.
Previous work has shown a role for the spindle assembly checkpoint (SAC) in
centrosome clustering, in allowing a longer time in metaphase, giving sufficient time
for the centrosome clustering to occur before anaphase onset (Weaver and Cleveland,
2005; Nezi and Musacchio, 2009; Maresca and Salmon, 2010). Therefore, it was
hypothesised that the MCF10A, HaCaT and J3B1A might have been able to cluster
their supernumerary centrosomes more efficiently if given more time in metaphase.
The proteasome inhibitor MG132 was used to prolong metaphase, and cells were
quantified after MG132 washout. No improvement on centrosome clustering occurred,
suggesting that the differences between the two groups of cells could not be attributed
to time in mitosis, but must be due to another independent mechanism.
The kinesin HSET has previously been identified as being essential for centrosome
clustering, by binding to microtubules and bringing the centrosomes together (dis-
cussed in more detail later) (Endow and Komma 1998; Basto et al. 2008; Kwon et
al. 2008). To determine if varying levels of HSET may account for differences in
centrosome clustering efficiency HSET levels were analysed by western blot analysis
in the panel of cell lines. HSET was ubiquitously expressed between all six cell
lines, therefore the level of HSET was not a limiting factor for centrosome clustering
efficiency. Similarly, later work in the panel of 16 breast cancer cell lines showed
that HSET was comparatively expressed, however, centrosome clustering efficiency
varied between the cell lines. Therefore, whilst all cell lines expressed this essential
component for centrosome clustering, there is still a further process of adaptation
which must occur for a cell to efficiently cluster.
It was observed that the epithelial cell lines, expressing E-cadherin had impaired
centrosome clustering compared to the fibroblast cell lines and RPE-1 which whilst
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of an epithelial origin no longer expresses E-cadherin. Differences in the ability of
cells with extra centrosomes to divide in a bipolar fashion have been previously
observed in Drosophila, where epithelial cells in the developing wing disks have
increased multipolar divisions when compared with neuroblasts upon SAK/PLK4
overexpression (Basto et al., 2008; Sabino et al., 2015). However, these differences are
not due to centrosome clustering but rather centrosome inactivation, characterised
by low centrosomal levels of pericentrin and γ-tubulin, which has been observed in
flies with extra centrosomes (Basto et al., 2008; Sabino et al., 2015). Overexpression
of moesin, the sole member of the conserved ezrin-radixin-moesin (ERM) family
of proteins, in Drosophila wing disks with extra centrosomes impairs centrosome
inactivation, leading to increased multipolar divisions in these cells (Sabino et al.,
2015). Nonetheless, no evidence of centrosome inactivation was observed in any of the
cell lines upon centrosome amplification, and all extra centrosomes in multipolar or
clustered spindles show similar levels of both pericentrin and γ-tubulin. In addition,
the levels of ERM proteins were unchanged in epithelial cells with or without E-
cadherin and did not correlate with the presence of centrosome amplification in a panel
of breast cancer cell lines. It is possible that the prevalence of mechanisms that allow
the formation of pseudobipolar spindles and survival of cells with supernumerary
centrosomes varies between cell types and organisms. Indeed, while Drosophila
neuroblasts cluster efficiently, induction of extra centrosomes in the mouse brain
showed that not all neuronal stem cells can cluster extra centrosomes, leading to
multipolar divisions and microcephaly (Basto et al., 2008; Marthiens et al., 2013).
To test the role of E-cadherin in centrosome clustering siRNA, shRNA and CRISPR-
Cas9 were used to deplete E-cadherin, resulting in increased centrosome clustering.
Therefore, showing that expression of E-cadherin impairs centrosome clustering.
This was supported in the RPE-1 cells where full-length E-cadherin was expressed
resulting in impaired centrosome clustering.
Changes in centrosome clustering upon loss of E-cadherin were not due to epithelial
to mesenchymal transition (EMT) as observed by no change in expression of EMT
markers. Similarly, no effect on cell rounding was observed upon loss of E-cadherin.
Cortical contractility has previously been identified as being important in centro-
some clustering, although the mechanism was not explored (Kwon et al., 2008).
Interestingly a link between E-cadherin and decreased cortical contractility has
been previously described (Hidalgo-Carcedo et al., 2011), therefore suggesting that
E-cadherin may impair centrosome clustering through decreased cortical contractility.
Hidalgo-Carcedo et al. reported that E-cadherin localises DDR1 to the cell-cell
contacts where through a signalling cascade it impairs phosphorylation of MLC,
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resulting in decreased contractility at the adherens junctions. They suggested that
this was important in collective cell migration, where the impairment of cortical con-
tractility as the adherens junctions was important for the maintenance of the cell-cell
adhesion, allowing for cells to move together rather than apart (Hidalgo-Carcedo et
al., 2011). Interestingly, when comparing DDR1 levels in the panel of six cell lines,
there was also a correlation of loss of DDR1 with increased centrosome clustering,
which correlates with E-cadherin levels. This hypothesis was then supported using
siRNA to deplete DDR1 which resulted in increased centrosome clustering in the
epithelial cell lines.
The previous work by Hidalgo-Carcedo et al. reported that E-cadherin is involved in
recruiting DDR1 to the cell membrane. Using calcium washout to deplete E-cadherin
they observed a loss of DDR1 at the membrane, which was restored upon the re-
addition of calcium and the return of E-cadherin to the membrane, from this they
stated that E-cadherin therefore recruits DDR1 to the membrane (Hidalgo-Carcedo
et al., 2011). However, the observation in the E-cadherin knockout (CDH1-/-) cell
lines, that DDR1 protein level is lost, draws this conclusion into question. It would
appear that E-cadherin does not just play a role in recruitment of DDR1 to the
membrane, but in its stabilisation, or indeed both its stabilisation and localisation.
There was no difference in DDR1 mRNA, suggesting that E-cadherin does not
control DDR1 transcription, but somehow regulates and stabilises the protein itself.
Whether this is through E-cadherin directly stabilising DDR1 or through a signalling
mechanism is still to be determined. One study has suggested that E-cadherin and
DDR1 can directly bind in their extracellular domains, however this work was done
with E-cadherin overexpression, and it is unknown if this binding may occur with
endogenous proteins (Wang, Yeh and Tang, 2009). The hypothesis that E-cadherin
leads to stabilisation and not just localisation of DDR1 is supported in the RPE-1 cell
line, where expression of E-cadherin is sufficient to drive DDR1 protein expression.
Conversely, DDR1 levels do not affect E-cadherin protein levels or its localisation as
previously shown in the MDCK epithelial cell line (Hidalgo-Carcedo et al., 2011).
Thus, it is likely that regulation of contractility by DDR1, and not adherens junctions
per se, is playing a role in centrosome clustering (Eswaramoorthy et al., 2010).
The hypothesis linking E-cadherin and DDR1 to impaired centrosome clustering
relied on decreased cortical contractility at the adherens junctions. To test this atomic
force microscopy was done showing that there was increased cortical stiffness/tension
in the CDH1-/- cell lines. This quantification works on the Sneddon model of
elasticity, which is based on the observations of objects of a different shape being
lowered into materials of known elasticity and then calculating the flex to establish
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a model. However, this model has limitations as it assumes that the cantilever is
being lowered onto an object (cell) with the same elasticity throughout. Therefore,
whilst the Sneddon model is currently the standard used for quantifying elasticity
within the field, further work is being undertaken to generate models which more
accurately reflect the lipid bilayer with different elasticity at the cortex compared to
the cytoplasm. Similarly, the Sneddon model would not take into account different
parts of the cortex having different stiffness/tension such as junctions.
Whilst the pathway linking E-cadherin and DDR1 to the downregulation of pMLC
is not fully understood, previous work suggests that DDR1 through Par3/Par6 may
inactivate RhoA via the recruitment of the RhoA negative regulator p190RhoGAP,
which in turn antagonise ROCK. Therefore, to test the role of this pathway on
centrosome clustering siRNA was used to deplete p190RhoGAP in epithelial cells. No
increase in centrosome clustering was observed, suggesting that p190RhoGAP is not
involved in the regulation of centrosome clustering by E-cadherin and DDR1. DLC3
is another RhoA negative regulator, which localises to focal adhesions to regulate
cell shape, however, similarly upon depletion by siRNA no effect on centrosome
clustering was observed (Hendrick et al., 2016). These observations would suggest
that RhoA GAPs that control cortical contractility are not involved in centrosome
clustering. RhoE, which can directly inhibit ROCK through direct binding, was
shown to control cortical contractility downstream of DDR1. RhoE may then directly
impair ROCK preventing actomyosin contractility (Riento et al., 2003) (Figure 6.1).
It is therefore suggested that DDR1 may potentially directly regulate RhoE, rather
than through a RhoA regulator. Nevertheless, it is possible that RhoA may play a
role, and this could be tested using siRNA or a RhoA inhibitor.
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Figure 6.1: Regulation of cortical contractility through RhoE
Schematic representation of RhoE mediated regulation of cortical contractility down-
stream of E-cadherin. RhoE may directly impair ROCK leading to increased acto-
myosin contractility leading to increased centrosome clustering efficiency.
Based on the observations of E-cadherin and DDR1’s regulation of cortical contrac-
tility impairing centrosome clustering, and the required role of HSET and astral
microtubules for this process, a two-stage model for centrosome clustering is proposed.
The first stage involves cortical contractility bringing the centrosomes into close
proximity, this is facilitated by the astral microtubules translating the actomyosin
contractility into centrosome movement. This could be through two potential mech-
anisms. The first is that the increased cortical contractility restricts centrosome
movement, possibly through the regulation of microtubule pulling forces that are
generated at the cortex. This restricted movement then allows HSET to bind and
cluster the centrosomes. Another hypothesis is that the increased contractility
destabilises the astral microtubules allowing them to be more free-moving across the
cortex bringing the centrosomes into closer proximity. Further work would need to be
done to elucidate this mechanism (discussed in more detail later). The second stage
where the centrosomes are close enough is facilitated by the kinesin HSET bringing
the centrosomes together (Figure 6.2). As HSET is a microtubule motor, that can
bind microtubules, it will require centrosomes to be in close enough proximity where
it can then bind to microtubules emanating from both centrosomes. Once bound
to these microtubules from multiple centrosomes HSET can then move along the
microtubules bringing the centrosomes together. If the centrosomes are too far apart,
then the microtubules will not be close enough for HSET to bind and therefore be
unable to cluster the supernumerary centrosomes.
The role of contractility at adherens junctions is complex. As described previously it
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Figure 6.2: Step-wise model for centrosome clustering
Schematic representation of the centrosome clustering model. It is proposed that
centrosome clustering occurs in a stepwise fashion. The first step depends on
cortical contractility and brings centrosomes together at a distance where anti-
parallel microtubules can interact. Following this, the second step requires the minus
end microtubule motor HSET, that bind to microtubules emanating from different
centrosomes and through their motor activity clusters extra centrosomes together.
has been reported that E-cadherin at adherens junctions impairs cortical contractility
(Hidalgo-Carcedo et al., 2011). However, other studies have shown that adherens
junctions display contractile tension (Lecuit and Yap, 2015). This tension is best
understood to play a role during morphogenesis (Martin and Goldstein, 2014; Mason
et al., 2016), however it has also been reported in stable monolayers independently of
morphogenesis, but the role that this contractility plays in an epithelial monolayer
is not understood. This contractile tension is generated through the actomyosin
complex which is coupled to E-cadherin, where they form actomyosin bundles which
form a ring, further stabilising the E-cadherin (Smutny and Yap, 2010; Priya, Yap
and Gomez, 2013; Wu et al., 2014). These actoymosin bundles are maintained by a
number of molecular processes, many relying on E-cadherin for their recruitment,
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such as RhoA (Ratheesh et al., 2012; Priya et al., 2015).
Previous work identified a role for certain formins, a diverse class of actin regulators
that influence filament dynamics and organisation, in controlling contractility at
adherens junctions (Kobielak, Pasolli and Fuchs, 2004; Carramusa et al., 2007;
Homem and Peifer, 2008; Mason, Tworoger and Martin, 2013; Grikscheit et al.,
2015; Rao and Zaidel-Bar, 2016). Whilst formins had been identified as localising to
adherens junctions, their role had been uncharacterised. Acharya et al. reported
that the formin mDia1 (Diaphanous 1) facilitated control of contractility at the
adherens junctions (Acharya et al., 2017). They showed that mDia1 was important
for reorganising F-actin into stable bundles that could then resist myosin-induced
stress. They also observed a role for mDia1 in stabilising tight junctions. Therefore,
loss of E-cadherin could also perturb control of cortical contractility, not only through
DDR1, but potentially through loss of mDia1 localisation as well. Therefore, further
understanding of the contrasting dynamics of E-cadherin and its control of cortical
contractility at adherens junctions is needed to fully understand how this then
facilitates centrosome clustering. The role of formins, and the actin bundles would
be particularly interesting to explore.
Recent work by Afshar et al. in Caenorhabditis elegans identified that the protein
phosphatase PPH-6 and one of its associated subunits SAPS-1 forms a complex
which is required for the contractility of the actomyosin network and proper spindle
positioning(Afshar et al., 2016). They showed that PPH-6/SAPS-1 regulated the
organisation of cortical myosin II, and contributes to cytokinesis by stimulating
actomyosin contractility. Similarly, the PPH-6/SAPS-1 is required for the generation
of pulling forces on the spindle poles during anaphase. Therefore, investigating
these proteins and their role in cortical myosin II in centrosome clustering may
help evaluate other mechanisms of cortical contractility independently of adherens
junctions in centrosome clustering.
The model proposed here of loss of E-cadherin as a mechanism of adaptation to
supernumerary centrosomes is important, particularly in light of the recent mouse
models developed to assess the role of centrosome amplification in tumourigenesis.
The majority of models showed that the generation of supernumerary centrosomes,
resulting from PLK4 overexpression was not sufficient to induce tumourigenesis
(Coelho et al., 2015; Serçin et al., 2015; Vitre et al., 2015). This is likely because
centrosome amplification induces a p53-mediated cell cycle arrest within normal cells
(Holland et al., 2012). However, in the absence of p53, induction of supernumerary
centrosomes was able to accelerate tumourigenesis in two different mouse models
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(Coelho et al., 2015; Serçin et al., 2015). A more recent study has questioned this
view, where Levine et al. reported that transient overexpression of PLK4 was able
to lead to tumourigenesis in some tissues, even in the presence of p53. Therefore,
the role of centrosome amplification in tumourigenesis is still disputed. Centrosome
amplification was shown to cause lymphomas and sarcomas in mice, which are
of mesenchymal origin, whereas epithelial tumours were not observed. Both the
lymphomas and sarcomas maintained high levels of supernumerary centrosomes
(Coelho et al., 2015). The induction of centrosome amplification in the developing
skin of p53 deficient mice was also reported to lead to accelerated tumour formation
and penetrance when compared to p53 deficiency alone. In contrast however, these
tumours did not display evidence of centrosome amplification, suggesting that
supernumerary centrosomes are not maintained within the epithelial compartment
(Serçin et al., 2015).
Taken together these results suggest that some tissues are more prone to mainte-
nance of centrosome amplification, whereas others require adaptation to maintain
proliferating populations of cells with extra centrosomes. The data demonstrate that
loss of E-cadherin might be one mechanism that allows epithelial cells to maintain
extra centrosomes by facilitating clustering. It would be interesting to assess if loss
of E-cadherin or DDR1 enables skin tumours to maintain their extra centrosomes.
Interestingly, more recent work showed squamous cell carcinoma (SCC) cells derived
from epithelial cells with supernumerary centrosomes, potentially conflicting with
the view that epithelial cells need to adapt to survive in the presence of centrosome
amplification, however, E-cadherin expression in these cells was not assessed (Levine
et al., 2017). It would be interesting to explore if E-cadherin may have been lost
prior to SCC development, where centrosome amplification may have driven loss of
E-cadherin in order to survive. There is already evidence suggesting that SCC cell
lines lose E-cadherin in their tumour development, suggesting that this could be a
process for maintaining their extra centrosomes (Hashimoto et al., 2012; Stewart and
Crook, 2017). However, no study looking at a correlation between supernumerary
centrosomes and E-cadherin expression has been carried out.
Whilst the large majority of tumours come from an epithelial background, centrosome
amplification is a common occurrence in cancer. This work would suggest that a
loss of E-cadherin could be a mechanism of adaptation, and indeed E-cadherin loss
is often observed in cancer. Cancer evolution results in changes in tumours overtime
with progressive mutations taking place. Therefore, it is unclear if centrosome
amplification may drive E-cadherin loss in order to survive, or if the loss of E-
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cadherin may lead to the accumulation of supernumerary centrosomes. Further work
would need to be done to explore which process drives the other.
E-cadherin loss is commonly associated with increased metastatic potential. This
could therefore help explain why centrosome amplification is correlated with later
stages and poor prognosis where not only are cells with centrosome amplification
already more invasive, but that a mechanism for adaptation to centrosome clustering
(loss of E-cadherin) also makes cells more metastatic.
6.1 Future directions
As strategies to inhibit centrosome clustering emerge from basic biology to allow
the development of specific inhibitors, approaches to identify patients that would
respond to such drugs will become essential (Rebacz et al., 2007; Kwon et al., 2008;
Ganem, Godinho and Pellman, 2009; Karna et al., 2011; Watts et al., 2013; Wu et
al., 2013). At present the only method for analysing if a patient has centrosome
amplification, and therefore might benefit from a centrosome amplification targeting
therapy, is to take a biopsy and then stain for centriole markers, this is therefore too
impractical based on invasiveness, time, expertise and cost to be done systematically.
Identifying features that permit cells to efficiently divide and proliferate in the
presence of extra centrosomes could be used as biomarkers to identify tumours
containing extra centrosomes. This work suggests that loss of E-cadherin, which
is routinely assessed in the clinic by immunohistochemistry, could potentially be
used to stratify which breast cancer patients would respond to drugs that target
centrosome clustering. Further exploring the use of E-cadherin and DDR1 loss as a
biomarker for treatment targeting centrosome amplification would be an interesting
approach towards personalised medicine. There are two different members of the
DDR family, DDR1 and DDR2. Interestingly, DDR switching is often described
within solid tumours where DDR expression goes from DDR1 to DDR2 expression
(Maeyama et al., 2008; Toy et al., 2015). It is possible that as tumours progress
and lose E-cadherin, and therefore lose DDR1 this may then allow for an increase in
DDR2 expression. However, bioinformatic and protein analysis would be required
to test this hypothesis. Therefore, it would be interesting to also explore if DDR1
switching to DDR2 is correlated with centrosome amplification and could be used as
a biomarker.
Whilst astral microtubules have previously been reported as having a role in facili-
tating centrosome clustering, and here the data supports that role by translating the
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cortical forces to the centrosomes, it is unclear how this mechanism functions. The
data show that centrosomes are closer in tripolar metaphases in CDH1-/- cell lines,
suggesting that the movement of the centrosomes is restricted. How contractility
might restrict centrosome movement during mitosis remains unclear. One possibility
is by regulating microtubule-pulling forces that are generated by motors at the
cortex, such as dynein. It has been previously proposed that efficient pulling forces
important for spindle positioning require the microtubule plus ends to be anchored to
a relatively stiff cortex (Carreno et al., 2008; Kunda et al., 2008). Indeed, actomyosin
contractility was shown to be important for dynein-mediated pulling forces on the
microtubules and to prevent membrane invaginations at the sites of microtubule
pulling forces in C. elegans embryos (Redemann et al., 2010; De Simone, Nédélec and
Gönczy, 2016). Thus, it is possible that in epithelial cells, low contractility could lead
to inefficient microtubule pulling forces at the cortex leading to increased random cen-
trosome movement that prevents efficient centrosome clustering. Another hypothesis
is that the additional contractility destabilises the centrosomes at the cortex making
them more free-moving. Understanding the astral microtubule dynamics in detail
would help to fully elucidate this model. This could be identified by doing live cell
imaging of the centrosomes, such as through GFP labelled centrin, to actively track
centrosome movement during mitosis. Whilst this will not elucidate microtubule
dynamics it will enable to distinguish if centrosomes are fixed or motile and therefore
distinguish between the two hypotheses. This would help to further illuminate the
clustering process. It would be predicted from the proposed 2-stage model that in
the initial stage centrosomes would move closer together, where HSET in the second
stage would then bring the centrosomes together more rapidly. However, this could
only be explored more fully through live-cell tracking.
Interestingly, upon mitotic entry, NuMA is released from the nucleus and displaced
LGN from E-cadherin forming the LGN/NuMA complex (Gloerich et al., 2017).
This complex can then facilitate the stabilisation of astral microtubule interactions
at the cell cortex, which in turn orientates the mitotic spindle. Therefore, in the
absence of E-cadherin this complex may already be stabilised, as the process of
displacement is not required, allowing for more stable astral microtubule associations
at the cortex. Exploring this mechanism more fully may help elucidate the process
for astral microtubules in translating the cortical forces to facilitate centrosome
clustering.
E-cadherin was initially shown to lead to the recruitment of DDR1 to the adherens
junctions. However, these experiments were based on the observations when E-
cadherin was removed by calcium wash-out coinciding with a loss of DDR1, which was
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rescued by re-addition of calcium. The data here suggest an alternative mechanism,
whereby DDR1 is not just localised due to E-cadherin, but that it is actually stabilised
by E-cadherin. Both localisation and stabilisation of DDR1 are not necessarily
exclusive, so E-cadherin may be important for both, and further understanding this
relationship would be an interesting area to explore. Whilst it has been proposed
that E-cadherin and DDR1 can directly bind in their extracellular domains, this was
done by overexpression of E-cadherin and it is yet to be reported if this happens
with endogenous proteins. It would therefore be interesting to explore if E-cadherin
and DDR1 bind in normal cellular conditions.
Similarly, whilst it is hypothesised that DDR1 may be able to directly regulate RhoE
and the signalling cascade reducing actomyosin contractility, this needs validation.
Indeed, depletion of RhoA and its effect on centrosome clustering was not explored,
and could still act as a potential link between DDR1 and RhoE through a yet to be
explored RhoA regulator.
This proposed two stage model fundamentally relies on increased cortical contractility
to facilitate the first stage of centrosome clustering. Control of cortical contractility
independently of E-cadherin may then lead to increased centrosome clustering. Ex-
ploring other mechanisms of cortical contractility regulation in centrosome clustering
would be an interesting future approach, such as depleting phosphatases which may
lead to accumulation of pMLC, and identifying if there is an increase in centrosome
clustering.
This thesis would suggest that adaptation to centrosome amplification, by centrosome
clustering, is required for the survival of epithelial cells as shown by the cell viability
experiments. However, it would be exciting to see if this could then be recapitulated
in vivo such as with the skin tumour model using PLK4 overexpression to induce
centrosome amplification. It would be expected that the loss of E-cadherin would
then allow for continued cell proliferation and survival, whereas the E-cadherin
positive cells would not survive due to the multipolar cell divisions. To test this an in
vivo model could be used where epithelial cells with supernumerary centrosomes are
injected sub-cutaneously compared to CDH1-/- cells with supernumerary centrosomes.
Based on the hypothesis it would be expected that the epithelial cells would not form
a tumour, whereas the CDH1-/- should form a tumour due to increased cell survival.
This would then confirm that E-cadherin loss is an adaptation mechanism in vivo
to centrosome amplification in epithelial cells. It would therefore be interesting
to examine how loss of E-cadherin and centrosome amplification synergise during
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Katsetos, C. D., Reddy, G., Dráberová, E., Smejkalová, B., Del Valle, L., Ashraf, Q.,
Tadevosyan, A., Yelin, K., Maraziotis, T., Mishra, O. P., Mörk, S., Legido, A.,
Nissanov, J., Baas, P. W., Chadarévian, J.-P. de, and Dráber, P. (2006). “Altered
cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic
gliomas and human glioblastoma cell lines.” In: Journal of neuropathology and
experimental neurology 65.5, pp. 465–477.
Kawamura, K., Fujikawa-Yamamoto, K., Ozaki, M., Iwabuchi, K., Nakashima, H.,
Domiki, C., Morita, N., Inoue, M., Tokunaga, K., Shiba, N., Ikeda, R., and
Suzuki, K. (2004). “Centrosome hyperamplification and chromosomal damage
after exposure to radiation.” In: Oncology 67.5-6, pp. 460–70.
Kawamura, K., Izumi, H., Ma, Z., Ikeda, R., Moriyama, M., Tanaka, T., Nojima,
T., Levin, L. S., Fujikawa-Yamamoto, K., Suzuki, K., and Fukasawa, K. (2004).
“Induction of centrosome amplification and chromosome instability in human
bladder cancer cells by p53 mutation and cyclin E overexpression”. In: Cancer
Research 64.14, pp. 4800–4809.
Kayser, G., Gerlach, U., Walch, A., Nitschke, R., Haxelmans, S., Kayser, K., Hopt,
U., Werner, M., and Lassmann, S. (2005). “Numerical and structural centrosome
aberrations are an early and stable event in the adenoma-carcinoma sequence of
colorectal carcinomas”. In: Virchows Archiv 447.1, pp. 61–65.
Kearns, W. G., Yamaguchi, H., Young, N. S., and Liu, J. M. (2004). “Centro-
some amplification and aneuploidy in bone marrow failure patients.” In: Genes,
chromosomes & cancer 40.4, pp. 329–33.
Keating, T. J. and Borisy, G. G. (2000). “Immunostructural evidence for the template
mechanism of microtubule nucleation.” In: Nature cell biology 2.6, pp. 352–357.
Keller, L. C., Romijn, E. P., Zamora, I., Yates, J. R., and Marshall, W. F. (2005).
“Proteomic analysis of isolated Chlamydomonas centrioles reveals orthologs of
ciliary-disease genes”. In: Current Biology 15.12, pp. 1090–1098.
Kfoury, Y., Nasr, R., Favre-Bonvin, a., El-Sabban, M., Renault, N., Giron, M.-L.,
Setterblad, N., Hajj, H. E., Chiari, E., Mikati, a. G., Hermine, O., Saib, a., Thé,
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